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Figure 1.1. a) Poisson distributions of stochastic mixtures of dendrimers with an average of 
four or five ligands. b) Distribution of species resulting from sequential 
conjugation of averages of four then five ligands. The chart represents the 
product of the two distributions. The black bar indicates the nominal material 
with four FA and five MTX. 7 
Figure 1.2. Ultra performance liquid chromatography (UPLC) chromatograms at 210 nm. a) 
As-received G5 dendrimer indicates the presence of trailing generation 
impurities as well as aggregtation defects. b) as-received acetylated G5 PAMAM 
(G5-Ac, red trace) contains high weight impurities with no ligand that co-elute 
with G5 monomers containing one ligand (G5-L1, green trace) in a conjugated 
sample (black trace). c) Conjugation to an rp-HPLC purified G5 monomer 
sample (red trace) has narrowed peak width and improved peak resolution 
compared to the as-received conjugation (black trace). Adapted and reprinted 
with permission from Polymer 2013, 54, 4126-4133. © 2013 Elsevier Ltd. 8 
Figure 1.3. HPLC chromatogram of an average conjugate overlaid with the predicted 
distribution for an average of two ligands-per-particle. Figure adapted and 
reprinted with permission of Biomacromolecules 2014, 15, 3215-3234. © 2014 
American Chemical Society. 9 
Figure 1.4. FLIM images of HEK293A cells incubated for 3 h with (a) PBS only, (b) G5-
NH2, (c) G5-NH2-TAMRA1, (d) G5-NH2-TAMRA2, (e) G5-NH2-TAMRA3, (f) 
G5-NH2-TAMRA4, (g) G5-NH2-TAMRA5+, and (h) G5-NH2-TAMRA1.5avg. (j) 
Color code for FLIM images. (k) Histograms of fluorescence lifetimes for FLIM 
images. Images were obtained with a 40× oil immersion objective. Reprinted 
and adapted with permission from Bioconjugate Chem. 2015, 26, 304-315. 12 
Figure 1.5. Hierarchical structure of collagen structures in tendon, skin, and bone. The AFM 
images show the D-spacing resulting from the parallel staggered alignment of 
the collagen microfibirls. Adapted and reprinted with permission from ACS 
Nano 2012, 6, 9503-9514. © 2012 American Chemical Society. 14 
Figure 1.6. AFM images illustrating Parallel and Oblique regions of Type I collagen fibrils. 
a) Parallel region showing multiple aligned fibrils (yellow arrows); b) Oblique 
region showing multiple fibrils with varying alignment (yellow arrows). Adapted 
and reprinted with permission from BoneKEy Reports 2015, 4, 697. 16 
Figure 1.7. Examples of cortical and trabecular bone. Images courtesy of Meagan Cauble. 16 
Figure 1.8. Boxplots of the D-spacing distribution of the collagen fibrils located in 
trabecular bundles obtained for sham, OVX+Vehicle (VEH), OVX+ALN, and 
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OVX+CatKI groups. There are significant differences in the degree of animal-
to-animal variability across treatments in trabecular bone (p=0.02, likelihood 
ratio Chi square test). The animal-to-animal variance for the OVX+Veh. 
Treatment was marginally significant (p=0.074). Both drug treatments 
introduced significant animal-to-animal variability in the bundle D-spacing (p b 
0.01). Reprinted and adapted with permission from Bone Reports 2016, 5, 243-
251. ©2016 The Authors. 17 
Figure 1.9. AFM images of collagen, with arrows showing local alignment of collagen 
patches. The alignment was determined using an autocorrelation-based method. 
The arrow lengths are scaled to show the degree of alignment. 18 
Figure 1.10. AFM images of FBP nanoparticles with folic acid, methotrexate, or leucovorin. 
a-c) FBP and ligand present at 2 nM. d) FA at 20 nM, FBP at 2 nM. e) MTX at 
1,000 nM, FBP at 2 nM. f) LEUC at 1,000 nM, FBP at 2 nM 21 
Figure 1.11. Cumulative density function (CDF) plots of selected the volumes FA-, MTX-, 
and LEUC-containing FBP nanoparticles. The similarity of the nanoparticle 
volume distributions was assessed using K–S statistics. The K–S testing showed 
the volume distributions of FBP nanoparticles formed from 20 nM FA + 2 nM 
FBP and 1000 nM LEUC + 2 nM FBP are not statistically different (p = 0.310). 
All other nanoparticle volume distributions were shown to be statistically 
different when evaluated with the K–S test. We hypothesize LEUC is effective 
as a folic acid rescue agent because the FBP nanoparticles formed at therapeutic 
concentrations of LEUC have the same volume distribution as the nanoparticles 
formed at healthy FA concentrations (20 nM). 23 
Figure 1.12. Representations of polymer-conjugate materials. For the PAMAM dendrimers, 
all terminal amines are acetylated following ligand conjugation. a) Folic acid 
(FA, red) conjugated directly to G5 PAMAM (black), producing G5Ac-FA4(avg); 
b) Distribution resulting from a stochastic conjugation with an average of 4 
ligands and 93 arms;  c) FA (red) conjugated to G5 PAMAM (black) via a 
cyclooctyne glycolic acid (COG)-amino acid linker (blue), producing G5Ac-
COG-FA1.0; d) FA (red) conjugated to poly(ethylene glycol) (black). Adapted 
and reprinted with permission from Bioconjugate Chem. 2017, 28, 2350-2360. 25 
Figure 1.13. a) Tryptophan fluorescence quenching upon addition of free FA or FA 
conjugate to FBP. FBP concentration was 58 nM. Note the strong fluorescence 
quenching at approximately 0.1 equivalents of G5Ac-COG-FA1.0. b) Titration of 
FBP into FA (50 nM) and G5Ac-FA polymer conjugates (50 nM). FA materials 
produced conformational changes throughout the protein population. For both 
experiments, excitation = 280 nm, emission = 342 nm; pH = 7.4 (1x PBS). Panel 
(b) reprinted and adapted with permission from Bioconjugate Chem. 2017, 28, 
2350-2360. 26 
Figure 1.14. Cumulative density function (CDF) plots of the measured volume distributions 
of 2 nM FBP, 20 nM FA + 2 nM FBP, and G5Ac-FA4(avg) + FBP nanoparticles. 
The similarity of the nanoparticle volume distributions was assessed using K−S 
statistics, which showed all nanoparticle volume distributions to be statistically 
different. Analysis of the volume distributions indicated that FBP nanoparticle 
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size increases with increasing G5Ac-FA4(avg)
 concentration. Reprinted and 
adapted with permission from Bioconjugate Chem. 2017, 28, 2350-2360. 27 
Figure 1.15. AFM images demonstrating the differences in aggregation when FBP is 
exposed to G5Ac-FA4(avg) and G5Ac-COG-FA1.0. Images reprinted with 
permission from Bioconjugate Chem. 2017, 28, 2350-2360. 28 
Figure 1.16. Example of AFM-IR, with a) a deflection image and b) IR spectra acquired at 
locations indicated by the squares on the image. The blue spectrum clearly 
shows the signals from poly(methyl methacrylate) beads (the circles) as 
compared to the epoxy (red trace). Acquired on a nanoIR2 from Anasys 
Instruments. 31 
Figure 2.1. The X-ray structure of folate receptor α with folic acid in the binding site. 45 
Figure 2.2. The structures of folic acid and a variety of antifolates 50 
Figure 3.1. The structures of folic acid (FA, vitamin B9), methotrexate (MTX), and 
leucovorin (LEUC). MTX is used for the treatment of cancer and rheumatoid 
arthritis. LEUC is administered for “folic acid rescue” after cancer treatment 
with MTX in order to reduce adverse events in patients due to the severe toxicity 
of the drug. 58 
Figure 3.2. AFM images of FBP nanoparticles formed in 1× PBS over a range of protein 
concentrations, including the physiological concentrations in tissue and blood 
(0.2–2 nM) and the concentration in human breast milk (100 nM). FBP 
nanoparticles were captured by spin-coating solutions containing the 
nanoparticles onto freshly-cleaved mica. Statistical data and the degree of 
aggregation of the particles are shown in Table 3.1. Histograms of the volume 
distribution of 2 nM FBP are provided in Figure 3.3. Plots and statistical analysis 
of the 0.2 nM FBP nanoparticle distribution are provided in Figure A.1. 61 
Figure 3.3. (a) AFM images of FBP nanoparticles formed from a range of FA : FBP ratios. 
For all samples, the FBP concentration was held constant at 2 nM in 1× PBS. 
AFM images were captured by spin-coating the solutions onto freshly-cleaved 
mica. As is evident from the 2 nM FA + 2 nM FBP image in panel A, the 
addition of FA to 2 nM FBP disrupts the FBP self-aggregation observed for FBP 
alone, resulting in a bimodal distribution (only the smaller nanoparticles are 
shown in the histograms, see Figure A.3 for the full distribution). (b) Histogram 
of the volumes of the FBP nanoparticles for all the FA : FBP ratios. With the 
exception of the 2 nM FA sample, apo- and ligand-bound FBPNP display 
similarly wide volume distributions. (c) Histogram of the volumes of FBP 
nanoparticles in only 2 nM FBP and 2 nM FA + 2 nM FBP. Most of the FA-
bound FBP nanoparticles are smaller and contained within a narrower 
distribution than observed for the 2 nM FBP. However, the large FBPNP contain 
96% of the FBP material. (d) Histogram showing the distribution of nanoparticle 
radii extrapolated from the detected FBP nanoparticle volumes. (e) Histogram of 
only 2 nM FBP and 2 nM FA + 2 nM FBP nanoparticle radii. The narrower 
distribution of the FA-bound FBP nanoparticles is clearly evident. 63 
 xv 
Figure 3.4. The 8-mer crystal structure of folate receptor-α (FBP without the GPI membrane 
anchor) with folic acid (FA) in the binding pocket.19 All the tryptophan residues 
are shown. The tryptophan residues participating in the pi-stacking interaction 
with the pterin ring system in FA are highlighted in cyan. The tryptophan 
residues interacting with the benzamine ring in FA are shown in magenta. The 
rearrangement of these two tryptophan is likely responsible for the fluorescence 
quenching observed upon ligand binding. 65 
Figure 3.5. The FBP fluorescence is measured upon addition of different folate and folinate 
materials. Leucovorin (LEUC) did not induce significant fluorescence quenching 
of FBP (black). Further addition of folic acid (FA) leads to quenching of the 
intrinsic tryptophan fluorescence (blue) that resembles FA quenching alone 
(green). Similarly, when methotrexate (MTX) is added to LEUC (red), the 
fluorescence is quenched approximately the same level as when MTX only is 
added to FBP (purple). The FBP concentration in all cases is 58 nM (pH 7.4, 1× 
PBS solution). 65 
Figure 3.6. (a) Exemplar AFM images of FBP nanoparticles formed from a range of MTX : 
FBP ratios. For all samples, the FBP concentration was held constant at 2 nM in 
1× PBS. FBP nanoparticles were captured by spin-coating solutions containing 
the nanoparticles onto freshly-cleaved mica. (AFM images of all of the MTX 
concentrations are provided in Figure A.5.) (b) Histogram of the volumes of the 
FBPNP for all the MTX : FBP ratios studied. A wide, tailing distribution is 
observed for all samples. (c) Histogram of the radii of the FBPNP for all MTX : 
FBP ratios. The radius data are extrapolated from the detected volumes of the 
FBPNP. 68 
Figure 3.7. Quantile–quantile (Q–Q) plots of the volumes of FA-, MTX-, and LEUC-
containing FBP nanoparticle plotted against ligand-free 2 nM FBP nanoparticle 
volumes. The square markers represent each decile of data. The dashed lines in 
the charts pass through the 1st and 3rd quartiles (25th and 75th percentiles) of 
the data. (a) Q–Q plot of the volumes of 2 nM FA- and MTX-containing FBP 
nanoparticles against the volumes of 2 nM apoFBP nanoparticles. (b) Q–Q plot 
of the volumes of 20 nM FA- and MTX-containing FBP nanoparticles against 
the volumes of 2 nM apo-FBP nanoparticles. (c) Q–Q plot of the volumes of 100 
nM FA- and MTX-containing FBP nanoparticles against the volumes of 2 nM 
FBP nanoparticles. These data suggests that at high MTX concentrations, the 
resulting FBP nanoparticles closely resembles the native form of FBP in both 
size and distribution, enabling effective transport and delivery to target cells. (d) 
Q–Q plot of the volumes of 10 nM FA-, 20 nM FA-, and 1000 nM LEUC-
containing FBP nanoparticles against the volumes of 2 nM FBP nanoparticles. 
These data indicate that at therapeutic levels of LEUC, the resulting FBP 
nanoparticles have a similar volume distribution as FBPNP formed at healthy 
levels of FA. This suggests that FBP nanoparticles containing LEUC follow the 
same trafficking and biodistribution pathways as FBP nanoparticles formed at 
healthy, or potentially even scarce, FA concentrations, facilitating cellular 
uptake of the vitamer and folic acid rescue. 72 
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Figure 3.8. Cumulative density function (CDF) plots of selected the measured volumes FA-, 
MTX-, and LEUC-containing FBP nanoparticles. The similarity of the 
nanoparticle volume distributions was assessed using K–S statistics. The K–S 
testing showed the volume distributions of FBP nanoparticles formed from 20 
nM FA + 2 nM FBP and 1000 nM LEUC + 2 nM FBP are not statistically 
different (p = 0.310). All other nanoparticle volume distributions were shown to 
be statistically different when evaluated with the K–S test. We hypothesize 
LEUC is effective as a folic acid rescue agent because the FBP nanoparticles 
formed at therapeutic concentrations of LEUC have the same volume 
distribution as the nanoparticles formed at healthy FA concentrations (20 nM) 
and a similar distribution to nanoparticles containing physiologically low FA 
concentrations (10 nM). 74 
Figure 4.1. Representations of polymer-conjugate materials used in this work. For the 
PAMAM dendrimers, all terminal amines are acetylated following ligand 
conjugation. (a) Folic acid (FA, red) conjugated directly to G5 PAMAM (black), 
producing G5Ac-FA4(avg); (b) distribution resulting from a stochastic conjugation 
with an average of 4 ligands and 93 arms; (c) FA (red) conjugated to G5 
PAMAM (black) via a cyclooctyne glycolic acid (COG)–amino acid linker 
(blue), producing G5Ac-COG-FA1.0; (d) FA (red) conjugated to poly(ethylene 
glycol) (black). 94 
Figure 4.2. Titration of FBP into FA (50 nM) and G5Ac-FA PAMAM polymer conjugates 
(50 nM). All curves with FA materials demonstrated that the presence of FA 
resulted in a decreased rate of fluorescence increase, as compared to apo-FBP 
(7.3 A.U./nM). These data indicate that even at greater than stoichiometric FBP 
concentrations, the FA materials produced conformational changes throughout 
the protein population. 96 
Figure 4.3. a) AFM images of FBP nanoparticles resulting from the addition of G5Ac to FBP 
(2 nM in 1x PBS). AFM images were captured by spin coating the solutions onto 
freshly-cleaved mica; b) Cumulative density function (CDF) plots the measured 
volumes G5Ac + FBP nanoparticles; c) Quantile-quantile (Q-Q) plots of the 
volumes of G5Ac + FBP nanoparticles plotted against the distribution of ligand-
free 2 nM FBP nanoparticle volumes. The square markers represent each decile 
of data. The straight lines in the charts pass through the 1st and 3rd quartiles (25th 
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ABSTRACT 
 
Serum proteins interact with small molecules and nanoparticles in blood, resulting in 
protein coronas. Protein coronas influence the bioidentity of the molecules and nanoparticles, 
playing critical roles in biotransport, uptake, and fate. Targeted therapeutics are often “tagged” 
for removal or sequestration before reaching their intended tissues.  
The research presented here is focused on characterizing and taking advantage of a 
particular protein corona – the self-aggregation of serum folate binding protein (FBP). FBP is 
derived from cellular folate receptors, and both bind strongly to folic acid (FA), as well as the 
antifolate drug methotrexate (MTX). FA has been explored as a targeting agent because folate 
receptors are overexpressed on a variety of human cancers. Translation to the clinic of FA-
targeted therapeutics has been challenging because the interaction of FBP with these materials 
has not been fully understood or appreciated: therapies tested in vivo are likely to operate by 
different mechanisms than those predicted by in vitro experiments in the absence of soluble FBP.  
 Using atomic force microscopy (AFM), we characterized the self-aggregation of FBP on 
a particle-by-particle basis at physiological concentrations. FBP self-aggregates into 
nanoparticles (forming FBPNP) at blood serum concentrations. We further explored the effect of 
concentration and ligand on the aggregation process. The introduction, and subsequent binding to 
FBP, of FA, MTX, or leucovorin (LEUC, a FA rescue agent) disrupted existing FBPNP, in most 
cases inducing reaggregation into new FBPNP. Healthy concentrations of FA and therapeutically 
relevant concentrations of LEUC produced FBPNP distributions that were not statistically 
different. This provided a new hypothesis for the perplexing phenomenon that LEUC must be 
used for FA rescue because high-dose FA itself provides no therapeutic benefit. FBPNP with 
therapeutic levels of FA or MTX had similar distributions, both of which were significantly 
different from LEUC-FBPNP. We postulated the degree of FBP aggregation acts as a signaling 
mechanism and dictates uptake of ligated species. 
 xxiii 
 We studied FBP aggregation with two FA-poly(amidoamine) (PAMAM) dendrimers and 
two FA-poly(ethylene glycol) (PEG) conjugates. Fluorescence spectroscopy experiments showed 
that FA and FA-conjugates induced conformational changes throughout the protein population, 
even with an excess of FBP. Using AFM, we demonstrated the PAMAM conjugates produced 
large aggregates at sub-stoichiometric concentrations. PAMAM-FA-FBPNP and FA-FBPNP 
have different distributions, suggesting that translation of targeted conjugates has been 
challenging because FBP does not traffic the conjugates like free FA. PEG should be used with 
caution because it disrupted healthy FBP aggregation, potentially inducing artificial folate 
deficiency. 
 Given the challenges associated with conjugated therapies, we sought to leverage FBP 
itself as a targeted vector. We hypothesized that pre-binding FBP to MTX would decrease 
toxicity and increase therapeutic efficacy. We tested this hypothesis in a KB xenograft tumor 
model in mice. Surprisingly, FBP alone inhibited tumor growth as compared to saline control 
and free MTX. This is the first time this therapeutic effect of FBP has been reported. We 
postulate the excess unbound FBP resulted in folate starvation of the tumors. The groups treated 
with MTX and FBP also showed inhibition of tumor growth, but toxicity increased with FBP 
concentration. It is likely that instead of specifically targeting cancer cells, FBP facilitated 
widespread uptake of MTX, resulting in systemic toxicity. The substantial reduction observed in 
tumor volume suggests that FBP alone could be employed as a chemotherapeutic. Future work 
should be focused on exploring this exciting possibility. 
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CHAPTER 1. Distributions: The Importance of the Chemist’s Molecular 
View of Biological Materials 
 
Rachel L. Merzel [Wallace], Bradford G. Orr, and Mark M. Banaszak Holl 
This chapter was submitted to Biomacromolecules as a Perspective. 
 
1.1. Abstract 
Characterization of materials with biological applications and assessment of 
physiological effects of therapeutic interventions are critical for translating research to the clinic 
and preventing adverse reactions. Analytical techniques typically used to characterize targeted 
nanomaterials and tissues rely on bulk measurement. Therefore, the resulting data represent an 
average structure of the sample, masking stochastic (randomly generated) distributions that are 
commonly present. In this Perspective, we examine almost 20 years of work our group has done 
in different fields to characterize and control distributions. We discuss the analytical techniques 
and statistical methods we use and illustrate how we leverage them in tandem with other bulk 
techniques. We also discuss the challenges and time investment associated with taking such a 
detailed view of distributions, as well the risks of not fully appreciating the extent of 
heterogeneity present in many systems. Through three case studies showcasing our research on 
conjugated polymers for drug delivery, collagen in bone, and endogenous protein nanoparticles, 
we discuss how identification and characterization of distributions – a molecular view of the 
system – was critical for understanding the observed biological effects. In all three cases, data 
would have been misinterpreted and insights missed if we had only relied upon spatially 
averaged data. Finally, we discuss how new techniques are starting to bridge the gap between 
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bulk and molecular level analysis, bringing more opportunity and capacity to the research 
community to address the challenges of distributions and their roles in biology, chemistry, and 
the translation of science and engineering to societal challenges. 
 
1.2. Introduction: Characterization of nanomaterials and nanostructures in biology 
In this Perspective, we consider nearly 20 years of effort in our group to characterize 
stochastic (randomly occurring) distributions arising from molecular level chemistry in a variety 
of synthetic and natural systems. As a research team composed primarily of chemists, engineers, 
and physicists with highly integrated medical collaborators and mentors, our group brings 
distinct perspectives and expertise to characterizing biological materials and systems. Generally, 
the extent of heterogeneity and the role material distributions play has not been fully appreciated.  
Here, we present three case studies in the arenas of targeted drug delivery and tissue analysis 
illustrating the importance of a molecular view of biomaterials and the specific contributions of 
our research to these fields. Specifically, we highlight examples of how detailed 
characterizations – and sometimes intentional removal – of distributions have proven critical to 
understanding the biological behavior. 
1.2.1. Analytical techniques for nanoscale characterization 
Most analytical techniques used to characterize nanoscale materials and nanostructures 
rely on bulk measurement. That is, they average over a much larger length scale than the 
constitutive molecules or nanomaterials. The resulting data represent an average molecular 
and/or nanoscale structure of the sample. For example, conventional spectroscopic techniques 
(e.g., NMR, IR, UV-Vis), X-ray diffraction (XRD), and dynamic light scattering (DLS) contain 
information regarding the distribution of sample with line-widths that are not simply interpreted 
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and are often convolved with other physical properties. The bulk characterization masks 
stochastic distributions present within the nanomaterials. If a new targeted nanoscale therapy 
comprises a stochastic distribution, it is difficult, if not impossible to know which species 
produced the observed physiological effect. In biological tissues, e.g. bone and skin, most 
characterization techniques hide natural heterogeneity or mask localized changes to micro- and 
nanostructure as a result of disease or therapeutic intervention because the analysis averages over 
microns to millimeters or even greater sample dimensions. Precise characterization of nanoscale 
materials and anatomical changes is critical to developing safe and targeted therapies, as well as 
understanding their physiological effects.1 
Molecular level characterization of samples and elucidation of structure is a challenging 
problem. In the research presented here, we primarily took advantage of two techniques to 
characterize and/or control distributions: reverse-phase high performance liquid chromatography 
(rp-HPLC) and atomic force microscopy (AFM). We complemented these methods with other 
bulk techniques, notably NMR and fluorescence spectroscopy, mass spectrometry, DLS, 
confocal microscopy, and fluorescence lifetime imaging microscopy (FLIM). We demonstrated 
that rp-HPLC can be used to separate trailing and branching defects in poly(amidoamine) 
(PAMAM) dendrimers2–5 and separate species with different number of hydrophobic ligands 
(dyes, drugs, targeting agents) attached to the hydrophilic backbone.6–10 AFM allowed for direct, 
representative imaging of samples and surfaces with nanometer precision in the x and y 
directions and sub-nanometer precision vertically.11–21 Importantly, AFM is a topographic 
technique, measuring the volume of imaged features along with surface morphology and material 
properties. Hierarchical features from the nanometer to micron scale can be characterized, and no 
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staining is required for contrast.15 The large number of individually characterized nanostructures 
in each AFM image enables robust statistical analysis.   
Researchers also turn to XRD because it can provide high resolution (sub-angstrom) 
information with structural information down to the molecular level. However, these values are 
calculated from combined measurements of a large sample set of molecules throughout the bulk 
material – microns to millimeters in the crystal. Crystal structures obtained by XRD represent a 
spatial average and tend to treat molecular differences as “disorder”, masking heterogeneity in 
the sample. Conversely, AFM typically produces images with slightly lower resolution but 
provides particle-by-particle measurements. This molecular level analysis is critical for assessing 
distributions in biological materials and relating changes in distributions to activity. 
In our research, we use molecular level and bulk techniques together to build greater 
scientific understanding. We take advantage of image processing software – particle counting, 
alignment mapping, etc. – to process large data sets with thousands of structures. We also use 
conventional cellular biology techniques such as confocal microscopy and flow cytometry to 
probe the biological implications of distributions. In sum, we make the case here for the 
investment in a molecular level analysis of biological materials and the importance of 
understanding the interplay between structural variation and function. 
1.2.2. Three cases for a molecular view of biological materials 
In the rest of this Perspective, we present three broad research studies illustrating the role 
distributions play in assessing biological materials and outcomes. The first section focuses on 
multivalent polymers as drug delivery vectors, specifically the challenges associated with 
heterogeneity resulting from sequential stochastic conjugations. The second section discusses 
inherent heterogeneity in tissue and changes to the hierarchical structure of collagen as functions 
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of disease and drug treatment. In the third section we return to drug delivery and combine our 
analyses of distributions in artificial and natural materials. We highlight our latest research on 
serum proteins and the role they play in trafficking and bioidentity of their ligands. Analysis of 
distributions of serum protein nanoparticles (aggregated protein) as functions of concentration 
and ligand yielded novel hypotheses on the relationship between protein aggregation and 
activity. This was particularly important for understanding the role of serum proteins in the 
trafficking of the multivalent polymers discussed in the first section. We emphasize how the 
success of this work depended on applying lessons on conjugation heterogeneity and collagen 
characterization from the first two research cases. We translated our understanding of material 
distributions derived from laboratory synthesis processes and inherently present in natural 
materials, as well as our expertise in AFM and image analysis, to exploring the relationship 
between structure, function, and activity in protein nanoparticles. In all three cases we 
demonstrate how key conclusions insights and conclusions would have been missed if we had 
only used techniques that measure over larger scales than the molecules or nanostructures in the 
biological materials 
1.3. Distributions in targeted nanoparticles 
1.3.1. History and motivation 
History and motivation. Over almost 20 years, our group and close collaborators have 
invested substantial research effort towards developing targeted therapeutics on a generation 5 
(G5) PAMAM dendrimer scaffold.6–9,22–34 In the mid-2000s, our colleagues developed a targeted 
dendrimer cancer therapeutic that demonstrated significant toxicity to tumor cells in vitro.30 The 
targeted dendrimer was cleared for Phase I clinical trials. However, sufficient quantities for a 
clinical trial (kilograms) could not be manufactured consistently, and the trial never moved 
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forward. Much of our work since that time has been aimed at trying to understand the challenges 
in scientific understanding, material processing and scale-up, and clinical translation that arise 
when a small number of ligands is conjugated to a comparatively large number of attachment 
sites.2–10 Note that G5 PAMAM has a theoretical 128 attachment sites (purified G5 PAMAM 
monomer – discussed below – has an average of 93 attachment sites).4 
In general, nanomaterials (particles, polymers, metals, micelles, etc.) have been a popular 
focus of research in biomedical applications, including targeted therapy, imaging, and 
diagnostics.35 The ability to attach multiple copies of ligands allows for enhanced multivalent 
targeting and increased drug payloads. The size of the materials enables them to escape renal 
filtration and facilitates longer blood circulation times, increasing the chances they will reach the 
target tissues36,37 (G5 PAMAM is approximately 5 nm in diameter). The enhanced permeability 
and retention (EPR) effect in leaky tumor vasculature is widely believed to contribute to 
increased therapeutic efficacy. These attractive advantages have continued to make multivalent 
nanomaterials a popular area of biomedical research.26,35,38–48 
1.3.2. Heterogeneity in conjugated nanomaterials 
Translation to the clinic of targeted multivalent nanomaterials has been difficult. Targeted 
nanomaterials that perform well in vitro often cannot be formulated on large scales or exhibit 
unexpected side effects and toxicity when tested in vivo. We postulate that many of these adverse 
effects arise from highly heterogenous mixtures resulting from multiple ligand conjugations.10 
Here, we provide brief context to highlight the scope of the challenge in creating homogenous 
conjugated nanomaterials, but a full accounting of these synthetic and characterization efforts is 
not the focus of this Perspective. Our group has already published extensively on this work, as 
well as our research on characterizing, controlling, and eliminating heterogeneous distributions 
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in this Journal10,49 and others.2–8,11,12 Here, we highlight a case in which we demonstrated in vitro 
the importance of explicit consideration of distributions in biological nanomaterials.9 
The arithmetic mean is the most commonly used parameter for characterizing the number 
of (functional) ligands on a nanomaterial. Usually this value is determined by bulk 
characterization such as NMR spectroscopy or gel permeation chromatography (GPC). The mean 
value fails to convey that the sample actually contains material with a distribution in the number 
of conjugated ligands. The conjugate distribution is binomial if the attachment of ligands is 
identical and independent of previous binding events. If the mean number of conjugated ligands 
is small (e.g., three drugs or four targeting agents) and the ratio of reacted sites to total initial 
number of sites is low compared to the number of attachment sites (e.g., 128 in a G5 PAMAM 
dendrimer), the distribution is Poissonian, 
not Gaussian.50,51 Characterization of 
nanomaterials subjected to sequential 
conjugations (e.g., a targeting agent and 
then a drug) is more complicated still 
because the distributions are 
multiplicative.2,3,10  
Consider a PAMAM dendrimer 
conjugate with a mean of four FA and five 
MTX. Figure 1.1a shows the distribution 
of species if only four FA or five MTX 
were conjugated to the dendrimer. Figure 
1.1b demonstrates the multiplicative effect 
Figure 1.1. a) Poisson distributions of stochastic mixtures of 
dendrimers with an average of four or five ligands. b) Distribution of 
species resulting from sequential conjugation of averages of four then 
five ligands. The chart represents the product of the two distributions. 
The black bar indicates the nominal material with four FA and five 
MTX.  
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of combining two Poisson distributions resulting from stochastic reaction conditions. At most, 3-
4% of the doubly conjugated sample material contains 4 FA and 5 MTX ligands. This does not 
take into account differences in reactivity between the ligands, site-blocking effects with 
increasing number of ligands conjugated, or autocatalysis of the conjugation process. All these 
factors can increase the heterogeneity of the system and further decrease the concentration of the 
mean average material. In many cases, the nominal “average” material may comprise less than 
one percent of the sample. As a result, it is difficult, if not impossible, to accurately assess the 
nanomaterial’s properties and activity, which is particularly important in biological applications. 
If these samples are tested for their therapeutic properties in vitro or in vivo, one or many of the 
species present may contribute to observed effects. Sample heterogeneity greatly complicates 
research on the mechanisms of action 
and side effects, as well as efforts to 
reproduce results and translate 
multivalent nanomaterials to the clinic. 
Heterogeneity in the scaffold 
itself is another factor to be considered. 
Our group has invested significant 
effort in characterizing and removing 
trailing generations and branching 
defects from commercial G5 PAMAM 
(Figure 1.2a).4,5 Our standard operating 
procedure is to purify commercially 
purchased PAMAM to G5 monomer 
a) 
b) c) 
Figure 1.2. Ultra performance liquid chromatography (UPLC) 
chromatograms at 210 nm. a) As-received G5 dendrimer indicates the 
presence of trailing generation impurities as well as aggregtation defects. 
b) as-received acetylated G5 PAMAM (G5-Ac, red trace) contains high 
weight impurities with no ligand that co-elute with G5 monomers 
containing one ligand (G5-L1, green trace) in a conjugated sample (black 
trace). c) Conjugation to an rp-HPLC purified G5 monomer sample (red 
trace) has narrowed peak width and improved peak resolution compared 
to the as-received conjugation (black trace). Adapted and reprinted with 
permission from Polymer 2013, 54, 4126-4133. © 2013 Elsevier Ltd. 
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before using it in conjugation reactions. If 
we do not take this extra step, shifts 
induced on the rp-HPLC column by each 
hydrophobic ligand will not be larger than 
the peak width of the mass distribution of 
the dendrimer (Figure 1.2b,c and Figure 
1.3).4,5,10 Even with G5 PAMAM 
monomer, techniques such as MALDI-
TOF-MS are of limited use because the 
mass shift is much narrower than the 
dendrimer mass distribution itself and the 
shot noise in the mass spectrometry 
measurement is approximately the same as 
the ligand mass. 
This brief background on nanomaterial-ligand distributions illustrates the scope of the 
challenge in designing targeted therapeutic, exclusive to issues such as toxicity and 
biodegradability. In this context, the next subsection discusses work from our group in which we 
demonstrated that the number of ligands determines outcome in vitro, highlighting the critical 
need for appreciation and consideration of heterogeneous distributions. 
1.3.3. Cellular uptake and fluorescence change with dye-dendrimer ratio. 
(Highlighting results from Bioconjugate Chem. 2015, 26, 304–315.)9   
This study was designed to examine the differences in activity between dendrimers with 
precise numbers of dyes and stochastic mixtures of material. In particular, we wanted to assess 
Figure 1.3. HPLC chromatogram of an average conjugate overlaid 
with the predicted distribution for an average of two ligands-per-
particle. Figure adapted and reprinted with permission of 
Biomacromolecules 2014, 15, 3215-3234. © 2014 American 
Chemical Society. 
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the implications of using fluorescence to assess cellular uptake and localization. Understanding 
the interaction between the dendrimer and dye and their response to cellular uptake is critical 
because the dendrimers are used as vectors for oligonucleotides, antibacterial agents and 
drugs.45,48,52–54 Fluorescent dyes are often attached to assess uptake and examine localization 
within the cells.55 
 We prepared three categories of G5 PAMAM dendrimers conjugated to TAMRA dyes: 
1) dendrimers with precisely one to four dyes attached; 2) dendrimers with five or more dyes 
attached; and 3) dendrimer containing a Poisson distribution of dye with an arithmetic mean of 
1.5 (Scheme 1). This last material consisted of mixture of dendrimers with 0, 1, 2, 3, 4, and 5 
dyes at 22%, 34%, 25%, 13%, 5% and 1%, respectively. The solution fluorescence properties 
(intensity and lifetime) of the free dye and each of the six conjugates were examined, in aqueous 
solutions and biologically relevant control solutions (e.g., cell lysate, with albumin, and in blood 
serum). We demonstrated that intensity increased and fluorescence lifetime decreased with 
increasing numbers of dyes (n), but these relationships were not linear. Confocal microscopy 
experiments showed that cellular uptake of the conjugates varied as function of n. It was 
necessary to apply correction factors determined from the solution experiments to accurately 
quantify the extent of uptake. The raw mean fluorescence intensities suggested that uptake 
decreased with n ≥ 2. However, once the corrections were applied, the data showed that cells 
took up more dendrimers with n ≥ 2 than n=1 material – the opposite trend of what the raw data 
indicated. The in vitro fluorescence properties of the stochastic material (n=1.5avg) is more 
complicated. Biodistribution can be affected by hydrophobicity, and material with different 
numbers of ligands can be “separated,” or fractionated, through interactions with 
biomolecules.56–59 Accurate determination of uptake would require knowing the number of 
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conjugated dyes per dendrimer (or hydrophobic ligands per polymer more generally), the 
fluorescent properties of the conjugates, and which species would be preferentially taken up. 
Application of the corrections showed that the mean fluorescence data for the stochastic mixtures 
had errors of at least 3- to 5-fold. Relative brightness in confocal microscopy fluorescence 
images cannot be relied upon to interpret cellular uptake without knowledge of the number of 
dyes per dendrimer. Caution is necessary when quantifying uptake of stochastic mixtures using 
mean fluorescence data.  
a) Stochastic conjugation of TAMRA to G5 PAMAM dendrimer. b) Isolation of G5-NH2-TAMRAn employing semi-preparative 
rp-HPLC. c) Reinjection of combined fractions on analytical rp-UPLC to determine purity. n = 1.5avg (black), 0 (red), 1 (orange), 
2 (yellow), 3 (green), 4 (blue), and 5+ (purple). Reprinted with permission from Bioconjugate Chem. 2015, 26, 304-315. 
 
Scheme 1.1. Synthesis, Isolation, and Characterization of G5-NH2-TAMRAn (n = 0, 1, 2, 3, 4, 5+, 1.5avg) samples 
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 FLIM experiments further emphasize this point. FLIM measurements are generally 
insensitive to changes in intensity but do depend on environmental conditions such as pH, ion 
concentration, and interactions with biomolecules.60 We postulated that changes in lifetime due 
to microenvironment would allow for investigation of internal cellular structures and would be 
small compared to differences in lifetime resulting from variation in the dye to dendrimer ratio. 
We measured fluorescence lifetime both in cells (Figure 1.4a-h) and in biologically relevant 
control environments. In both cases, we found that changes in lifetime were of similar magnitude 
whether the dye ratio was held constant or the environment was held constant. The n=1 and n=5+ 
dendrimers had the longest lifetimes in cells, a phenomenon which was duplicated in control 
Figure 1.4. FLIM images of HEK293A cells incubated for 3 h with (a) PBS only, (b) G5-NH2, (c) G5-NH2-TAMRA1, (d) G5-
NH2-TAMRA2, (e) G5-NH2-TAMRA3, (f) G5-NH2-TAMRA4, (g) G5-NH2-TAMRA5+, and (h) G5-NH2-TAMRA1.5avg. (j) Color 
code for FLIM images. (k) Histograms of fluorescence lifetimes for FLIM images. Images were obtained with a 40× oil 
immersion objective. Reprinted and adapted with permission from Bioconjugate Chem. 2015, 26, 304-315. 
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solutions (Figure 1.4j). Surprisingly, the n=1.5avg mixture had the lowest lifetime and did not 
show any of the high lifetime components observed in the other high lifetime materials, even 
though 34% of the stochastic mixture comprised n=1 dendrimer. These data show that lifetime 
alone cannot be used to interpret biological microenvironments if the precise number of dyes per 
dendrimer is not known, a situation made even more complicated if the sample has been 
biologically fractionated. 
Overall, these results illustrate the complications associated with testing stochastic 
mixtures of conjugated polymers for targeted therapy or for probing intracellular structure. The 
fluorescence properties alone obtained from stochastic mixtures are not reliable measures of 
uptake or localization in a cell. Differences in the distribution from batch to batch may also 
change observed outcomes. Appreciation of the challenges imposed by stochastic mixtures is 
critical for developing new therapies, understanding their biological effects and mechanisms of 
action, and facilitating their translation into the clinic. 
1.4. Distributions in collagen structure 
In the first case study, we discussed distributions in artificial materials (multivalent 
polymer conjugates) generated for biological applications. This second case illustrates the 
inherent nature of material distribution in tissue, specifically collagen in bone. Our knowledge of 
statistical methods for studying distributions from our work on multivalent polymer conjugates 
translated to our research on tissue, but we also developed new methods for characterizing 
distributions of natural nanostructures and microstructures imaged by AFM.  
Type I collagen is the most abundant protein in the body, and therefore, detailed 
understanding of collagen structure is critical for assessing the effectiveness and impact of a 
wide variety of diseases and treatments.61–65 Our group has studied naturally occurring 
 14 
distributions over multiple levels of the hierarchical nature of collagen (Figure 1.5). The work 
presented here summarizes our efforts characterize distributions of repeating nanoscale features 
resulting from the packing of collagen molecules and microstructure and alignment of collagen 
fibers. We explore the relationship between changes to collagen nanostructure and 
microstructure as a function of bone type, diseases (osteoporosis induced by estrogen depletion), 
and treatment. We emphasize how macroscopic analysis methods fail to detect changes in 
collagen architecture that contribute to the inherent heterogeneity in collagenous tissue. 
1.4.1. A brief introduction to collagen 
 Type I collagen forms the structural scaffold bones, dentin, skin, and tendon.61–65 As 
illustrated in Figure 1.5, type I collagen assembles into hierarchical structures, forming 
microfibrils, fibrils, fibers or bundles, and tissues.14–19,64,66–76 Various models have been 
proposed for fibril assembly and the origin of D-spacing. In 1963, the Hodge Petruska model 
depicted the collagen molecules parallel to 
each other but staggered, resulting in a 
repeating gap/overlap pattern that gave 
rise to the single 67 nm D-spacing value.66 
According to the Orgel model for fibril 
assembly, five microfibrils (each 
composed of three collagen molecules 
twisted in an α-helix) are packed quasi-
hexagonally in the equatorial plane and 
supertwisted axially.67 This is a 3D model 
for fibril assembly based on XRD studies.  
Figure 1.5. Hierarchical structure of collagen structures in tendon, 
skin, and bone. The AFM images show the D-spacing resulting from 
the parallel staggered alignment of the collagen microfibirls. Adapted 
and reprinted with permission from ACS Nano 2012, 6, 9503-9514. © 
2012 American Chemical Society. 
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Both the Hodge Petruska and Orgel models require a single value for the D-spacing of type I 
collagen, which is commonly reported as 67 nm from XRD, EM, or computational models of the 
collagen molecule. Each of these techniques provide an average representation of the structure.  
Conversely, our group has focused on a fibril-by-fibril approach to collagen analysis. 
Using AFM, we acquired images across heterogenous tissue surfaces (bone, skin, tendon, and 
tail from sheep, rats, rabbits, and monkeys) to obtain a representative data sets containing 
thousands of fibrils.13–20 We then quantified the D-spacing on a fibril-by-fibril basis using two 
dimensional fast Fourier transform (2D FFT) analysis. The inclusion of thousands of fibrils 
allowed for statistically robust analyses. We have demonstrated non-Gaussian distributions in 
collagen nanomorphology, with D-spacing measured from 59 nm to 75 nm.13–20 We found that, 
in general, there is very little variation in D-spacings within bundles (groups of aligned fibrils) 
but large variations between bundles.18 Existing models of collagen structure cannot explain 
these D-spacing distributions, but a recent study documented changes in collagen structure at all 
levels of hierarchy, including D-spacing, as a function of disease.65 Nevertheless, the formation 
and assembly of collagen fibrils affect the properties of the tissue. Research is still ongoing to 
understanding the physiological processes, mechanical stresses, and diseases that affect the 
distributions of D-spacings in tissues. 
1.4.2. Fibril-by-fibril and multimicron approaches 
(Highlighting results from BoneKEy Rep. 2015, 4, 69720 and Bone Reports 2016, 5, 243–251.21)   
In more recent work, we have developed methods for hand-coding the alignment of 
collagen fibrils. (Figure 1.6).20  We documented surface heterogeneity and changes in collagen 
microstructure that would not be reflected in average values incorporating measurements from 
many fibrils over a larger area of the tissue surface. 
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Here, we highlight a case in which microstructures changed as a function of disease – estrogen 
depletion modeling osteoporosis – and treatment with three different drugs. In sum, the study 
involved analyzing a total of 5,673 fibrils from 84 rabbits split into seven treatment groups.20,21 
After ovariectomy-induced estrogen depletion, the osteoporosis drugs were given to the rabbits 
as a preventive, not as treatment. Note that 
all the imaging and analysis was carried 
out blind to the identity of the samples. 
Microstructures in the images were hand-
coded as bundles if 3-15 fibrils aligned in 
the same direction and were associated 
with one another and sheets if more than 
20 fibrils aligned in the same direction and 
continuous with surrounding bone. 
Together, bundles and sheets were 
considered to contain parallel fibrils and 
non-aligned fibrils were oblique (Figure 
1.6). This coding scheme captured at least 
95% of all the measured fibrils.  
Importantly, changes to collagen microstructures were observed in cortical bone 
(compact bone that makes up the long bones, e.g., femur) but not in trabecular bone (“spongey” 
bone that remodels faster than cortical bone, e.g., the interior of vertebrae) (Figure 1.7). In the 
control cortical bone, estrogen depletion caused a statistically significant change in the 
proportions of parallel and oblique fibrils: incidence of parallel fibrils decreased and oblique 
Figure 1.6. AFM images illustrating Parallel and Oblique regions of 
Type I collagen fibrils. a) Parallel region showing multiple aligned 
fibrils (yellow arrows); b) Oblique region showing multiple fibrils 
with varying alignment (yellow arrows). Adapted and reprinted with 
permission from BoneKEy Reports 2015, 4, 697. 
Figure 1.7. Examples of cortical and trabecular bone. Images 
courtesy of Meagan Cauble. 
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fibrils increased. In the treated 
animals, the two drugs currently in 
the clinic partially prevented this 
change, while the experimental 
drug fully prevented it. 
In both trabecular and 
cortical bone, the mean D-spacing 
value and the overall D-spacing 
distributions did not change with 
treatment. In bundles, no 
signification differences existed 
between the groups (Figure 1.8). However, treatment induced significant animal-to-animal 
variability in bundle D-spacing in trabecular bone. That is, the D-spacing means and 
distributions in trabecular bone remained the same, but D-spacings in trabecular bundles were 
different from animal-to-animal. The control rabbits displayed zero variability (including 
incorporation of a random effect for the animal) in their bundle distributions, ovariectomized 
rabbits had non-significant animal-to-animal variability, and the two treatment groups both had 
significant variability. The phenomenon was not observed in cortical bone. As trabecular bone is 
responsible for bone growth and remodeling, changes to trabecular collagen structure is of 
consequence. 
More generally, these results provide important insight on the range of reactions to 
therapies. The differences in response and outcome will likely be even more pronounced in more 
genetically diverse populations, e.g., humans. These trends would have been missed if 
Figure 1.8. Boxplots of the D-spacing distribution of the collagen fibrils located 
in trabecular bundles obtained for sham, OVX+Vehicle (VEH), OVX+ALN, 
and OVX+CatKI groups. There are significant differences in the degree of 
animal-to-animal variability across treatments in trabecular bone (p=0.02, 
likelihood ratio Chi square test). The animal-to-animal variance for the 
OVX+Veh. Treatment was marginally significant (p=0.074). Both drug 
treatments introduced significant animal-to-animal variability in the bundle D-
spacing (p b 0.01). Reprinted and adapted with permission from Bone Reports 
2016, 5, 243-251. ©2016 The Authors. 
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employing techniques that only capture the arithmetic mean of D-spacing values average of 
microns to millimeters (such as XRD) – all values would have been the same and no information 
regarding the drug effects would have been obtained.  
Given the time and labor investment necessary for hand-coding fibril alignment, but we 
sought ways to speed up and streamline the process. With collaborators, we developed an auto-
correlation approach to recognize patterns and quantitatively assess the degree of fibril alignment 
(Figure 1.9).21 The full image level analysis (Figure 1.9) generates vector fields that 
mathematically approximate collagen fibril alignment. These vector fields were used to compute 
an information-theoretic entropy value: a fibril alignment parameter (FAP). We applied this 
approach to assessing fibril alignment in cortical and trabecular 
bone in estrogen depleted and treated animals. FAP distributions 
showed trabecular fibril alignment shifting towards cortical FAP 
distributions after ovariectomy. In cortical bone, estrogen 
depletion affected the formation of bundles and sheets. The three 
drugs examined affected alignment in cortical and trabecular 
bone differently. In one case, the drug moved FAP distributions 
in opposite directions in cortical and trabecular bone. The ability 
to quickly obtain fibril alignment information across a 
multimicron scale is important. Together D-spacing analysis, 
hand coding of microstructures, and the FAP distributions 
provide data on multiple levels of the collagen hierarchical 
structures, which is critical for understanding and treating 
disease.  
Figure 1.9. AFM images of collagen, 
with arrows showing local alignment of 
collagen patches. The alignment was 
determined using an autocorrelation-
based method. The arrow lengths are 
scaled to show the degree of alignment. 
a) Collagen with a substantial 
concentration of parallel fibrils. b) 
Collagen with a with a substantial 
concentration of oblique fibrils. 
Reprinted and adapted with permission 
from Bone Reports 2016, 5, 243-251. 
©2016 The Authors. 
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1.4.3. Implications for treatment of bone diseases 
The research summarized in this section demonstrates the importance of studying 
distributions in multiple levels of the hierarchical structure in bone and other tissues. We 
emphasize how characterization of collagen structure distributions by AFM and image analysis 
should inform research on disease mechanisms and treatments. Because collagen is so abundant 
in the body, greater scientific understanding of the relationship between changes in multiple 
levels of collagen hierarchical structure and observed physiological outcomes would streamline 
the development of new therapies for a wide variety of diseases. Research efforts should be 
focused on creating methods of accelerating molecular and fibril level analysis while ensuring 
sampling is representative of the heterogenous tissue surface. 
1.5. Distributions in natural nanoparticles 
The previous two sections focused on characterizations of material distributions resulting 
from a laboratory synthesis, tissue biosynthesis, and tissue disease and drug treatment. Our more 
recent efforts combined aspects of this previous work on synthetic and natural materials: we 
investigated the relationship between distribution and function in intentionally created and 
controlled nanoparticles made of endogenous serum proteins. This research applies the analytical 
methods and statistical expertise our group has developed through our earlier research, described 
above. Specifically, we leveraged our experience making and characterizing dendrimer 
conjugates with precise ligand ratios and translated the AFM imaging and statistical methods 
developed in our collagen research to study distributions in the protein nanoparticles. Our 
overarching goal was to understand the role serum folate binding protein (FBP) plays in folic 
acid (FA) and antifolate (aFA) drug trafficking. We also hypothesized that the protein itself 
could be used as a targeted vector, eliminating many of the challenges associated with stochastic 
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or precisely-defined conjugated polymers. Our conclusions highlight the need of a molecular 
approach to nanoparticle characterization in biological systems and the importance of employing 
complementary analytical methods. 
1.5.1. Folate binding protein nanoparticles 
(Highlighting results from Chin. Chem. Lett. 2015, 26, 426-43077 and Nanoscale 2017, 9, 2603-
2615.)11  
The structure and function of serum FBP have been extensively detailed by ourselves11–
13,49,77 and others.78–93 For the purposes of this Perspective, it is important to note that FBP is 
derived from membrane bound folate receptors (FRs) and plays a critical role in the complex, 
multi-protein process of cellular uptake of FA and in embryonic development.90–100 FRs bind 
strongly to FA (nanomolar dissociation constant) and are overexpressed on many types of human 
cancers because rapidly dividing cancer cells require high levels of FA for DNA synthesis.101–104 
As a result, researchers, including ourselves as described in the ligand conjugation section above, 
have extensively explored FA as a targeting ligand.105,106,99,100,107–111,27,49,11,6,22 Many of these 
conjugated targeted drug delivery agents suffer from the same heterogenous distributions 
discussed above, but upon injection they also interact with serum FBP before ever reaching the 
target cells. FA and the antifolate (aFA) drug methotrexate (MTX) have the same binding 
affinity for serum FBP as they do for FRs.104 Additionally, the binding of FA or MTX to FBP 
triggers FBP aggregation and protein corona formation.11–13,49 Protein coronas often define 
biological identity, so the trafficking, uptake, and therapeutic efficacy of these materials are 
dictated by FBP before they reach the targeted tumor cells.112–118 FA-targeted therapies in vivo are 
likely to operate by different mechanisms than those predicted by in vitro experiments in the 
absence of soluble FBP, complicating interpretation of results and clinical translation.  
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 Our first goal was to 
develop a better understanding of 
the interactions between FBP and 
small molecules (FA and aFAs). 
Earlier studies of serum FBP were 
limited by the detection limits of 
the bulk analytical techniques use 
such as DLS, GPC, IR 
spectroscopy.78–86 Conversely, our attempts to use techniques like DLS were inhibited by the 
nanomolar protein concentrations required to reflect biological concentrations, the low scattering 
cross section of the nanoparticles, and biases towards detecting larger particle aggregates. 
Instead, we characterized FBP aggregation on a particle-by-particle basis using AFM (Figure 
1.10).11 This enabled investigation of FBP aggregation at physiologically and therapeutically 
relevant concentrations. In many ways, our approach was very similar to the fibril-by-fibril 
analysis with collagen, and many of the same image analysis techniques and statistical methods 
were used. The large number of particles imaged allowed for statistically robust analyses of the 
volume distributions. With hundreds to thousands of FBP nanoparticles (FBPNP) analyzed in 
each image, examining the distribution of particle volumes (as opposed to primarily relying on 
the mean volumes) proved critical in developing novel hypotheses on the biotrafficking of FA, 
MTX, and leucovorin (LEUC, a vitamer of FA).   
We showed that at physiological blood serum concentrations of FBP (2 nM), unligated 
FBP aggregates into nanoparticles comprised of approximately 6-8 proteins. Interestingly, this 
agreed well with the reported 8-mer crystal structure of FR-α from which the majority of serum 
Figure 1.10. AFM images of FBP nanoparticles with folic acid, methotrexate, 
or leucovorin. a-c) FBP and ligand present at 2 nM. d) FA at 20 nM, FBP at 2 
nM. e) MTX at 1,000 nM, FBP at 2 nM. f) LEUC at 1,000 nM, FBP at 2 nM 
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FBP is derived.103 When FA was added to FBP at concentrations equivalent to FA deficiency in 
human adults, FBP aggregated into a bimodal distribution: nanoparticles of approximately four 
FBP and 600 FBP (Figure 10a). The non-uniform volume distribution of FBPNP at low FA 
concentrations is consistent with previously reported FA-induced apo-holo FBP aggregation.80 
The change in FBP volume distribution compared to healthy levels of FA suggest altered 
trafficking, biodistribution, and uptake processes that may be associated with symptoms of folate 
deficiency. Low concentrations of MTX resulted in larger nanoparticles (approximately 30 FBP), 
and low levels of LEUC completely inhibited aggregation (Figure 10b,c). When the 
concentration was increased to physiologically healthy or therapeutically relevant levels of FA, 
MTX, or LEUC the FBPNP volume distribution became more monodisperse with 6-8 FBP per 
nanoparticle (Figure 10d-f), again the same as the number of proteins crystal structure.  
Most surprisingly, our analyses of FBPNP volume distributions presented new 
hypotheses on the trafficking of LEUC and why it can be used as a FA rescue agent. Following 
treatment with MTX, LEUC is administered to mitigate toxicity caused by inhibition of FA 
activity. FA will not provide therapeutic benefit – LEUC must be used instead. The reason for 
this and the mechanism of action of LEUC has not been not well understood. Most investigations 
of LEUC have focused at the cellular level, not considering the role of intravenous FBP. 
Examination of the FBPNP volume distributions showed that FBPNP in the presence of 
high (therapeutic) doses of FBP was nearly identical to FBPNP containing therapeutic doses of 
MTX (Figure 1.11). The body would likely traffic both sets of FBPNP through the same 
biological pathways,119,120 preventing FA from acting as a rescue agent, especially because FA 
and MTX are believed to enter cells via different uptake pathways, potentially triggered by the 
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FBP aggregation state. Conversely, FBPNP with 
high doses of LEUC and physiological levels of 
FA had volume distributions that were not 
statistically different. This suggests LEUC is 
trafficked to cells through the same pathways as 
FA and can facilitate FA rescue by bypassing the 
MTX uptake pathway. These results provided the 
first hypothesis on the perplexing observation that 
FA itself cannot provide a therapeutic FA rescue 
benefit, requiring LEUC to be used instead. Had 
we only relied upon bulk measurements and mean 
size values in the data analysis, these connections 
likely would have been missed. The possible role of FBP particle size is particular interesting in 
light of binary gate “lock and key” or “switch” analogies often employed when developing 
biological models of action. If particulate size is a factor in determining uptake rates, this 
suggests the analogy of a fuzzy logic gate is more appropriate for this case as opposed to a binary 
logic gate. 
1.5.2. Conjugation dependent interactions with folate binding protein 
(Highlighting results from Biomacromolecules 2016, 17, 922-92749 and Bioconjugate Chem. 
2017, 28, 2350-2360.12) 
Here, we bring this Perspective full circle to where we started with targeted polymer 
conjugate and illustrate how we applied lessons from all the research we have highlighted to this 
point. As we discussed above in detail, sample heterogeneity has plagued the translation into the 
Figure 1.11. Cumulative density function (CDF) plots of 
selected the volumes FA-, MTX-, and LEUC-containing 
FBP nanoparticles. The similarity of the nanoparticle 
volume distributions was assessed using K–S statistics. The 
K–S testing showed the volume distributions of FBP 
nanoparticles formed from 20 nM FA + 2 nM FBP and 
1000 nM LEUC + 2 nM FBP are not statistically different 
(p = 0.310). All other nanoparticle volume distributions 
were shown to be statistically different when evaluated 
with the K–S test. We hypothesize LEUC is effective as a 
folic acid rescue agent because the FBP nanoparticles 
formed at therapeutic concentrations of LEUC have the 
same volume distribution as the nanoparticles formed at 
healthy FA concentrations (20 nM). 
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clinic of FA-targeted polymer therapeutics.2–10 Our particle-by-particle work on the interactions 
between small molecule (FA, MTX, and LEUC) with FBP11,77 (as well as previous research with 
FA-conjugates and FBP6,11,22,27,49,110,111) informed our guiding hypothesis that the identity of the 
conjugate itself could dictate the interaction with serum proteins, notably FBP. The combination 
of conjugation heterogeneity and unnatural serum protein aggregation processes likely leads to 
unexpected biological outcomes and failure in clinical translation efforts. The AFM and image 
analysis methods originally developed for our investigations of natural collagen distributions 
again proved critical in assessing FBP nanoparticle distributions. In contrast to our small 
molecule-FBP and collagen work, however, we used molecular level approaches in combination 
with solution fluorescence spectroscopy. The results discussed below demonstrate the risk in 
interpreting molecular interactions and structural information from only bulk techniques 
reporting averaged measurements. FBPNP distributions were dictated by both the chemical 
identity of the polymer scaffold and the conjugation method, but fluorescence spectroscopy 
experiments partially masked nuances in these results. The role both factors play in protein 
corona formation and ultimate fate of the targeted conjugate is often under appreciated. 
Following a similar approach as we used on our studies of small molecule-FBP 
interactions, we directed our efforts towards characterizing the FA-conjugate-FBP interactions. 
We compared four FA-polymer conjugates: 1) G5Ac-COG-FA1.0; 2) G5Ac-FA4(avg); and 3) 
poly(ethylene glycol)-FA (PEG-FA) of two different polymer chain lengths (Figure 1.12). The 
first – G5Ac-FA4(avg) was a stochastic mixture with a mean of four FA conjugated to the 
dendrimer (Figure 1.12a). Based on the Poisson distribution, approximately 20% of the samples 
had four FA conjugated (Figure 1.12b). The second conjugate, G5Ac-COG-FA1.0 had precisely 
one FA conjugated through a cyclooctyne glycolic acid-amino acid linker (Figure 1.12b). This 
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conjugate was synthesized and isolated by rp-HPLC methods similar to those described above.6–9 
The PEG-FA conjugates (Figure 1.12d) were commercially available. Chain lengths of 2 kDa 
and 30 kDA were used in this study. NMR spectroscopy was used to quantify the concentration 
of active FA-conjugated material (PEG2kDa-FA ~25%; PEG30kDa-FA ~15%).  
Tryptophan fluorescence quenching experiments – carried out in solution at protein 
concentrations an order of magnitude higher than physiological levels (58 nM vs. 2 nM) – 
indicated that free FA and G5Ac-FA4(avg) induced similar changes in FBP conformation upon 
binding (Figure 1.13). This effect was observed whether the conjugate was added to an excess of 
FBP (Figure 1.13a) or FBP was added to an excess of (Figure 1.13b). The data also showed that 
Figure 1.12. Representations of polymer-conjugate materials. For the PAMAM dendrimers, all terminal amines are acetylated 
following ligand conjugation. a) Folic acid (FA, red) conjugated directly to G5 PAMAM (black), producing G5Ac-FA4(avg); b) 
Distribution resulting from a stochastic conjugation with an average of 4 ligands and 93 arms;  c) FA (red) conjugated to G5 
PAMAM (black) via a cyclooctyne glycolic acid (COG)-amino acid linker (blue), producing G5Ac-COG-FA1.0; d) FA (red) 
conjugated to poly(ethylene glycol) (black). Adapted and reprinted with permission from Bioconjugate Chem. 2017, 28, 2350-
2360.  
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any amount of FA (free or conjugated) 
was sufficient to induce conformational 
changes and subsequent fluorescence 
quenching throughout the entire protein 
population. G5Ac-COG-FA1.0 resulted in 
significantly larger protein conformational 
changes, even in substoichiometric 
amounts of the conjugate. It bound 
essentially irreversibly to FBP and could 
not be displaced from the binding pocket 
by large excesses of free FA.49 These data 
agreed with previous experiments 
demonstrating the same binding effect to 
surface-anchored FBP.6 The PEG 
conjugates resulted in very little 
fluorescence quenching, likely due to the 
long polymer chain blocking access to the 
binding pocket.49,12 
Particle-by-particle analysis by 
AFM revealed important distinctions in 
the conjugate-protein interactions. The 
fluorescence data indicated free FA and G5Ac-FA4(avg) had similar binding interactions with 
FBPNP, but the FBPNP volume distributions were significantly different. FBPNP containing 
Figure 1.13. a) Tryptophan fluorescence quenching upon addition of 
free FA or FA conjugate to FBP. FBP concentration was 58 nM. Note 
the strong fluorescence quenching at approximately 0.1 equivalents 
of G5Ac-COG-FA1.0. b) Titration of FBP into FA (50 nM) and G5Ac-
FA polymer conjugates (50 nM). FA materials produced 
conformational changes throughout the protein population. For both 
experiments, excitation = 280 nm, emission = 342 nm; pH = 7.4 (1x 
PBS). Panel (b) reprinted and adapted with permission from 
Bioconjugate Chem. 2017, 28, 2350-2360. 
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free FA were smaller than unligated 
FBPNP (Figure 1.14). Conversely, upon 
binding to G5Ac-FA4(avg), FBP rearranged 
into substantially larger nanoparticles. 
Consistent with the fluorescence data, 
G5Ac-COG-FA1.0 resulted in very large 
aggregates with each conjugate inducing 
conformational changes and aggregation 
in more than one protein (Figure 1.15). 
This agrees will with our fluorescence data 
in Figure 13 demonstrating even with an 
excess of FBP, G5Ac-COG-FA1.0 induced conformational changes throughout the protein 
population, resulting in fluorescence quenching. We postulate the long COG linker facilitates the 
strong binding interaction and FBP conformational changes, a phenomenon which we cover 
extensively elsewhere. PEG conjugates of all chain lengths disrupted FBP aggregation and no 
nanoparticles were observed. 
 In combination, these results illustrate both the risk of relying solely on bulk techniques 
to characterize these systems and the challenges of translating FA-targeted therapies into the 
clinic. The underlying assumption of FA-targeted therapies is that they are trafficked in the body 
like FA. That is, they should work because they go to cells and tissues with enhanced uptake of 
FA. The fluorescence spectroscopy data alone suggested that G5Ac-FA4(avg) would likely have 
been a good candidate for a targeted therapeutic because they induced the same degree of 
conformational change in FBP. However, as shown in Figure 14, the opposite trends in 
Figure 1.14. Cumulative density function (CDF) plots of the 
measured volume distributions of 2 nM FBP, 20 nM FA + 2 nM FBP, 
and G5Ac-FA4(avg) + FBP nanoparticles. The similarity of the 
nanoparticle volume distributions was assessed using K−S statistics, 
which showed all nanoparticle volume distributions to be statistically 
different. Analysis of the volume distributions indicated that FBP 
nanoparticle size increases with increasing G5Ac-FA4(avg) 
concentration. Reprinted and adapted with permission from 
Bioconjugate Chem. 2017, 28, 2350-2360. 
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nanoparticle size upon ligand binding 
make it likely free FA and G5Ac-FA4(avg) 
would not follow the same trafficking and 
uptake pathways. Along the same lines, 
the very large aggregates with G5Ac-COG-
FA1.0 would be expected to exhibit 
different behavior in vivo. In contrast to 
the dendrimer conjugates, the AFM data 
showed no nanoparticles were present in samples containing PEG. The fluorescence 
spectroscopy data suggested that a weaker binding interaction between PEG-FA and FBP, but 
that alone does not demonstrate the extent of disruption in the system. PEG is the most common 
polymer in biomedical applications and is used to inhibit the formation of deleterious protein 
coronas on targeted conjugates.116,121 It is therefore not surprising that PEG disrupted already 
existing FBPNP. PEG-containing FA-targeted conjugates likely would not follow the 
biotrafficking pathways of FA, and the inclusion of the polymer in rationally designed targeted 
vectors warrants consideration.  
1.5.3. Implications for targeted drug delivery 
Protein aggregation is often considered to be an indication of disease or disfunction, such 
as -amyloid formation associated with Alzheimer’s disease.122 However, decade’s worth of 
FBP aggregation data, including ours, indicate that FBP aggregation is a healthy and natural 
process and that understanding the changes in particle aggregate distribution as  a function of 
changes in conditions is critical to understanding and controlling function.11,78–86 FBP plays a 
central role in cellular uptake of FA and is essential for healthy embryonic development. In this 
Figure 1.15. AFM images demonstrating the differences in 
aggregation when FBP is exposed to G5Ac-FA4(avg) and G5Ac-COG-
FA1.0. Images reprinted with permission from Bioconjugate Chem. 
2017, 28, 2350-2360. 
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context, we hypothesized that pre-binding MTX to FBP before injecting it would enhance 
targeting of tumor cells and decrease off-target uptake. We carried out an in vivo experiment 
treating mice bearing xenograft tumors with MTX pre-bound to FBP.123 Surprisingly, FBP alone 
was observed to dramatically inhibit tumor growth as compared to saline control and free MTX. 
In this case, there is no need to include a toxic chemotherapeutic such as MTX. This suggests 
that solely by manipulating the concentration level of endogenous FPB, a wide range of tumor 
types could be treated. We hypothesize the excess unbound FBP resulted in folate starvation of 
the tumors. The groups treated with MTX and FBP also showed inhibition of tumor growth, but 
toxicity increased with FBP concentration. It is likely that instead of specifically targeting the 
cancer cells, FBP facilitated widespread uptake of MTX, resulting in systemic toxicity. Future 
studies will investigate the therapeutic efficacy of FBP over a wide range of concentrations, as 
well as exploring how FBP-induced folate starvation could be synergistic with other therapies. 
This promising research on using an endogenous protein alone without a toxic small molecule is 
a completely novel approach in this field. 
As demonstrated through the research presented here, heterogeneity and serum protein 
interactions have proven to be two significant obstacles to clinical translation or targeted 
therapeutics. Researchers may turn more towards protein-based therapies to mitigate the 
challenges, in addition to avoiding problems of immunogenicity and biodegradability. Protein 
carriers also mitigate manufacturing, immunogenicity, and biodegradability problems associated 
with synthetic drug delivery vectors. One of the powerful achievements in drug delivery over the 
last decade is Abraxane, an albumin-bound form of paclitaxel.124–128 Researchers recently 
reported a cancer vaccine using albumin as a carrier showing great promise in in vivo trials.129 
Many more albumin-based approaches are currently in clinical trials. Taking advantage of 
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natural and health protein aggregation processes may indeed provide a key to avoiding the 
challenges of heterogeneous distributions in synthetic and natural drug delivery materials. 
1.6. Conclusions and future outlook 
In this Perspective we examined almost two decades of our research team’s work to 
characterize heterogeneous distributions in multivalent polymers, collagen hierarchical structure, 
and serum protein nanoparticles. By tracing through the history of our work, we illustrated how 
our most recent work on protein nanoparticles leveraged all our collaborative knowledge and 
expertise on distributions. We showed how our methods were widely applicable and translated 
between research projects characterizing distributions created in both synthetic materials and 
inherently present in natural tissues. In each of the research cases, we emphasized how our 
unique molecular level analytical and statistical approaches were critical for interpreting data, 
understanding biological results, and facilitating development of new insights and hypotheses 
that would be missed through bulk measurements. As a set, the examples and discussion 
included here are intended to make a convincing case for the importance of a molecular level 
view of biological materials. We encourage investment in the development of methods to expand 
scientific understanding of the interplay between molecular level distributions and structural 
variation and function.  
 Relatively new techniques are starting to bridge the gap between bulk analytical methods 
and molecular level analysis. For example, combined AFM and IR spectroscopy allows for IR 
spectra to be acquired with as high as approximately 10 nm lateral resolution (Figure 1.16). In 
our current research efforts, we are employing AFM-IR to examine changes in mineral-collagen 
ratio throughout bone as a function of disease and treatment; identify microdamage that leads to 
failure in anterior cruciate ligaments; investigate uptake of nanoplastics into mussels; study the 
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chemical composition of atmospheric particles; and characterize the composition of a variety of 
composite polymers. As techniques that enable nanoscale, molecular, or chemical identity level 
characterization (e.g., AFM-IR, 
AFM-mass spectrometry, and 
single particle tracking) become 
more widely available, the broader 
research community will have 
more capacity to address the 
challenges of heterogeneity and 
distributions presented here. 
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2.1. Abstract 
Serum proteins represent an important class of drug and imaging agent delivery vectors. 
In this mini-review, key advantages of using serum proteins are discussed, followed by the 
particular advantages and challenges associated with employing soluble folate binding protein. In 
particular, approaches employing drugs that target folate metabolism are reviewed. Additionally, 
the slow-onset, tight-binding interaction of folate with folate binding protein and the relationship 
to a natural oligomerization mechanism is discussed. These unique aspects of folate binding 
protein suggest interesting applications for the protein as a vector for further drug and imaging 
agent development. 
2.2. Introduction  
In the body, drugs are transported in the blood where they can encounter over 100,000 
proteins. The vast majority of these proteins are albumin (55%) and immunoglobulins (38%), 
such as IgG, IgA, and IgM, with smaller amounts of lipoproteins and transferrin.1 All drugs or 
drug delivery scaffolds come into contact with these proteins, and the complexes formed often 
dominate the observed pharmacokinetics and biodistribution. These protein–drug interactions 
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have long played a significant role in small molecule drug design and are now recognized to 
greatly complicate the development of new drug delivery scaffolds in the field of nanomedicine.2 
One solution to this challenge is the judicious selection of an endogenous serum protein as the 
delivery scaffold for a given drug, imaging agent, or theranostic combining therapy and 
imaging.3 Of the serum proteins, albumin has garnered the most attention and resulted in clinical 
applications.4–6 There are currently seven clinically approved drugs or imaging agents employing 
the albumin scaffold, with applications including the treatment of metastatic breast cancer 
(Abraxane1) and diabetes (Levemir®, Victoza®) and imaging of cardiovascular and cerebral 
circulation ( 99mTc-Albures, Vasovist®) and lymph nodes (99mTc-Nanocol). Albumin is currently 
being explored for a variety of other applications, including theranostics [7,8]. Transferrin has 
also been explored for drug and imaging agent delivery; however, transferrin-based systems have 
yet to reach the clinic.9 Both albumin (66.5 kDa) and transferrin (78 kDa) have molecular 
weights above the renal clearance threshold, contributing to long circulation times. Both proteins 
accumulate in malignant and inflamed tissue due to the enhanced permeation and retention 
(EPR) effect and internalize into cells via receptor specific endocytosis processes. These 
favorable properties, and the successes noted above, have prompted extensive research into both 
of these proteins, with over 4,000 papers published to date. 
 Despite these successes, the toxicity of small molecule cancer therapeutics remains a 
significant challenge. Off-target dosing (uptake of the cancer therapeutic by healthy cells as well 
as the tumor cells) leads to a wide range of side effects, sometimes necessitating sub-optimal 
dosing, which can lead to worse outcomes for patients. To address this problem, researchers have 
worked to develop targeted therapeutics that deliver drug to tumor cells while avoiding healthy 
cells. Folic acid (FA) is a widely studied targeting ligand for both molecular and nanoscale 
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cancer therapies because folate receptors (FRs) are overexpressed on the surfaces of the cancer 
cell membranes10,11 Folate is necessary for thymidine biosynthesis, and hence for de-novo DNA 
biosynthesis, and so rapidly dividing cancer cells increase the concentration of FRs on plasma 
membrane surfaces. To date, seven  FA-targeted cancer therapeutics have advanced to clinical 
trials, but none have progressed to full clinical development. Even with targeted drug delivery 
agents, dose-limiting toxicity due to uptake by healthy cells remains a problem. Additionally, the 
expression of FRs on the surfaces of tumor cells is highly variable both from individual to 
individual and within a given cancer type. The folate metabolic pathway is also the target for 
inhibitors of dihydrofolate reductase (DHFR).12–15 Clinically approved DHFR-inhibitor drugs are 
used to treat a variety of cancers and autoimmune diseases (methotrexate, pemetrexed), bacterial 
infections (trimetrexate, piritrexim), and malaria (pyrimethamine). 
 Can the substantial advantages of employing an endogenous serum protein for drug 
delivery be combined with drugs designed to target and inhibit the folate metabolic pathway? 
This minireview discusses recent advances in the understanding of soluble folate binding protein 
(FBP) and possible applications of this protein for drug delivery. First, we review the structure 
and hypothesized functions for FBP, including possible roles in folate metabolism. The 
approaches for isolation of the protein are also discussed. Second, we examine recent data 
regarding the detailed binding mechanism of FBP with FA, FA-conjugates, and antifolate (aFA)-
conjugates. Third, we discuss the outlook for folate binding protein as a transport agent for 
therapeutics and imaging agents, including advantages and challenges of this approach. 
2.3. The structure, function, and isolation of folate binding protein 
Folate binding protein (FBP) is a 30 kDa glycoprotein containing 222 amino acids 
present in 1–2 nmol/L concentrations in human serum and other body fluids and 100 nmol/L 
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concentrations in milk.16–20 The functions of FBP in the 
body are not well understood, but it has been hypothesized 
to regulate the trafficking and homeostasis of folate, protect 
against folate degradation, and shield against bacterial 
utilization of folate. FBP is closely related to two isoforms 
of membrane-bound FRs: FRa and FR-b, both of which are 
connected to plasma cell membranes via glycosylphosphatidylinositol (GPI) anchors.17,21 A third 
isoform, FR-g, is a secreted protein and lacks the signal for modification with a GPI anchor. 
Soluble FBP inherently lacks a GPI modification. X-ray crystal structures of the FA-bound 
protein were recently reported (Figure 2.1).14,15 FBP is obtained on the gram scale by purification 
of whey protein.20,22–26, although engineered proteins have been expressed in Chinese Hamster 
Ovary (CHO) cells.14  
Glycosylation of the protein is not required for the FA-binding activity of soluble FBP.27–
29 The quaternary structure of FBP changes as a function of FA-binding, consistent with a slow-
onset, tight-binding interaction. At micromolar concentrations, the binding of FA to FBP also 
induces a self-assembly/aggregation process that has been examined in vitro.30,31 Interestingly, 
the aggregation of FR-a in the cell membrane has been shown to be an integral part of FA-
binding and cellular internalization.32,33 Recently, it was discovered that FBP internalizes into 
cells via a megalin-mediated endocytosis pathway,34 suggesting the possibility of megalin 
playing a direct role in folate metabolism. This observation is particularly interesting for the use 
of FBP in chemotherapeutic targeting. 
Figure 2.1. The X-ray structure of folate 
receptor α with folic acid in the binding site. 
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2.4. The binding mechanism of folic acid to folate binding protein 
Folic acid binds to FBP via a slow-onset, tight-binding mechanism (Equation 1).35 The 
initial FBP interaction with folic acid is followed by a reorganization of the protein structure, 
leading to the observed nanomolar FA–FBP binding constant. The induction of structural change 
in the FBP upon binding FA is characterized by quenching of the inherent tryptophan 
fluorescence in FBP [30,36]. The change in structure is hypothesized to lead to reduction of the 
number hydrophobic residues on the protein surface, resulting in a FA-ligand induced 
aggregation of the protein.37,38  
 
At pH 7.4, the degree of aggregation (n) is dependent on FBP concentration. As measured by 
gel-filtration, at concentrations of 1–10 nmol/L, FBP–FA is monomeric, whereas a tetramer 
(FBP–FA)4 and a nonamer (FBP–FA)9, were observed for concentrations of 1.0 mmol/L and 10 
mmol/L, respectively. Ultracentrifugation experiments indicated that oligomers as high as (FBP–
FA)30 were present for 100 mmol/L solutions of FBP. High performance liquid chromatography 
(HPLC) and sodium dodecyl sulfate-poly(acrylamide) gel electrophoresis (SDS–PAGE) both 
indicate the formation of three new species upon FA binding to FBP.39 The HPLC studies are 
particularly interesting as they provide a ready method for quantifying the relative amounts of 
each species present in solution. More work is needed to understand how these three species 
relate to tetramers, nonamers, and other species reported in the fluorescence, gel-filtration, and 
ultracentrifugation studies. These data indicate that a monomer structure is anticipated to be the 
dominant form of the protein in most biological tissues where the FBP concentration is 1–2 
nmol/L; however, these reported oligomerization properties may play an important role in the 
binding and aggregation of FR-a in the cell membrane prior to internalization. A stopped-flow 
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kinetic study examined the relative binding strengths of folic acid to FBP and to albumin.36 This 
comparison is of particular interest since albumin has a concentration of 0.6–0.7 mmol/L in 
blood, or a factor 500,000 more concentrated than FBP. FBP binds FA tightly with a Kd < 1.3 
nmol/L, whereas albumin exhibits much weaker binding with a Kd of 21 2.1 mmol/L. For human 
plasma, this indicates that FBP will be fully bound by folate, with the remaining 7– 30 nmol/L of 
folate present more weakly associated with albumin. The values of Kd suggest that about 3% of 
folate in human serum will be present in free form. Lowering the pH from 7.4 to the more acidic 
values commonly found in endosomes activates deoligomerization of the FBP and release of the 
bound FA. 
2.5. The binding mechanism of folic acid conjugates to folate binding protein 
There has been a substantial amount of interest in using FA-conjugates for targeted drug 
and imaging agent delivery10,11,40–50 and for targeted polymer vectors.51–55 Based on the FBP and 
albumin concentrations present in human serum,36 FA-conjugates employed at a micromolar 
concentration would be expected to interact extensively with albumin as well as to saturate all 
available soluble FBP. The rate of binding to FBP already present in serum would be determined 
by the koff of existing bound FA and the production of new FBP. This suggests that both FBP and 
albumin could play useful roles in biodistribution of FA-conjugates; however, this aspect of 
their in vivo delivery has been poorly explored to date. Generally, it has been presumed that 
small molecule conjugates will bind with equal or lesser affinity to FBP (or FR-α) as compared 
to FA. HPLC and SDS–PAGE assessment of the interaction of FBP with FA-conjugates of 
generation 5 poly(amidoamine) (G5 PAMAM) dendrimer indicated the formation of complexes 
and that these complexes were stable to the addition of further free of FA.39 It has been a goal to 
design polymer conjugates that have increased avidity for membrane bound FR-α due to 
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multivalent binding,52 and surface-bound FBP has been used to model FR-α.53,56 The surface 
plasmon resonance (SPR) technique used to quantify binding in many of these studies detected 
an increase in binding with the number of FA attached to the polymer, as well as evidence of a 
tightly bound fraction that did not desorb over ∼5–10 min of the experiment. This behavior was 
attributed to multivalency, with increasing numbers of FA giving greater avidity. Unfortunately, 
SPR, which is only sensitive to changes in surface mass, is unable to detect the changes in 
protein structure that occur during a slow-onset, tight-binding mechanism. Subsequent studies 
employing G5 PAMAM dendrimer containing just one FA per polymer particle exhibited the 
same irreversible binding to the FBP that had 
been ascribed to 2–4 FA conjugated to a single 
dendrimer multivalently binding to 2–4 FBP.57 In 
addition, it was demonstrated that the increase in 
binding constant was proportional to total FA 
concentration. These data led to a closer analysis 
of the work of Holm, Hansen et al. and the 
assignment of a slow-onset, tight binding mechanism for the interaction of FA-conjugates of G5 
PAMAM with FBP, as illustrated in Figure 2.2. SPR binding studies of methotrexate-conjugates 
of G5 PAMAM monomer and dimer species were also consistent with this binding mechanism.58 
Additional experiments are needed to fully explore the nature of the polymer structure, molecular 
weight, and topological constraints associated with these FBP interactions. Namely, this type of 
binding can only be achieved if the polymer does not bind to FBP prior to the binding of FA; 
however, following FA-binding and the rearrangement of the protein surface, it must be 
 
 G5-FA  + FBP G5-FA-FBP G5-FA-FBP*
kon k2
koff
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favorable for a network of van der Waals interactions to form between the polymer and the 
protein. 
2.6. Outlook for folate binding protein as a transport agent for therapeutics and imaging 
agents: Advantages and challenges 
Serum binding proteins offer an important vector for the transport of drugs and imaging 
agents.3 Albumin has the advantages of being the most common serum protein (0.6–0.7 mmol/L) 
and is promiscuous in terms of binding to a wide range of hydrophobic molecules.3–6. It is also 
large enough at 66.5 kDa to avoid renal clearance. By way of contrast, FBP is present at just 1–
2 nmol/L in blood and at 30 kDa is cleared by the kidney; however, these differences offer an 
interesting opportunity to engineer FBP for drug delivery. First, if longer circulation times are 
desired, the natural oligomerization mechanism of FBP provides an opportunity to form dimer, 
tetramers, or larger species that will be above the renal threshold for clearance. Can the degree of 
oligomerization be controlled by the binding strength between FBP and the FA-conjugate? The 
interaction with FBP provides a pathway to avoid renal clearance for a wide variety of FA-
conjugated materials. Indeed, such an oligomerization process may already be occurring in vivo. 
Second, the much lower plasma concentration of FBP may be coupled to a more specific, and 
more active, endocytosis mechanism than the pathway(s) employed by albumin. The recent 
discovery of a megalin-mediated endocytosis pathway for FBP 34 is very promising, as this could 
provide a route for the uptake of the FBP/FA-conjugate complexes. Again, it is possible such a 
pathway is already followed in vivo by FA-conjugates and/or that additional studies could further 
develop this mechanism as an important approach to selective uptake. Third, FBP, as part of the 
folic acid metabolic pathway, is mechanistically linked to a highly successful class of drugs, 
namely the aFAs, which include methotrexate, pemetrexed, raltitrexed, trimetrexate, and 
pyrimethamine (Figure 2.3).12,59 By developing methods to strongly bind aFA-conjugates to FBP 
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prior to injection into the bloodstream, it may be possible to increase the specificity of targeting 
of the antifolate drug as a chemotherapeutic agent. Like albumin, FBP oligomers should 
passively target the tumor via the EPR effect.3 Then, up-regulated megalin receptors, which have 
been observed in the T-47D and MCF-7 breast cancer lines60 and in prostate cancer tissue,61 can 
play a role in active uptake of the FBP. It has already been demonstrated that megalin up-
regulation can be employed for targeted delivery using apolipoproteins.60 Based on these 
literature reports, targeting of prostate and breast cancer using FBP appears to be a particularly 
promising area to explore. 
In addition to cancer applications, antifolates have also been employed for control of 
malaria. Indeed, proguanil and pyrimethamine were the drugs of choice prior to development of 
widespread resistance to this therapy.62,63 Toxicity and efficacy concerns with the artemisinin-
based combination therapies have caused pyrimethamine-based therapy to remain the best option 
for intermittent preventative treatment for pregnant women and infants. The high-level of 
expression of megalin in the infant intestine suggests that FBP-based vectors may be a generally 
effective approach to drug delivery. Pre-binding the drug to FBP may assist in both uptake and 
subsequent transport of the drug. 
 
Figure 2.2. The structures of folic acid and a variety of antifolates 
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2.7. Summary 
Serum binding proteins show exceptional promise for drug and imaging agent delivery 
applications,3 and numerous successful therapeutics based on albumin are currently in the 
clinic.4–6 FBP, another serum protein, is of particular interest because of its role in folate 
metabolism and the natural oligomerization process that occurs when FA binds to FBP. The FA–
FBP interaction has been shown to proceed through a slow-onset, tight-binding mechanism 
leading to changes in the quaternary structure of the protein. In addition, the pH dependence of 
both FA-binding and oligomerization contribute to a natural release mechanism for materials 
inside the cell. These three facets of this protein's behavior offer a powerful set of tools for 
designing the next generation drug and imaging agent delivery materials. 
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3.1.  Introduction 
Serum proteins are known to interact with small molecules and nanoparticles in blood 
and therefore play a critical role in the transport, cellular uptake, and efficacy of both small 
molecule and nanoparticle drugs.1,2 Human blood serum has over 100,000 proteins, which makes 
predicting the interactions between serum proteins and drugs, and the resulting biological effects, 
a challenging task. In many cases, drug delivery researchers try to shield small molecule, 
nanoparticle, or protein-based drugs from serum proteins using a poly(ethylene glycol) (PEG) 
shell in order to avoid the formation of protein coronas that have a deleterious effect on the 
biodistribution and efficacy of the drug.3,4 However, in this study, we have sought to exploit and 
understand the interaction of a particular serum protein, folate binding protein (FBP), with folic 
acid (vitamin B9 and cancer targeting agent). We have also explored the interactions of FBP with 
methotrexate (an antifolate drug) and leucovorin (a vitamer of folic acid) (Figure 3.1). Our 
results have implications for dosing schedules and new drug development.5 
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Generally, the aggregation of proteins is 
associated with disease – the most commonly cited 
example of this is amyloid-β deposits linked with 
Alzheimer’s disease.6 Recently, however, we have 
probed the formation of natural protein nanoparticles 
that are likely involved in transporting small molecules 
in the blood stream of healthy individuals. We have 
demonstrated that folate binding protein (FBP) exhibits 
concentration- and ligand-dependent aggregation into 
nanoparticles at human blood serum concentrations. 
FBP is particularly interesting because it has been hypothesized to regulate the trafficking and 
homeostasis of folic acid (FA), protect against FA degradation, and shield against bacterial 
utilization of FA.7–11 FA binds very strongly to FBP with a nanomolar dissociation constant, 
which is postulated to be critical for cellular uptake because FA is not synthesized by animals but 
must be obtained in the diet.12–17 FA, is required for the synthesis of DNA and plays a key role in 
neural tube development and brain function in fetuses and infants.18–20 Quickly dividing cancer 
cells require large amounts of FA for DNA synthesis, and as a result, the cancer cells display 
upregulation of folate receptors (FRs) on their outer cell membranes. As such, FA has been 
extensively used as a targeting ligand for drugs and imaging agents.12,16,17 This strategy of 
making FA-drug and FA-dye conjugates has had demonstrated success in vitro, but none of these 
systems have successfully advanced through clinical trials. 
Beyond FA-targeted drug delivery systems, FBP is of further interest because the protein 
is known to bind to members of the antifolate (aFA) class of drugs, which have applications in 
Figure 3.1. The structures of folic acid (FA, 
vitamin B9), methotrexate (MTX), and 
leucovorin (LEUC). MTX is used for the 
treatment of cancer and rheumatoid arthritis. 
LEUC is administered for “folic acid rescue” 
after cancer treatment with MTX in order to 
reduce adverse events in patients due to the 
severe toxicity of the drug. 
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the treatment of cancer, inflammation, malaria, and bacterial infection. For this study, we focus 
on the aFA methotrexate (MTX), along with the vitamer leucovorin (LEUC, folinic acid). MTX 
is an FA antagonist and exerts its anti-proliferative effects by competitively inhibiting 
dihydrofolate reductase (DHFR), thereby blocking purine, thymidine, and some amino acid 
synthesis.21,22 LEUC is used as a folic acid rescue agent following treatment with MTX. The 
importance of DHFR inhibition has led many MTX pharmacology studies to focus at the cellular 
level; however, MTX delivery to the cancer cell is a critical step in achieving an effective 
therapeutic index. This drug is given systemically (intravenously or intramuscularly) and 
distributes through the body via the blood, encountering FBP, which we argue has profound 
implications on transport and delivery. None of the FA-targeted or aFA therapies mentioned 
above have exploited the aggregation properties of FBP discussed here, and more generally, the 
research community has paid relatively little attention to the role of FBP in the transport and 
uptake of these targeted systems, with the notable exceptions of Birn et al. and Kur et al. (vide 
infra).23,24 
FBP is a ∼30 kDa glycoprotein present at 1–2 nM concentrations in human serum and 
other body fluids and 100 nM concentrations in milk.7–9,25,26 FBP is believed to be derived from 
two isoforms of membrane-bound folate receptors (FR-α and FR-β) that have undergone 
cleavage of the glycosylphosphatidylinositol (GPI) tails anchoring the receptors in the plasma 
membrane.26,27 A third isoform, FR-γ, is a secreted protein and lacks the signal for modification 
with a GPI anchor. Bovine FBP (bFBP)28 and human FBP (hFBP) have >80% homology, 
including 100% homology for the 21 key residues making up the FA binding site19,29 and have 
been found to exhibit similar aggregation phenomena to those we describe in this paper.9–11,30–34 
For this work, we have employed the more accessible bFBP. 
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The previous FBP aggregation studies have explored the interaction of FBP with FA and 
aFAs in the nanomolar to micromolar concentration range. These efforts clearly demonstrate the 
self-aggregating characteristics of FBP, as well as the ligand-dependent aggregation. In 
particular, it has been recently noted that the aggregates formed are quite stable,9 suggesting they 
could play an important role in biological FA transport. However, the results of these studies 
were difficult to apply to understanding the challenges for the delivery of aFA drugs and FA-
targeted therapeutics since they are mostly performed at concentrations (~0.2–10 μM, and 
sometimes higher) substantially above the physiologically relevant concentrations of FBP (0.2–2 
nM). We chose to re-examine the self-aggregation and ligand-induced aggregation of FBP in the 
0.2–100 nM concentration range. In this study we used atomic force microscopy (AFM) to 
characterize the folate binding protein nanoparticles (FBPNP) on a particle-by-particle basis and 
to obtain a direct measure of particle size distribution. Our attempts to use lightscattering at these 
physiological concentrations were complicated by the low scattering cross-sections of the small 
particles and the technique’s strong signal bias to large particle sizes. Generally, we found that 
FA, LEUC, and MTX interact with FBP to form nanoparticles composed of ~4–15 proteins (n ~ 
4–15, n = number of proteins in each FBPNP) with volumes of ∼300–800 nm3 (radii ~ 3–6 nm). 
However, FBPNP size distributions vary dramatically, and importantly, with changing ligand 
concentrations. We also observed self-aggregation of apo-FBP at physiological concentrations. 
3.2.  Results and discussion 
Nanoparticles of FBP, FA–FBP, MTX–FBP, and LEUC–FBP formed in 1× PBS were 
examined by AFM as function of FBP concentration and ligand : FBP ratio. We were 
particularly interested in both the self- and ligand-induced aggregation of FBP over the 
physiological protein concentration range of 0.2–100 nM. In brief, samples were prepared using 
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10 to 20 nM stock solutions of FBP and the ligand of choice. For example, a 1:1 ratio FBP:FA 
sample was created by adding 20 μL of 20 nM FBP to 160 μL of PBS, then adding 20 μL of 20 
nM FA, resulting in a clear, colorless solution. The FA–FBP nanoparticles were captured by 
spin-coating at 3,000 RPM 20 μL of the FBPNP solution onto a freshly cleaved mica surface. 
We have previously found this to be a useful method for isolating nanoparticles from solution 
and avoiding aggregation associated with concentrating solutions or drying samples.35,36 After 
spin-coating, the mica surface was washed to remove the buffer salt. AFM imaging was 
performed in tapping mode. The volumes of the FBPNP were extracted directly from the AFM 
data. We estimated the number of FBP in each particle by calculating the volume of one FBP 
using a density of 1.1 cm3 g−1 . Assuming a spherical aggregate in solution, the detected volume 
of each FBPNP was used to extrapolate the radius of each particle. 
3.2.1.  Concentration dependence of FBP nanoparticle formation at physiological pH and salt 
concentrations 
 Using AFM, we studied the concentration-dependent aggregation of FBP in 1× PBS over 
the protein concentration range of 0.2–100 nM (Table 3.1, Figure 3.2, Figure 3.3, S3.1 and 
S3.2†). In the distribution of nanoparticle volumes, the most commonly occurring species 
(mode) was a single FBP (calculated volume: 45 nm3), representing 10% and 18% of the total 
Figure 3.2. AFM images of FBP nanoparticles formed in 1× PBS over a range of protein concentrations, including the 
physiological concentrations in tissue and blood (0.2–2 nM) and the concentration in human breast milk (100 nM). FBP 
nanoparticles were captured by spin-coating solutions containing the nanoparticles onto freshly-cleaved mica. Statistical data and 
the degree of aggregation of the particles are shown in Table 3.1. Histograms of the volume distribution of 2 nM FBP are 
provided in Figure 3.3. Plots and statistical analysis of the 0.2 nM FBP nanoparticle distribution are provided in Figure A.1. 
 62 
particles measured for 0.2 nM and 2 nM solutions, respectively. In both cases the particle 
distribution formed a long tail to higher volumes. At 2 nM FBP, which is the physiological 
concentration of FBP in human blood, we characterized FBPNP with a mean volume of 605 nm3 
(n ∼ 13, radius = 4.6 nm). In this sample, ∼3% of particles had a volume of 13 ± 1 proteins. At 
0.2 nM FBP, which is more representative of some tissue concentrations, we observed FBPNP in 
which the mean volume was 565 nm3 (n ~ 13, radius = 4.7 nm); ~5% of particles had a volume 
of 13 ± 1 proteins. Comparing the 0.2 nM and 2 nM FBP, 90% of the particles formed at 0.2 nM 
are slightly smaller than those present at 2 nM (Figure A.1b). For the largest 10% of the 
particles, the FBPNP volumes in the two samples are the same. At 20 nM FBP and 100 nM FBP, 
we observed extensive aggregation into FBPNP of similar sizes as the samples at lower 
concentrations. However, these more concentrated solutions resulted in multilayers of particles 
on mica surface, making it impossible to obtain accurate volume measurements for individual 
nanoparticles.  
Table 3.1. Summary of mean, median, and mode of FBP nanoparticle volumes formed over a range of concentrations of FBP in 
1× PBS. Particle volumes and distributions were determined by analyzing AFM images of FBP nanoparticles captured by spin-
coating the solutions onto freshlycleaved mica 
 FBP Conc. 
[nM] 
Particle  
count 
Mean Volume [nm
3
] 
(Mean Radius) [nm] 
Mean # FBP 
per particle 
(n) 
Volume 
Median  
[nm
3
] 
Volume  
Mode  
[nm
3
] 
Folate 
binding 
protein 
0.2 1928 565 ± 557 
(4.7 ± 1.5) 13 371 72 
2 738 605 ± 1160 
(4.6 ± 1.8) 13 316 58 
20 
Multilayers of overlapping particles 
 accurate volume measurements could not be generated 
100 
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Figure 3.3. (a) AFM images of FBP nanoparticles formed from a range of FA : FBP ratios. For all samples, the FBP 
concentration was held constant at 2 nM in 1× PBS. AFM images were captured by spin-coating the solutions onto freshly-
cleaved mica. As is evident from the 2 nM FA + 2 nM FBP image in panel A, the addition of FA to 2 nM FBP disrupts the FBP 
self-aggregation observed for FBP alone, resulting in a bimodal distribution (only the smaller nanoparticles are shown in the 
histograms, see Figure A.3 for the full distribution). (b) Histogram of the volumes of the FBP nanoparticles for all the FA : FBP 
ratios. With the exception of the 2 nM FA sample, apo- and ligand-bound FBPNP display similarly wide volume distributions. (c) 
Histogram of the volumes of FBP nanoparticles in only 2 nM FBP and 2 nM FA + 2 nM FBP. Most of the FA-bound FBP 
nanoparticles are smaller and contained within a narrower distribution than observed for the 2 nM FBP. However, the large 
FBPNP contain 96% of the FBP material. (d) Histogram showing the distribution of nanoparticle radii extrapolated from the 
detected FBP nanoparticle volumes. (e) Histogram of only 2 nM FBP and 2 nM FA + 2 nM FBP nanoparticle radii. The narrower 
distribution of the FA-bound FBP nanoparticles is clearly evident. 
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The self-aggregation behavior observed for FBP below 10 nM runs counter to previous 
reports of FBP behavior.30,34 The existence of FBPNP at these physiologically relevant 
concentrations suggests self-aggregated FBP is a naturally occurring nanostructure and 
potentially critical to the transport and delivery of FA, MTX, LEUC, and other aFAs. It is also 
worthwhile to consider these findings in the context of the self-aggregation results of apo-FBP at 
100 nM – the concentration of FBP in human breast milk. This sample displays a high degree of 
FBPNP formation, pointing towards the potential importance of the nanoparticulate form of the 
protein in the trafficking and delivery of folate to infants. These results are especially interesting 
given that infants have higher intestinal expression of megalin,23,37 which was recently reported 
to play a role in cellular uptake of FBP and FA.23,24,37 As demonstrated here (vide infra) and in 
our recently published work,38 FA binds to FBP and alters the distribution of FBPNP present in 
solution. The high degree of aggregation at 100 nM FBP provides a potential mechanism for the 
protection and transport of FA from mother to infant. 
3.2.2.  Nanoparticles of FA-FBP at physiological pH, protein, and salt concentrations 
Although by AFM we observed self-aggregation of FBP at concentrations as low as 0.2 
nM in 1× PBS, our data indicate that the addition of folic acid (FA) affects FBPNP properties 
and composition. That is, FA binds to already self-aggregated FBP, altering the nanoparticle 
volume distribution. This is consistent with previous work demonstrating that at close to neutral 
pH values, FA binds FBP with a nanomolar dissociation constant and induces a structural change 
in the protein.19,20,31,39,40 Recent reports of the crystal structures of FR-α and FR-β demonstrate 
the conformational changes in protein structure induced by ligand binding Figure 3.4).19,20 A 
number of other studies, including recent work from our group, have investigated the ligand-
induced changes in protein structure and intrinsic tryptophan fluorescence.31,32,38 We 
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demonstrated that upon titrating FBP with FA, 
approximately 50% of the native tryptophan fluorescence is quenched (Figure 3.5). The 
structural change in FBP upon ligand binding buries some of the more hydrophobic residues in 
the interior of the protein and exposes a more hydrophilic surface. The studies referenced above 
illustrate how the ligand-induced hydrophilic association of FBP has been well-documented by 
bulk measurements, but AFM has allowed characterization of this phenomenon on a particle-by-
particle basis over physiologically-relevant concentration ranges. 
When FBP was exposed to FA at a 1:1 ratio (2 nM FA + 2 nM FBP), a bimodal 
distribution of FBPNP was formed (Figure 3.3a, Table 3.2), clearly indicating that the binding of 
FA to FBP disrupts the apo-FBP nanoparticles resulting from self-aggregation. The larger 
FBPNP within the bimodal distribution had a mean volume of ~27,500 nm3 (n ~ 611, radius = 
17.7 nm). For the smaller FBPNP, we observed a mode of approximately one FBP (n = 1) and 
mean volume of 167 nm3 (n ~ 4, radius = 3.1). Interestingly, given the general consensus in the 
Figure 3.4. The 8-mer crystal structure of folate receptor-α 
(FBP without the GPI membrane anchor) with folic acid (FA) 
in the binding pocket.19 All the tryptophan residues are shown. 
The tryptophan residues participating in the pi-stacking 
interaction with the pterin ring system in FA are highlighted in 
cyan. The tryptophan residues interacting with the benzamine 
ring in FA are shown in magenta. The rearrangement of these 
two tryptophan is likely responsible for the fluorescence 
quenching observed upon ligand binding. 
 
Figure 3.5. The FBP fluorescence is measured upon 
addition of different folate and folinate materials. 
Leucovorin (LEUC) did not induce significant 
fluorescence quenching of FBP (black). Further addition of 
folic acid (FA) leads to quenching of the intrinsic 
tryptophan fluorescence (blue) that resembles FA 
quenching alone (green). Similarly, when methotrexate 
(MTX) is added to LEUC (red), the fluorescence is 
quenched approximately the same level as when MTX only 
is added to FBP (purple). The FBP concentration in all 
cases is 58 nM (pH 7.4, 1× PBS solution). 
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literature that FA-binding induces aggregation,9–11,30–34 most of the ligand-bound FBPNP were 
smaller and contained within a narrower distribution that was observed for the 2 nM FBP alone. 
However, the large FBPNP contain 96% of the FBP material. (The full analysis, including 
histograms and statistical plots for the 2 nM FA + 2 nM FBP sample, are included in Figure A.3. 
For clarity and scaling issues, only the smaller FBPNP from this sample are included in the 
figures in the main body, Figure 3.3) The non-uniform distribution of FBPNP observed at these 
low FA concentrations is particularly interesting, as 2 nM FA would represent a severe folate 
deficiency in humans, in whom normal serum folate levels range from 10 to 40 nM.41 The non-
uniform distribution of FBPNP is consistent with aggregation of apo- and holo-FBP, as has been 
previously documented at low FA concentrations.11 A fluorescence quenching experiment in 
which FBP was titrated into FA yielded results consistent with these previous observations 
(Figure A.4). Although more experiments are required, particularly in the complex environment 
of blood serum, altered trafficking, biodistribution, and cellular uptake in the non-uniform FA-
bound FBPNP may be associated with the symptoms resulting from folate deficiency. 
When the FA:FBP stoichiometry was varied to higher concentrations of FA (10 nM to 
100 nM), the FBPNP no longer exhibited bimodal distributions and gave mean volumes of 
∼300–700 nm3 (n ~ 3–5, radii ~3–5 nm, Table 3.2, Figure 3.3), in close agreement with the 
volumes of apo-FBPNP (Table 3.1). Given the similarity between the FBPNP volumes in the 
higher ratio FA and the apo-FBP samples, it is interesting to consider the physiological role of 
the nanoparticulate form of FBP in the cellular endocytotic uptake pathway. Several recent 
studies of the role of folate and its cellular uptake have demonstrated that FA and FBP are taken 
up into cells via a complex mechanism involving several membrane-bound proteins. Birn et al. 
demonstrated the importance of megalin, a low density lipoprotein endocytotic receptor, in the 
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FBP uptake pathway.23 Kur et al. examined embryotic neural tube development and 
demonstrated that uptake of folate into neuroepithelial cells involves an endocytotic mechanism 
with a complex of soluble FBP, membrane-bound folate receptors, and megalin.24 
3.2.3.  Nanoparticles of MTX-FBP at physiological pH, protein, and salt concentrations 
Methotrexate (MTX) is a widely used antifolate (aFA) drug for the treatment of cancers, 
particularly pediatric leukemia, and rheumatoid arthritis (RA).42,43 For cancer therapy, MTX is 
delivered systemically (intravenously), usually at doses in the 1–10 μM range. For the treatment 
of RA, MTX is traditionally given orally or intramuscularly, but reaches blood concentrations 
ranging from 500 nM at 5 hours post dosing, 100 nM at 30 hours post dosing, and 20 nM at 52 
hours after dosing.43 Therefore, there are substantial concentrations of MTX in blood available to 
interact with FBP. Although MTX functions as a dihydrofolate reductase (DHFR) antagonist, it 
is known to bind to FBP.20,21 This is unsurprising given the structural similarities between FA 
and MTX (Figure 3.1), but MTX has 100–200× lower binding affinity to FBP than FA to 
FBP.20,44–48 The binding interaction between MTX and membrane-bound folate receptors (from 
which FBP is derived) has been well characterized, including by X-ray crystallography.20 In 
addition, our group and others31 have characterized the tryptophan fluorescence quenching of 
FBP upon titration with MTX (Figure 3.5). Similar to FA, the native FBP tryptophan 
fluorescence was quenched by approximately 45%, suggesting ligand binding, protein 
reorganization, and disruption of apo-FBPNP. 
As with FA, we examined the interaction of MTX with FBP at physiological pH, protein, 
and salt concentrations and characterized the resulting FBPNP using AFM (Table 3.2, Figure 
3.6, and S3.5). Like the FA–FBP nanoparticles, the largest MTX-bound FBPNP volumes were 
observed when both ligand and protein were at 2 nM. In this case, the FBPNP had a mean 
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volume of 1,293 nm3 (n ~ 29, radius = 6.3). The histograms shown in Figure 3.6b (volume) and 
3.6c (radius) demonstrate that unlike with FA at 2 nM, neither a bimodal distribution nor a 
narrowing of FBPNP volume distribution is observed with MTX. Above 2 nM MTX, up to 1,000 
nM (1 μM) MTX, FBPNP sizes remained consistent at volumes of ∼500–800 nm3 (n ~ 11–18, 
radii ~4.5–5.5 nm). The variation FBPNP volume as a function of ligand concentration suggests 
that degree of protein aggregation could play an important role in the trafficking and cellular 
uptake of the drug. 
Figure 3.6. (a) Exemplar AFM images of FBP nanoparticles formed from a range of MTX : FBP ratios. For all samples, the FBP 
concentration was held constant at 2 nM in 1× PBS. FBP nanoparticles were captured by spin-coating solutions containing the 
nanoparticles onto freshly-cleaved mica. (AFM images of all of the MTX concentrations are provided in Figure A.5.) (b) 
Histogram of the volumes of the FBPNP for all the MTX : FBP ratios studied. A wide, tailing distribution is observed for all 
samples. (c) Histogram of the radii of the FBPNP for all MTX : FBP ratios. The radius data are extrapolated from the detected 
volumes of the FBPNP. 
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Table 3.2. Summary of mean, median, and mode of nanoparticle volumes formed upon exposure of 2 nM FBP to FA, MTX, or 
LEUC. Particle size and distributions were determined by analyzing AFM images of FBP nanoparticles captured by spin-coating 
the solutions onto freshly-cleaved mica 
 Ligand  conc.  
[nM] 
Particle  
Count 
Mean Volume [nm
3
] 
(Mean Radius) [nm] 
Mean # FBP 
per particle 
(n) 
Volume 
Median  
[nm
3
] 
Volume  
Mode  
[nm
3
] 
Folic acid 
2 
45 27,500 ± 25, 200  
(17.7 ± 4.0) 611 20,600 14,000 
282 167 ± 204 
(3.1 ± 0.9) 4 96 72 
10
a) 1836 356 ± 337   
(4.0 ± 1.2) 8 246 71 
20
a) 1862 275 ± 237 
(3.8 ± 1.0) 6 203 65 
100 2024 720 ± 659 
(5.0 ± 1.7) 16 504 47 
Methotrexate 
2 289 1293 ± 803 
(6.3 ± 1.7) 29 1219 57 
20
b) 798 495 ± 495 
(4.4 ± 1.5) 11 309 57 
100
b) 1425 795 ± 640 
(5.3 ± 1.6) 18 628 97 
500
b) 1912 757 ± 719 
(5.1 ± 1.8) 17 474 46 
1000
c) 1660 697 ± 620 
(5.0 ± 1.6) 15 490 74 
Leucovorin 
2 No particles observed 
20 1580 224 ± 235 
(3.5 ± 1.0) 5 146 55 
100 730 503 ± 458 
(4.5 ± 1.4) 11 386 58 
500 1384 665 ± 634 
(4.9 ± 1.7) 15 461 57 
1000 1888 299 ± 316 
(3.8 ± 1.1) 7 198 47 
 
3.2.4.  Nanoparticles of LEUC-FBP at physiological pH, protein, and salt concentrations 
Leucovorin (LEUC, folinic acid) is a vitamer of folic acid and is used in folic acid rescue 
following treatment of cancer or arthritis with MTX.43,49–52 The mechanism of action of 
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leucovorin in folic acid rescue is still debated. Interestingly, LEUC is effective at reducing 
toxicity of MTX but FA is not, and the reason for this is not yet fully understood. 
Using the same AFM techniques described above, we imaged solutions of LEUC and 
FBP at physiological protein concentration (Table 3.2, Figure A.6). No FBPNP formation was 
observed at 2 nM LEUC + 2 nM FBP, in direct contrast with the FA and MTX solutions. This 
indicates that the presence of LEUC both disrupts the normal FBP aggregation process and fails 
to cause ligand-induced aggregation. Some initial formation of FBPNP was observed at a 10:1 
ratio of LEUC:FBP (20 nM LEUC + 2 nM FBP), but substantial FBPNP were not observed until 
the LEUC concentration was increased to 100 nM. Examination of the crystal structure of FA 
bound to FBP shows two tryptophan residues participate in the strong binding interaction 
through pi–pi stacking with both the benzamine ring and the pteridine ring (Figure 3.4). Groups 
who have examined the binding of FA and MTX to FBP in detail have remarked on the 
importance of this pi-stacking interaction in the binding of FA and MTX to FBP.19,20 LEUC, 
however, lacks the pteridine ring, and in fact, lacks planar geometry due to the presence of a 
quaternary carbon, preventing the pi–pi stacking interaction (Figure 3.1). When present in high 
enough concentration, however, LEUC induced formation of FBPNP of comparable volume to 
the FBPNP containing FA and MTX. 
Our FBP fluorescence quenching data also suggest that the interaction between FBP and 
LEUC is different than FA/FBP and MTX/FBP interaction. As shown in Figure 3.5, LEUC did 
not induce a conformational change in the FBP protein structure that is known to lead to 
quenching of the intrinsic tryptophan fluorescence. Sequential titration of FBP with LEUC 
followed by FA or MTX did result in quenching of the intrinsic fluorescence to the same level 
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observed with FA or MTX alone. This indicates that FA and MTX are capable of displacing 
LEUC from the FBP binding pocket. 
3.2.5.  Statistical evaluation of FBP nanoparticle distributions: implications for transport and 
delivery of FA, MTX, and LEUC 
We employed quantile–quantile (Q–Q) plots to provide a qualitative comparison of 
FBPNP distributions. The technique plots the quantiles (i.e., a percentage or fraction of a data set 
below a given value) of one data set against the quantiles of the second data set. In Figure 3.7, 
we plotted the FBPNP volume distributions of FA- and MTX-containing FBP against the 
FBPNP distribution formed from apo-FBP at 2 nM. In all cases, the dashed lines pass through 
the first and third quartiles (25th  and 75th percentiles) of the data. We note that at 2 nM FA or 
MTX the FBPNP size distributions are substantially different (Figure 3.7a). (Only the smaller 
FBPNP in the 2 nM FA + 2 nM FBP distribution are plotted so different ligand concentrations 
can be easily compared. Figure A.3 shows the full Q–Q and CDF plots of 2 nM FA + 2 nM 
FBP.) At 20 nM FA or MTX, the two FBPNP distributions are more similar, but both 
populations of ligand-bound FBPNP are systematically smaller than the 2 nM apo FBPNP 
(Figure 3.7b). When the ligand concentrations are increased to 100 nM FA and 1000 nM MTX, 
the ligandbound and ligand-free FBPNP distributions are nearly identical (Figure 3.7c). That is, 
at high MTX concentrations, the resulting FBPNP distribution closely resembles the distributions 
of nanoparticles present in solutions of both apo-FBP and FBP with 100 nM FA. However, the 
FBPNP formed at these high MTX concentrations (mimicking therapeutic blood levels) did not 
have the same volume distribution as those formed from physiological levels of FA (10–40 nM). 
The different FBPNP size distribution may be consistent with different mechanisms of cellular 
uptake of FA and MTX. A number of in vitro studies have presented evidence that FA and MTX 
follow different cellular internalization pathways: MTX is postulated to enter cells via the 
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reduced folate carrier while FA is taken up through membrane-bound folate receptors.8,53 
However, these studies have been performed in vitro without controlling for FBP concentration 
Figure 3.7. Quantile–quantile (Q–Q) plots of the volumes of FA-, MTX-, and LEUC-containing FBP nanoparticle plotted against 
ligand-free 2 nM FBP nanoparticle volumes. The square markers represent each decile of data. The dashed lines in the charts pass 
through the 1st and 3rd quartiles (25th and 75th percentiles) of the data. (a) Q–Q plot of the volumes of 2 nM FA- and MTX-
containing FBP nanoparticles against the volumes of 2 nM apoFBP nanoparticles. (b) Q–Q plot of the volumes of 20 nM FA- and 
MTX-containing FBP nanoparticles against the volumes of 2 nM apo-FBP nanoparticles. (c) Q–Q plot of the volumes of 100 nM 
FA- and MTX-containing FBP nanoparticles against the volumes of 2 nM FBP nanoparticles. These data suggests that at high 
MTX concentrations, the resulting FBP nanoparticles closely resembles the native form of FBP in both size and distribution, 
enabling effective transport and delivery to target cells. (d) Q–Q plot of the volumes of 10 nM FA-, 20 nM FA-, and 1000 nM 
LEUC-containing FBP nanoparticles against the volumes of 2 nM FBP nanoparticles. These data indicate that at therapeutic 
levels of LEUC, the resulting FBP nanoparticles have a similar volume distribution as FBPNP formed at healthy levels of FA. 
This suggests that FBP nanoparticles containing LEUC follow the same trafficking and biodistribution pathways as FBP 
nanoparticles formed at healthy, or potentially even scarce, FA concentrations, facilitating cellular uptake of the vitamer and folic 
acid rescue. 
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or considering the implications of FBPNP-mediated transport. Further studies both in vitro and in 
vivo controlling for the FBP concentration are necessary to establish the role of FBP in the 
cellular internalization of FA and MTX.  
We also compared the LEUC-containing FBPNP volume distributions with the FBPNP 
made from 10 nM FA + 2 nM FBP and 20 nM FA + 2 nM FBP. As can be seen in Figure 3.7d, 
the LEUC-containing FBPNP have a similar distribution to the FBPNP induced by both 10 nM 
and 20 nM FA, but the FBPNP in all these ligand-containing populations are systematically 
smaller than 2 nM apo-FBPNP. This suggests that at therapeutic levels of LEUC, the FBPNP 
formed resemble the FBPNP present at both slightly deficient and healthy levels of FA. We 
hypothesize this indicates that FBPNP containing LEUC follow the same trafficking and 
biodistribution pathways as FBPNP formed at these FA concentrations. These data could 
indicate a passive targeting mechanism, which facilitates cellular uptake of LEUC because the 
FBPNP resemble proteins carrying healthy levels of folate. It is interesting to note that at high 
(micromolar) LEUC concentrations, the FBPNP distribution differs significantly from the 
FBPNP at the same MTX concentration, but matches that of the FA-containing FBPNP at 
normal physiological levels. This suggests that LEUC is trafficked to cells similarly to FA, and 
at high concentrations is able to bypass the MTX uptake pathway to facilitate folic acid rescue. 
This hypothesis provides a mechanistic explanation for the perplexing observation that high 
concentrations of FA fail to provide a therapeutic benefit. Note that the FBPNP generated from 
apo-FBP, 1,000 nM MTX, and 100 nM FA have the same volume distributions (Figure 3.7c). 
To obtain quantitative comparisons of the ligand-free and ligand-containing FBPNP 
volume distributions, we plotted the data as cumulative density functions (CDFs) and employed 
the Kolmogorov–Smirnov (K–S) test (Figure 3.8). Consistent with the Q–Q plots, the K–S test 
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indicated that FBPNP volume distributions of 20 nM FA + 2 nM FBP and 1000 nM LEUC + 2 
nM FBP are not statistically different (p = 0.31, Figure 3.8d). All other K–S test comparisons 
rejected the null hypothesis, signifying that other FBPNP volume distributions are statistically 
significant from each other (p < 0.05). For example, the FBPNP volume distribution of 2 nM FA 
+ 2 nM FBP is different from the distributions of 2 nM FBP and 2 nM MTX + 2 nM FBP. 
Figure 3.8. Cumulative density function (CDF) plots of selected the measured volumes FA-, MTX-, and LEUC-containing FBP 
nanoparticles. The similarity of the nanoparticle volume distributions was assessed using K–S statistics. The K–S testing showed 
the volume distributions of FBP nanoparticles formed from 20 nM FA + 2 nM FBP and 1000 nM LEUC + 2 nM FBP are not 
statistically different (p = 0.310). All other nanoparticle volume distributions were shown to be statistically different when 
evaluated with the K–S test. We hypothesize LEUC is effective as a folic acid rescue agent because the FBP nanoparticles 
formed at therapeutic concentrations of LEUC have the same volume distribution as the nanoparticles formed at healthy FA 
concentrations (20 nM) and a similar distribution to nanoparticles containing physiologically low FA concentrations (10 nM). 
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However, we do not ascribe biological significance to some of these statistically significant 
populations, particularly in the case of 2 nM apo-FBP, 100 nM FA + 2 nM FBP, and 1000 nM 
MTX + 2 nM FBP. (The K–S test comparison of FBPNP with 100 nM FA and 1000 nM MTX 
indicated the samples are statistically different with p = 0.018). The Q–Q plot comparing these 
samples (Figure 3.8c) shows the FBPNP to be nearly identical in volume distribution. These 
samples are likely to behave similarly biologically and may indicate FA and MTX are trafficked 
via the same pathways. 
The quantitative results of our CDF and K–S test analysis are consistent with the Q–Q 
plot analysis of FBPNP volume distributions. Based on the consistency of the qualitative and 
quantitative statistical analyses, we propose LEUC is effective as a folic acid rescue agent 
because the FBPNP formed at therapeutic concentrations of LEUC have the same volume 
distribution as the FBPNP formed at healthy FA concentrations and a similar distribution the 
FBPNP formed at physiologically low FA concentrations (10 nM). We hypothesize this enables 
LEUC to bypass the MTX trafficking pathway and be delivered to cells at high enough 
concentrations to be therapeutic. 
The likelihood of proteins to aggregate has been a matter of extensive study due to the 
role of aggregates in Alzheimer’s disease. Methods, such as the TANGO simulation,54–56 have 
been developed to assess the propensity for aggregation of particular protein sequences. 
Although the TANGO simulation has limitations for our system (it was developed to study 
amyloid-β formation and the code assumes a concentration of at least 10 μM), the program 
output indicated that analogous sequences near the N-terminii of both bovine and human FBP 
have a 99% aggregation tendency (Figure A.7 and Figure A.8). These sequences are in ideal 
positions for initiating aggregation between proteins. We note with interest that these sequences 
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that have been associated with disease-based aggregation may also play a role in the protein 
aggregation for a normal, healthy physiological process. While we are still investigating the 
aggregation process (via NMR and further AFM studies), the TANGO analysis does suggest one 
potential mechanism. Similar conclusions regarding the presence of a hydrophobic patch on FBP 
were previously reached by Holm et al. based upon disruption of the FBP aggregates using 1-
anilinonapthalene-8-sulfonate (ANS).33 
3.2.6.  Biotrafficking, drug transport, and uptake 
Our AFM imaging studies indicate that FBPNP are formed at healthy levels of FA and 
under therapeutically relevant concentrations of MTX and LEUC (Table 3.2), with FBPNP 
volumes ranging generally from ∼300–800 nm3 (n ~ 4–15, radii ~ 3–6 nm). The consistency in 
volume across several orders of magnitude of ligand binding affinity point to the potentially 
biologically robust nature of FBPNP and suggest a role in the lifetime and biodistribution of the 
vitamin and drugs, as well as in cellular uptake. However, we have demonstrated that the overall 
distribution of FBPNP volumes vary as a function ligand concentration. We hypothesize these 
changes in FBPNP volume distributions dictate the trafficking and biodistribution of the bound 
small molecules, pointing towards important differences in the mechanism of cellular delivery of 
FA, MTX, and LEUC. 
The conventional view has been that FA is taken up into cells via direct interaction 
between the vitamin and membrane-bound folate receptors, followed by receptor-mediated 
endocytosis.12–17 This mechanism has been invoked for the uptake of FA-targeted drug conjugate 
systems and imaging agents. This strategy has demonstrated some success in vitro but as of yet, 
has failed to successfully transfer to in vivo systems and the clinic. Recent reports have shown 
that megalin (LRP2) is critical for the cellular uptake of FBP, and consequently FA.23,57 Megalin 
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is highly expressed in the epithelial tissues in the brain, kidney, yolk sac, and intestines, all areas 
known to have high folate resorption. Kur et al. demonstrated in vivo the importance of megalin 
in folate uptake and its role in embryonic neural tube development using megalin knockdown 
mice embryos.24 They showed that megalin and membrane-bound folate receptors are critical for 
the receptor-mediated endocytosis of the FA–FBP complex. These studies demonstrate that the 
cellular uptake pathway of FA is a complex, multi-component process in which we are 
continuing to investigate the role of FBPNP. 
3.2.7.  Implications for drug delivery: pre-formation of FBP nanoparticle and dosing schedule 
The highly robust formation process of FBPNP suggests that relatively simple 
modifications to the delivery and/or dosing schedule of MTX could potentially improve drug 
efficacy and decrease toxicity for cancer and rheumatoid arthritis therapies. Taking advantage of 
the natural FBPNP formation process, the MTX-bound FBPNP could be pre-formed and the drug 
administered as a protein nanoparticle. Given the binding of MTX to FBP, dosing schedules 
could also be modified from existing protocols in order to accommodate the production rate of 
FBP. The drug would only be injected at a frequency that would ensure FBP is available to 
traffic the drug to intended locations, helping to prevent off-target toxicity and improving the 
therapeutic index of MTX. 
These ligand-driven aggregation phenomena are important from the point of view of drug 
biodistribution and may also have key roles in delivery and uptake.58 For example, materials of 
~30 kDa or with a hydrodynamic radius of ~5 nm are below the kidney filtration limit and are 
excreted in urine, whereas larger particles are trafficked to the liver. The presence of strong 
aFA–protein interactions may also provide alternate pathways for drug transport into cancer 
cells57 and cells infected by pathogens utilizing protein transporter pathways.23 
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3.2.8.  Trafficking mechanism for leucovorin 
This report presents evidence as to why LEUC is an effective folic acid rescue agent 
while FA itself is not, a phenomenon that is not well understood. The FBPNP formed at 
therapeutic concentrations of LEUC have the same volume distribution as FA-containing FBPNP 
at healthy FA concentrations. We propose that this allows LEUC at high enough concentrations 
to have a therapeutic effect by following the same trafficking and biodistribution pathways as 
FA. This passive targeting mechanism allows a high dose of LEUC to be delivered to cells, 
facilitating folic acid rescue. 
3.3. Conclusions 
Using primarily AFM, we have examined the self- and ligand-induced aggregation of 
folate binding protein (FBP) over the physiological concentration range of 0.2 nM to 100 nM. 
We have discussed some potential implications for vitamin and antifolate drug trafficking 
resulting from FBP nanoparticle (FBPNP) formation. Upon analyzing our AFM data on the 
FBPNP, our major conclusions and related biological hypotheses for future work are as follows: 
C1. Even in the absence of ligand, FBP at physiological concentrations of ~2 nM self-
aggregates to form nanoparticles with a mean of ~12–14 proteins. 
 
C2. In the presence of 2 nM folic acid (FA, which is below healthy human blood serum 
levels of 10–40 nM) FBP at 2 nM demonstrates complex aggregation properties, resulting 
in a bimodal distribution of FBPNP. The FBPNP comprising this bimodal population 
differs significantly in both volume and distribution from the FBPNP formed at healthy 
levels of FA. 
 
C2-H. It is possible the change in aggregation properties at low FA levels contributes 
to the deleterious health effects resulting from folate deficiency. 
 
C3. In the presence of 2 nM methotrexate (MTX), FBP at 2 nM aggregates into FBPNP 
of a different volume distribution than the nanoparticles formed at 2 nM FA. The FBPNP 
formed at 100 nM FA or 1,000 nM MTX and 2 nM FBP are similar in volume 
distribution to both each other and to apo-FBPNP at 2 nM.  
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C3-H. This suggests that at therapeutically relevant concentrations, MTX-containing 
FBPNP are biologically trafficked like the native protein. 
 
C4. Low concentrations of 2 nM leucovorin (LEUC) disrupt already existing apo-FBPNP 
and inhibit new nanoparticle formation, in contrast to the strong binding of FA and MTX 
to FBP that maintain the aggregation properties of FBP. 
 
C5. The distribution of FBPNP in the presence of 1,000 nM LEUC, the approximate 
therapeutic blood serum concentration, is similar to the FBPNP distribution at 
physiologically healthy FA concentrations.  
 
C5-H. This new insight provides a hypothesis for the transport of LEUC in the folic 
acid rescue procedure: the LEUC-containing FBP aggregates resemble the 10–40 
nM FA-containing FBPNP distribution, allowing LEUC to be trafficked like FA and 
enhancing cellular uptake and facilitating its therapeutic effect. 
 
FBP nanoparticles could potentially be exploited for targeted drug delivery applications. 
Protein nanoparticles are already critical formulations currently used in the clinic. Particularly, 
albumin has been extensively exploited as a scaffold for increasing efficacy and decreasing 
toxicity of small molecule therapeutics and imaging agents.1 There are currently drug delivery 
and imaging systems employing an albumin scaffold, with applications in the treatment of 
metastatic breast cancer and diabetes and imaging of cardiovascular and cerebral circulation and 
lymph nodes. Of particular interest is Abraxane®, a formulation of paclitaxel (Taxol®) and 
albumin to give nanoparticle albumin-bound paclitaxel (nab-paclitaxel). The formulation process 
yields nanoparticles with a reported diameter of ~130 nm (DLS measurement). While 
Abraxane® has had marked success in treating advanced stages of metastatic breast cancer, non-
small cell lung cancer, and pancreatic cancer, therapies with an albumin scaffold suffer from the 
promiscuous nature of albumin in regards to small molecule binding and biological trafficking. 
Conversely, small molecule–FBP binding interactions, and thus the resulting FBPNP, are highly 
specific, pointing to the critical role of the protein and the aggregation process in the transport 
and delivery of FA and aFA drugs to cells. 
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3.4. Experimental 
3.4.1.  Materials 
All materials purchased from commercial sources were used without further purification, 
unless otherwise noted. Folic acid (FA), methotrexate (MTX), and leucovorin (LEUC) were 
purchased from Sigma-Aldrich and used as received. FA, MTX, and LEUC were shielded from 
light when handling. 
3.4.2.  Extraction and purification of FBP 
FBP was purified from whey protein powder using a folic acid affinity column as 
previously described.38 In brief, Sepharose 4B beads (200 mL) were activated with cyanogen 
bromide and subsequently conjugated to FA. A pH 7.0 2% (w/v) solution of whey protein was 
centrifuged (20,000g) for 20 minutes, and the supernatant was isolated and run through the 
affinity column. Unbound protein was washed away with 1 M NaCl (2 L) until the solution ran 
clear, and then the column was washed with nanopure water (at least 2 L). FBP was released 
from the column using 0.3 M acetic acid solution (300 mL) and the desired protein was collected 
in fractions. Fractions containing FBP with at least 90% purity were combined and the pH was 
adjusted to 7.0 by addition of 5.0 M NaOH. Purity of the isolated FBP was assessed by SDS-
PAGE and MALDI-TOF-MS (Figure A.9). 
3.4.3.  AFM sample preparation 
FBP and ligand + FBP solutions were made using serial dilutions. In all cases, FBP was 
added to 1× PBS (free of Mg2+ and Ca2+), and then the ligand was added. For example, to form 
100 nM FA + 2 nM FBP, 20 μL of 20 nM FBP in PBS was added to 160 μL PBS, after which 20 
μL of 1 μM FA was added to the diluted FBP solution. The resulting nanoparticle solutions were 
stored at 4°C and shielded from light. Before AFM imaging, mica was glued onto 15 mm 
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diameter steel AFM pucks. The mica was cleaved using adhesive tape immediately before using. 
Samples were spin-coated at 3,000 RPM onto the freshly cleaved mica. Samples dissolved in 
PBS were rinsed with nanopure water (∼0.5 mL) to remove the salt and dried under a stream of 
N2 for ~5 minutes. Samples containing FA, MTX, or LEUC were shielded from light during the 
spin-coating process. 
3.4.4.  Atomic force microscopy (AFM) imaging and image analysis 
All AFM imaging was carried out in air-dry conditions using a PicoPlus 5500 AFM 
(Agilent). Imaging was performed in tapping mode using Aspire CT300R probes (NanoScience, 
AZ; silicon cantilever, nominal radius 8 nm, force constant 40 N m−1, resonance frequency 300 
kHz, length 125 μm). For the 3.5 × 3.5 μm images in which FBPNP were quantified, line scan 
rates were set at 0.5 Hz and at 1024 pixels per line (~3.4 nm per pixel). Random locations on the 
mica surface were imaged. 
The AFM images were analyzed and the volume of the FBP nanoparticles (FBPNP) were 
determined using SPIP (v6.2.6, Image Metrology, Hørsholm, Denmark). For the FBPNP size/ 
volume analysis, AFM images were processed and analyzed as follows: all images were flattened 
with a 2nd degree global plane correction and with the Z offset with the “Bearing Height to Zero” 
(SPIP “Best Practices” for particle detection). The image was then further filtered with a 1st 
order linewise leveling and the background set to zero. Finally, the image was smoothed using 
the Mean 3 × 3 filter. (The Mean 3 × 3 filter improved the signal-to-noise and allowed for faster 
FBPNP volume calculation over the entire image.) For each image, 10 FBPNP of a range of sizes 
randomly distributed over the field were selected. A line scan was performed across each 
FBPNP, and the diameter and Z-range (height) recorded. Then, using the “Particle & Pore 
Analysis” feature in SPIP, the volumes of the 10 selected FBPNP were measured. For each 
 82 
FBPNP, the threshold (bottom plane) of each particle was set so that the detected particle size 
matched the markers used to measure the FBPNP diameter in the line scan. The “Detected 
Diameter,” “Detected Height,” and “Detected Volume” were recorded. A threshold for the 
overall image was selected based on the modal threshold from measuring the 10 FBPNP 
individually. This global threshold was applied to all the FBPNP in the image. The radii of the 
particles were extrapolated using the “Detected Volume” data, assuming the FBPNP are 
spherical in solution. Because the FBPNP were sometimes close together or overlapping, the 
selected global threshold sometimes registered distinct FBPNP as one object. There were also 
sometimes very large aggregates or contaminants (dust) in the images. In order to account for 
this, FBPNP with volumes larger than 3,000 nm3 (~67 FBP) were excluded from the mean 
volume and radius calculations. (The exception is 2 nM FA + 2 nM FBP in which we treated the 
sample as bimodal). We checked our statistical analyses including the FBPNP larger than 3000 
nm3, and the differences when those particles were included was negligible. For the 10 FBPNP 
originally analyzed in order to determine the threshold, we compared their volumes determined 
from the globally applied threshold with the manually measured volumes; in all cases the 
difference was less than 10%. 
In order to ensure that the Mean 3 × 3 filter was not changing the detected shapes or 
volumes of the FBPNP, line scans of several FBPNP before and after the Mean 3 × 3 smoothing 
filter was applied were compared. The two line scans showed no difference in height or shape, 
and there was less than 4% difference in particle volume for the same FBPNP in images 
processed by the two different methods. We also wanted to ensure that the same particle volumes 
were reproducibly measured across different image sizes and pixel densities. For select cases, the 
above procedure was followed to characterize FBPNP volumes in 1.5 × 1.5 μm images of the 
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same sample. In the 1.5 × 1.5 μm images, FBPNP volumes within 10% of the 3.5 × 3.5 μm 
analysis were obtained. 
The number of FBP in each FBPNP was determined by first calculating the volume of 
one FBP, assuming a molecular weight of 30 kDa and a density of 1.1 g cm−3. The volume of 
one FBP was estimated to be 45 nm3. 
3.4.5.  Fluorescence measurements 
Full experimental details can be found in previously published work.38 Briefly, all 
fluorescence experiments were performed on a Varian Cary Eclipse Fluorescence 
Spectrophotometer. The excitation wavelength was 280 nm. The temperature was controlled to 
22°C. 
 
Supplementary information in Appendix A. 
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4.1. Abstract 
Serum proteins play a critical role in the transport, uptake, and efficacy of targeted drug 
therapies, and here we investigate the interactions between folic acid−polymer conjugates and 
serum folate binding protein (FBP), the soluble form of the cellular membrane-bound folate 
receptor. We demonstrate that both choice of polymer and method of ligand conjugation affect 
the interactions between folic acid−polymer conjugates and serum FBP, resulting in changes in 
the folic acid-induced protein aggregation process. We have previously demonstrated that 
individual FBP molecules self-aggregate into nanoparticles at physiological concentrations. 
When poly(amidoamine) dendrimer−folic acid conjugates bound to FBP, the distribution of 
nanoparticles was preserved. However, the dendritic conjugates produced larger nanoparticles 
than those formed in the presence of physiologically normal human levels of folic acid, and the 
conjugation method affected particle size distribution. In contrast, poly(ethylene glycol)−folic 
acid conjugates demonstrated substantially reduced binding to FBP, did not cause folic acid-
induced aggregation, and fully disrupted FBP self-aggregation. On the basis of these results, we 
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discuss the potential implications for biodistribution, trafficking, and therapeutic efficacy of 
targeted nanoscale therapeutics, especially considering the widespread clinical use of 
poly(ethylene glycol) conjugates. We highlight the importance of considering specific serum 
protein interactions in the rational design of similar nanocarrier systems. Our results suggest that 
prebinding therapeutic nanocarriers to serum FBP may allow folate-specific metabolic pathways 
to be exploited for delivery while also affording benefits of utilizing an endogenous protein as a 
vector. 
4.2. Introduction 
Nanoparticles have been investigated for targeted therapeutic applications, and protein 
coronas often define their biological identity, biodistribution, therapeutic efficacy, and ultimate 
fate.1−7 As such, the formation of unwanted protein coronas that remove targeted nanoparticles 
from their therapeutic pathway has proven a major challenge in the clinical development of 
therapeutic nanoscale drug conjugates (nanocarriers). There has been substantial effort invested 
in trying to understand how protein coronas form and to mitigate their deleterious effects on the 
biotransport and off-target fate of nanoscale therapeutics.8−13 However, there are over 100,000 
blood serum proteins,14,15 which makes predicting the interactions between serum proteins and 
nanocarriers a particularly challenging task. The most notable advance on prevention of protein 
coronas is the development of “stealth nanocarriers”, most commonly achieved by conjugating 
poly(ethylene glycol) (PEG) onto the nanocarrier’s surface.5,16,17 
Generally, protein coronas are discussed as forming around nonendogenous nanoscale 
objects, but we argue that the selfaggregation of endogenous serum proteins into nanoparticles 
should also be considered a type of protein corona. The selfaggregation of serum proteins 
carrying vitamins, drugs, other small molecules, and nanocarrier conjugates affects the 
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biotransport and cellular uptake of the materials, just as with protein coronas that form around 
exogenous nanoparticles. As we discuss, it may be possible to exploit serum protein 
selfaggregation into natural protein coronas for targeted drug delivery.  
This work explores the interaction of folate binding protein (FBP) with folic acid 
(FA)−polymer conjugates. FBP is a glycoprotein (~30 kDa) present in 1−2 nM concentration in 
human blood serum and 100 nM concentration in human breast milk.18−20 Serum FBP is likely 
derived from two isoforms of membrane-bound folate receptors (FRs) via cleavage of their 
glycosylphosphatidylinositol (GPI) anchors.21,22 The concentration-dependent self-aggregation of 
serum FBP has been well-documented over the past several decades, and it has generally been 
observed that FBP molecules have an increasing tendency to self-associate with increasing 
concentration.23−26 
Researchers have also extensively studied FA-induced FBP aggregation and particle 
formation.24−31 This aggregation is important in the context of the substantial amount of research 
and attention FA targeting on a variety of different platforms has received.32−39 FA is an 
attractive targeting ligand in drug delivery systems due to its (1) high binding affinity to FR/FBP, 
(2) stability, (3) ability to be conjugated to a variety of different nanoparticulate and polymeric 
platforms, and (4) affinity for membrane-bound FRs that are overexpressed on many human 
cancers. In the field of targeted drug delivery, including in research on FA-targeted therapeutics, 
the majority of the work has focused at the cellular level, i.e., with the assumption that vectors 
are delivered to the targeted tissues as administered and that conjugated FA is free to interact 
with FRs on the cell surface.40−42 It is assumed that once the targeted vectors interact with the 
FRs, the therapeutic will be taken up via receptor-mediated endocytosis. However, intravenously 
administered FA-targeted therapeutics will interact with and bind to serum FBP just as strongly 
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as they will to cellular FRs. In large part, the design process is missing the critical consideration 
of specific serum protein interactions (and not just the nonspecific formation of potentially 
deleterious serum protein coronas) between the targeted nanocarrier and serum proteins during 
transport to the cell. In this report, we probe the interaction of FA-dendrimer and FA-PEG 
conjugates with serum FBP and characterize the resulting particle distributions. 
FA binding to FBP is important for its biotransport and delivery and enhances both 
symmetric (apo−apo or holo− holo) and asymmetric (apo−holo) protein aggregation.25,28 The 
increased tendency toward both symmetric and asymmetric aggregation has been attributed to 
conformational changes in the FBP that occur upon FA binding. There are limited data on the 
binding of other small molecules, such as FA-antagonist drugs (antifolates) like methotrexate 
(MTX), to FBP. A 2009 study by Bruun et al. compared FA- versus MTXinduced changes to the 
intrinsic FBP fluorescence, relating the results to changes in protein conformational structure. 
Crystal structures of FA and MTX bound to FR were published by Chen et al. (2013)43 and 
Wibowo et al. (2014),44 confirming the conformational changes that occur with ligand binding. 
Our group recently examined FBP aggregation in the presence of FA, MTX, and 
leucovorin (LEUC, a vitamer of FA).45,46 Due to technique and detection level limitations, the 
earlier studies on serum FBP were carried out at FBP concentrations at least an order of 
magnitude above physiological levels. In our recent report, we used atomic force microscopy 
(AFM) to investigate FBP aggregation as a function of protein and ligand concentration and 
ligand identity at FBP concentrations similar to those found in human blood (~1−2 nM) or other 
bodily fluids (100 nM). FBP aggregation was observed at all protein concentrations, but the 
degree of aggregation varied as a function of ligand identity and concentration. That FBP 
aggregation was maintained at physiologically normal or therapeutically relevant concentrations 
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of FA, MTX, and LEUC indicated the importance of self- aggregated FBP in the biotransport 
and cellular uptake of FBP-bound small molecules. Previous reports have noted that FBP 
aggregates are quite stable,29 further supporting this hypothesis. Additionally, cell culture media 
contain very high concentrations of FA (~10 μM), and therefore, aggregation of FBP in the 
media and of FRs in the membranes is expected in cell culture experiments. This is in fact 
consistent with reports of FR clustering, as well observations that many FRs are taken up in one 
endocytosis event.47,48 The recent work of Birn et al.49 and Kur et al.,50 in which they 
demonstrated in vitro and in vivo the critical role of FBP in cellular uptake of FA, further 
supports these conclusions. 
In addition to our work with small molecules, we also recently studied the binding 
interaction of FA−polymer (dendrimer and PEG) conjugates51,52 and FA-conjugated iron oxide 
nanoparticles with FBP.53 The FA-dendrimer conjugates had an equal or greater affinity for FBP 
as compared with free FA; one FA-dendrimer conjugate was able to displace FA from the FBP 
binding pocket and was not removed with large excesses of free FA. In the presence of FA-iron 
oxide, FBP aggregation was significantly enhanced. These results highlight the importance of 
considering the interactions of FBP with FA-targeted materials. 
On the basis of these observations and given the extensive efforts employing FA-
dendrimer and FA-PEG conjugates as targeted drug imaging delivery agents,51−66 in this report 
we have investigated interactions of serum FBP with four different FA-targeted dendrimer and 
PEG conjugates and have characterized the resulting nanoparticle distributions. We demonstrate 
the formation of a natural protein corona and highlight how this process is likely critical for the 
trafficking of therapeutic nanocarriers to their intended physiological targets. We discuss the 
potential implications of this particular interaction for FA-targeted drug nanocarriers. We further 
 92 
consider how it may be possible to take advantage of FBP-specific metabolic pathways in order 
to use the protein itself as a targeted carrier and/or drug delivery agent. 
4.3. Results and discussion 
In these studies, we used fluorescence spectroscopy and AFM to investigate the 
interaction of FBP (2 nM) with several FA− polymer conjugates, which have applications in 
targeted drug delivery. The binding of these conjugates to FBP directly affects FBP aggregation 
around the conjugate, sometimes resulting in FBP nanoparticles (FBPNP). Therefore, an 
understanding of the binding-induced FBP aggregation (or lack thereof) is crucial for accurately 
assessing the biotransport and cellular uptake of the FA-targeted conjugates. In this case, AFM 
afforded us the ability to directly acquire data on the volume distribution of a statistically 
relevant number of FBPNP on a particle-by-particle basis. AFM analysis of the FBPNP volume 
distribution generally showed that both the type of polymer conjugated to FBP and the method of 
conjugation itself played a critical role in the FBP self-aggregation process. We demonstrated 
that by changing the polymer we could either completely inhibit or substantially enhance FBP 
aggregation. Our attempts to use techniques such as dynamic light scattering to analyze these 
samples were inhibited by the necessity to work at low physiologically relevant concentrations of 
FBP, the low scattering cross section of the polymeric nanoparticles, and the bias of the 
technique toward larger particles. 
The FA−polymer conjugate and FBP binding interactions were explored as a function of 
FA-conjugate:FBP ratio, under solution conditions that mimicked the pH and salt concentration 
of human blood serum (1× PBS). Samples were prepared using 10−20 nM stock solutions of 
FBP or the FA conjugate. For example, a 1:1 ratio FBP:FA-conjugate sample was created by 
adding 20 μL of 20 nM FBP to 160 μL of PBS, then adding 20 μL of 20 nM FA-conjugate, 
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resulting in a clear, colorless solution. The resulting nanoparticles were captured by spin-coating 
at 3,000 rpm 20 μL of the FBPNP solution onto a freshly cleaved mica surface. We have 
previously found this to be a useful method for isolating nanoparticles from solution and 
avoiding aggregation associated with concentrating solutions or drying samples.67,68 After spin-
coating, the mica surface was washed to remove the buffer salt. AFM imaging was performed in 
tapping mode, and the volumes of the FBPNP were extracted directly from the AFM data. We 
estimated the number of FBP in each particle by calculating the volume of one FBP using a 
protein mass of 29.1 kDa and a density of 1.1 cm3 g-1. Assuming a spherical aggregate in 
solution, the detected volume of each FBPNP was used to extrapolate the nominal radius of each 
particle in solution. 
4.3.1. Polymer conjugates 
Highly water-soluble polymers such as PEG and poly(amidoamine) (PAMAM) 
dendrimers have been popular in the development of FA-targeted delivery systems because they 
solubilize hydrophobic FA and drugs.69−71 In the case of dendrimers, multiple attachment points 
are available for small molecules. As such, in this work we investigated the interaction of serum 
FBP with four FA− polymer conjugates: two PAMAM conjugates and two PEG conjugates of 
different polymer lengths. Both generation 5 (G5) PAMAM species were fully acetylated after 
ligand conjugation in order to make the polymer neutral under physiological conditions, thereby 
decreasing the cytotoxicity of the polymer.54,59,72 The use of these four different polymer−FA 
conjugates illustrated how both polymer type and method of conjugation can significantly alter 
interactions with serum proteins. 
 
 
 94 
 
The first of these polymer conjugate studied was G5 PAMAM with a stochastic average 
of four FA (G5Ac-FA4(avg)) conjugated directly to each dendrimer through an amide bond Figure 
4.1a). The average of four FA per dendrimer was the goal of the synthesis and determined to 
have been achieved by 1H NMR (Figure B.1 in Supporting Information), but since the number of 
ligands on a dendrimer follows a Poisson distribution,69,73−75 approximately 20% of the sample 
had the average four FA molecules per dendrimer (Figure 4.1b). (This polymer conjugate also 
has an average of two fluorescein isothiocyanate molecules per dendrimer.) 
The second G5 PAMAM polymer conjugate studied had one FA per dendrimer 
conjugated through a cyclooctyne glycolic acid−amino acid linker (G5Ac-COG-FA1.0) (Figure 
a)
c)
d)
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Figure 4.1. Representations of polymer-conjugate materials used in this work. For the PAMAM dendrimers, all terminal amines 
are acetylated following ligand conjugation. (a) Folic acid (FA, red) conjugated directly to G5 PAMAM (black), producing G5Ac-
FA4(avg); (b) distribution resulting from a stochastic conjugation with an average of 4 ligands and 93 arms; (c) FA (red) 
conjugated to G5 PAMAM (black) via a cyclooctyne glycolic acid (COG)–amino acid linker (blue), producing G5Ac-COG-FA1.0; 
(d) FA (red) conjugated to poly(ethylene glycol) (black). 
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4.1c). Our methods for generating a sample with a precise ratio of ligand to dendrimer have been 
reported in detail elsewhere.51,76−78 In brief, reverse-phase high performance liquid 
chromatography was used to isolate a G5 PAMAM sample with one COG linker per dendrimer. 
Copper-free, strain-promoted click chemistry was then used to conjugate FA to the dendrimer. 
The driving motivation for this early work was to remove heterogeneity from polymer conjugate 
samples in order to identify which species were producing observed biological effects. The third 
and fourth polymer conjugates used in this work were commercially available FA conjugated to 
either 2 kDa or 30 kDa PEG, respectively (Nanocs, Inc.) (Figure 4.1d). NMR spectroscopy was 
used to quantify the percentage of FA-conjugated material in the purchased materials (PEG2kDa-
FA ~25%; PEG30kDA-FA ~15%). 
4.3.2. FBP tryptophan fluorescence quenching as a function of polymer conjugate 
As reported in the work of Hansen and Holm27,31 and by our group,45,46,52,53 quenching of 
the native tryptophan fluorescence can be used to assess structural reorganization of FBP upon 
ligand binding. In our previous work, we particularly compared the fluorescence quenching 
observed when free FA and FA−polymer conjugates were titrated into FBP.52 Notably, G5Ac-
COG-FA1.0 produced a high degree of fluorescence quenching as compared to free FA or G5Ac-
FA4(avg), even at G5Ac-COG-FA1.0 concentrations as low as 0.1 equivalent per FBP. This suggests 
that each G5Ac-COGFA1.0 was capable of influencing the conformation, and therefore the 
fluorescent properties, of more than one, and up to 10, FBP. That is, not every G5Ac-COG-FA1.0 
was necessarily bound to FBP, but those that were only directly interacted with the binding 
pocket of one FBP. The conformational changes from these binding events propagated 
throughout the protein population, resulting in substantially decreased intrinsic fluorescence. 
AFM data presented in this report (vide infra) support this conclusion of induced protein 
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conformational change. For PEG-FA conjugates, the magnitude of quenching was the same as 
with free FA, but the extent of binding decreased with increasing polymer chain length, leading 
to the hypothesis that the PEG chain was inhibiting access of the FA to the FBP binding site. 
Here, we have extended our investigation of FBP fluorescence quenching upon ligand  
binding by performing the titration in the reverse order so that FBP was added in increasing 
concentrations into FA or FA−polymer conjugates (Figure 4.2). The excitation wavelength for 
the intrinsic tryptophan fluorescence was 
280 nm, and emission was detected at 342 
nm. The presence of FA or any FA-
conjugated material resulted in less FBP 
fluorescence intensity, as compared to 
apo-FBP (7.4 AU/nM). These data 
indicate that even when FBP was present 
in excess, FA or an FA-conjugate 
enhanced symmetric and asymmetric FBP 
self-aggregation and induced 
conformational changes throughout the 
protein population. This is a well-known 
effect;23−31 our method of titrating the FBP into the FA or FA conjugate clearly demonstrated 
that the conformational change continued up to 4 or 5 equivalents of protein. Interestingly, the 
trace for the G5AcCOG-FA1.0 fluorescence intensity shows two distinct slopes: the first slope (0.7 
AU/nM FBP) corresponds to fluorescence up to approximately stoichiometric ratios of FBP and 
G5AcCOG-FA1.0, and the second slope (2.8 AU/nM FBP) corresponds to superstoichiometric 
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Figure 4.2. Titration of FBP into FA (50 nM) and G5Ac-FA PAMAM 
polymer conjugates (50 nM). All curves with FA materials 
demonstrated that the presence of FA resulted in a decreased rate of 
fluorescence increase, as compared to apo-FBP (7.3 A.U./nM). These 
data indicate that even at greater than stoichiometric FBP 
concentrations, the FA materials produced conformational changes 
throughout the protein population. 
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FBP concentrations. The curves showing a slower rate of change for G5Ac-COG-FA1.0 compared 
to FA and G5Ac-FA4(avg) (4.0 and 3.8 AU/nM FBP, respectively) indicate that G5Ac-COG-FA1.0 
induced a greater conformational change in FBP as compared to the conformational change 
induced by other FA materials. This resulted in enhanced asymmetric aggregation of bound and 
unbound FBP, as demonstrated by the AFM data in following sections. 
4.3.3. AFM imaging and analysis: G5Ac + FBP 
To determine if acetylated G5 PAMAM (G5Ac) itself affected the FBP aggregation 
process, FBP (2 nM) was exposed to G5Ac at varying concentrations. The volume distributions of 
the resulting FBPNP (Table 4.1, Figure 4.3) were compared to apo-FBPNP (2 nM).46 G5Ac + 
FBP nanoparticles (radius of ~4.4− 5.5 nm) comprised on average 10−13 30 kDa species (FBP 
monomers and G5 PAMAM dendrimers) compared to the mean of 13 protein molecules for apo-
FBPNP (radius of ~4.6 nm). (See Figure B.2 for histograms of the FBPNP volume and radius 
distribution.) Statistical analyses of the G5Ac + FBP nanoparticles showed the volume 
distributions were similar to the apo-FBP for all G5Ac concentrations. At 0.5 nM and 2 nM G5Ac, 
a Kolmogorov−Smirnov (K−S) test demonstrated that the volume distributions were not 
statistically different from the apo-FBPNP volume distribution (p = 0.13 and 0.26, respectively). 
All other pairwise comparisons indicated that the populations were statistically different, but we 
do not necessarily ascribe biological or physiological difference to them. Cumulative density 
function (CDF) plots (Figure 4.3b) and quantile−quantile (Q−Q) plots (Figure 4.3c) illustrate the 
similarities of the distributions, indicating that G5Ac itself did not substantially interfere with 
natural FBP aggregation. Previously reported fluorescence quenching data support this 
conclusion.52 
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G5 PAMAM conc.
(nM)
Particle 
Count
Mean Volume (nm3)
[Mean Radius] (nm)
Mean # 30kDa 
species
(n)
Volume
Median 
(nm3)
Volume 
Mode 
(nm3)
2 nM FBP N/A 738
610 ± 1160
[4.6 ± 1.8]
13 320 60
2 nM FBP
+
G5Ac
PAMAM
0.5 457
550± 560 
[4.5 ± 1.6]
12 330 70
2 339
570 ± 650
[5.4 ± 1.5]
13 280 50
5 406
460 ± 470  
[4.4 ± 1.4]
10 300 120
50 216
580 ± 600  
[4.6 ± 1.6]
13 370 80
Table 4.1. Summary of mean, median, and mode of nanoparticle volumes formed upon exposure of 2 nM FBP to varying 
concentrations of G Ac (1x PBS). Particle size and distributions were determined by analyzing AFM images of FBP nanoparticles 
captured by spin-coating the solutions onto freshly-cleaved mica. 
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Figure 4.3. a) AFM images of FBP nanoparticles resulting from the addition of G5Ac to FBP (2 nM in 1x PBS). AFM images 
were captured by spin coating the solutions onto freshly-cleaved mica; b) Cumulative density function (CDF) plots the measured 
volumes G5Ac + FBP nanoparticles; c) Quantile-quantile (Q-Q) plots of the volumes of G5Ac + FBP nanoparticles plotted against 
the distribution of ligand-free 2 nM FBP nanoparticle volumes. The square markers represent each decile of data. The straight 
lines in the charts pass through the 1st and 3rd quartiles (25th and 75th percentiles) of the data. Q-Q plots compare the quantiles of 
one population against the quantiles of a second population. 
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4.3.4. AFM imaging and analysis: G5Ac-FA4(avg) + FBP 
In the presence of G5Ac-FA4(avg) (0.5−50 nM polymer), FBP (2 nM) remained aggregated 
in well-defined, discrete nanoparticles (Table 4.2, Figure 4.4a). FBP and G5 PAMAM both have 
similar molecular weights (~30 kDa) and volumes. Therefore, the measured volumes of FBPNP 
include both 30 kDa species. The volume data provided no information on the ratio of protein to 
polymer; only an estimate of the number of 30 kDa species could be extrapolated. We expected 
that each G5Ac-FA4(avg) was directly bound to only one FBP, i.e., no multivalent binding.
52 
However, it is possible that the conformational change in FBP resulting from binding event 
induced asymmetrical apo−holo aggregation. 
 
Polymer Conj. +
2 nM FBP
Conc.
[FA conc.]
(nM)
Particle
Count
Mean Volume [nm3]
[Mean Radius] (nm)
Mean 
#30kDa 
species
(n)
Volume
Median
(nm3)
Volume
Mode
(nm3)
G5Ac-FA4(avg)
0.5
[2]
1,813
640± 600
[4.9 ± 1.6]
14 450 60
2
[8]
1,087
790 ± 580
[5.4 ± 1.5]
18 660 100
5
[20]
618
1,120 ± 820
[6.0 ± 1.8]
25 928 60
50
[200]
multilayers of particles à could not measure volume accurately
G5Ac-COG-FA1.0
0.2 410
227 ± 251
[3.5 ± 1.0]
4 150 100
0.5 243
820 ± 746
[5.3 ± 1.8]
18 594 100
1.0 multilayers of particles/polymer à could not measure volume accurately
2.0 15
32700 ± 20600
[19 ± 3.9]
730 very few particles
PEG(2kDa)-FA 2-200 no particles observed
PEG(30kDa)-FA 2-200 no particles observed
Table 4.2. Summary of mean, median, and mode of nanoparticle volumes formed upon exposure of 2 nM FBP to varying 
concentrations of G5Ac-FA4(avg), G5Ac-COG-FA1.0, and PEG-FA conjugates (1x PBS). Particle volume and distributions were 
determined by analyzing AFM images of FBP nanoparticles captured by spin-coating the solutions onto freshly-cleaved mica. 
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The binding of G5Ac-FA4(avg) to FBP preserved the natural nanoparticulate form of the 
protein, but the resulting particles were slightly larger than apo-FBPNP and dramatically larger 
than FBPNP formed in the presence of physiological levels of FA (Figure 4.4b).46 FBPNP 
volume increased with G5Ac-FA4(avg) concentration. The Q−Q plots of these data further highlight 
this result. In Figure 4.5a, the Q−Q plots show that the volume distributions of G5Ac-FA4(avg) + 
FBP nanoparticles were similar to the volume distribution of apo-FBPNP. In Figure 4.5b, the Q− 
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Figure 4.4. a) AFM images of FBP nanoparticles resulting from the addition of G5Ac-FA4(avg) to FBP (2 nM in 1x PBS). AFM 
images were captured by spin coating the solutions onto freshly-cleaved mica; b) Cumulative density function (CDF) plots of the 
measured volume distributions of 2 nM FBP, 20 nM FA + 2 nM FBP,46 and G5Ac-FA4(avg) + FBP nanoparticles. The similarity of 
the nanoparticle volume distributions was assessed using K-S statistics, which showed all nanoparticle volume distributions to be 
statistically different. Analysis of the volume distributions indicated that FBP nanoparticle size increases with increasing G5Ac-
FA4(avg) concentration. 
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Q plots demonstrate that the volumes of G5Ac-FA4(avg) + FBP nanoparticles were significantly 
larger than nanoparticles generated from 20 nM FA + 2 nM FBP. 
 
4.3.5. AFM imaging and analysis: G5Ac-COG-FA1.0 + FBP 
FBP (2 nM) was exposed to G5Ac-COG-FA1.0 over a concentration range of 0.2−20 nM 
(Table 4.2, Figure 4.6). Substantially lower concentrations of conjugate as compared to the G5Ac-
FA4(avg) experiments were used in this case because at higher concentrations of G5Ac-COG-FA1.0 
very large aggregates and multilayers of polymer were observed in the AFM images. It is 
interesting to compare these AFM results with the fluorescence quenching data highlighted in 
our previous work, particularly the fact that G5Ac-COG-FA1.0 induced a large conformational 
change in FBP (see discussion above).52 By AFM, this phenomenon was observed as asymmetric 
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Figure 4.5. Quantile-quantile (Q-Q) plots of nanoparticle volume distributions. The square markers represent each decile of data. 
The dashed lines pass through the 1st and 3rd quartiles (25th and 75th percentiles) of the data. a) Q-Q plots of the volumes of G5Ac-
FA4(avg) + FBP nanoparticles plotted against the ligand-free volume distribution of 2 nM FBP nanoparticles; b) Q-Q plots of the 
volume distribution of G5Ac-FA4(avg) + FBP nanoparticles plotted against the nanoparticle volume distribution of 20 nM FA + 2 
nM FBP. This is approximately the healthy physiological concentration of FA in blood serum. Q-Q plots compare the quantiles 
of one population against the quantiles of a second population. 
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aggregation between apo and holo FBP. 
Our AFM results showed  substantial 
aggregation at substoichiometric levels of 
G5Ac-COG-FA1.0, with excess polymer 
observed on the mica surface, which is 
particularly evident in the images of 2 nM 
and 8 nM G5Ac-COG-FA1.0 + 2 nM FBP 
(Figure 4.6). While the present studies 
demonstrate a much more dramatic effect, 
this is consistent with our previous AFM work showing that at low concentrations of FA, FBP 
undergoes asymmetrical apo−holo aggregation.46 
We hypothesize that G5Ac-COG-FA1.0 induced much more fluorescence quenching52 and 
FBP aggregation compared to G5Ac-FA4(avg) because of the long glycolic acid−amino acid linker 
between the polymer and the ligand (Figure 4.1c). The distance afforded the G5 PAMAM arms 
sufficient room to interact with the FBP once it underwent a conformational change upon ligand 
binding. This hypothesis is consistent with previous work from our group in which we 
demonstrated that G5Ac-COG-FA1.0 bound irreversibly to FBP due to a network of nonspecific 
van der Waals interactions between the G5 PAMAM and the protein (a slow-onset, tight-binding 
mechanism).51,76 In the case of G5Ac-FA4(avg), the G5 PAMAM was held more closely to the FA 
and the binding pocket, and we hypothesize that the dendrimer arms could not interact with large 
enough area of the protein surface to form a strong van der Waals network. 
0.2 nM G5Ac-COG-FA1.0
2 nM FBP
0.5 nM G5Ac-COG-FA1.0
2 nM FBP
1 nM G5Ac-COG-FA1.0
2 nM FBP
2 nM G5Ac-COG-FA1.0
2 nM FBP
8 nM G5Ac-COG-FA1.0
2 nM FBP
20 nM G5Ac-COG-FA1.0
2 nM FBP
Figure 4.6. AFM images of FBP nanoparticles resulting from the 
addition of G5Ac-COG-FA1.0 to FBP (2 nM in 1x PBS). AFM images 
were captured by spin coating the solutions onto freshly-cleaved 
mica. 
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4.3.6. AFM imaging and analysis: PEG-FA + FBP 
PEG2kDa-FA and PEG30kDa-FA at both 2 and 20 nM were added to FBP (2 nM), a 
concentration at which apo-FBPNP are known to be present.46 (Higher PEG-FA concentrations 
resulted in a multilayer coating of polymer on the mica surface.) In all cases, the PEG-FA 
conjugates disrupted the existing FBP nanoparticles, and very few were observed by AFM 
(Table 4.2, compare Figure B.3to Figure 4.4a and Figure 4.6). That is, PEG-FA conjugates upset 
the natural FBP aggregation process. 
Our previously published fluorescence quenching data indicated that the shorter PEG-FA 
conjugates do bind to FBP and induce a conformational change in the FBP, but the binding 
affinity was significantly decreased due to the interference of the PEG chain blocking access to 
the binding pocket.52 The steric constraints imposed by the longer PEG chains resulted in greatly 
reduced binding and subsequent fluorescence quenching. Given that PEG-FA did demonstrate 
some binding interaction with FBP, it is likely that the PEG chain in close proximity to the 
protein blocked FBP self-aggregation, observed by the lack of FBPNP in the AFM images. 
4.3.7. Potential implications for drug delivery: targeted biotransport and efficiency 
Our recent work demonstrated that when physiological concentrations of FBP are 
exposed to free FA at healthy serum levels, FBPNP formed that comprised an average of six 
proteins subunits.46 We hypothesize that the nanoparticulate form of FA-carrying FBP is critical 
for the delivery and cellular uptake of the vitamin, consistent with the hypotheses of Birn49 and 
Kur.50 
With FA-targeted drug delivery, the goal is to have the targeted conjugates trafficked 
similarly to FA in order to take advantage of cellular overexpression of FRs on diseased cells. 
Therapeutic efficacy and decreased toxicity are dependent on targeted biological transport to and 
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successful uptake by the intended tissues. However, FBPNP containing PAMAM-FA conjugates 
were larger than natural FBPNP (apo and FA-bound), which could have implications for the 
trafficking, biodistribution, and efficacy of the targeted conjugates. In direct contrast to the effect 
of PAMAM on FBP aggregation, PEG disrupted the natural and healthy FBP aggregation 
processes, suggesting that PEG-containing FA-targeted vectors may not be trafficked as 
intended. PEG is the most commonly used polymer for biomedical applications, including in 
nanocarrierbased drug delivery, and therefore, its use and role in preventing protein coronas 
warrant consideration in the rational design of targeted vectors. Furthermore, the disruption of 
natural FBP aggregation may also impact normal FA distribution and metabolism. 
Given the highly specific metabolic pathway of FBP and the critical role we postulate 
FBP plays in the trafficking process, we propose that FBPNP itself can be used as a targeted 
nanocarrier, leading to decreased off-target toxicity and increased efficacy. That is, we propose 
to take advantage of this naturally occurring protein corona for use in targeted drug delivery. 
This could be accomplished by prebinding the drug to FBP before administering it. We are 
currently carrying out in vivo experiments with MTX to test this hypothesis. The ability 
demonstrated in this paper to tune the size of the generated FBPNP using different polymers and 
conjugation methods also presents the attractive possibility of expanding this work to include 
polymer nanocarriers. The use of self-aggregated serum proteins as targeted therapeutic 
nanocarriers is not unprecedented. Abraxane, formulation of albumin and paclitaxel, yields 
nanoparticles with a reported 130 nm diameter.14,15 Abraxane is the only solid nanoparticle 
therapy currently in the clinic, but it has demonstrated substantial success in the treatment of 
breast, lung, and pancreatic cancers. In this case, it is believed the drug remains bound to 
albumin, and the uptake into cells follows the albumin trafficking pathways. However, albumin 
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is the most common human serum protein, and as a result, the treatment suffers from its 
promiscuous nature and widespread distribution throughout the body. The metabolic pathway of 
FBP is much more specific, which presents the possibility of using it in a targeted fashion as an 
endogenous protein nanocarrier. 
4.4. Conclusions 
Using fluorescence spectroscopy and AFM, we examined the aggregation of FBP in the 
presence of four different FA− polymer conjugates with applications in FA-targeted drug 
delivery. The degree of aggregation of FBP varied with both polymer type and conjugation 
method. These data demonstrate the importance of considering the interactions between targeted 
polymer nanocarriers and serum proteins to which they bind. 
In general, when G5 PAMAM-FA conjugates bound to FBP, the natural FBP self-
aggregation process was preserved, although with some notable differences in FBPNP size as 
compared to the natural aggregation process. Conversely, PEGFA conjugates completely 
disrupted FBP self-aggregation. The disruption of natural FA-trafficking pathways from PEG 
conjugation will likely have important implications for delivery and efficacy of the targeted 
therapeutic, which may point toward why FA-targeted PEG conjugates have yet to be widely 
adopted in the clinic. To be successful in designing and deploying targeted polymer vectors, 
researchers must consider the effect of PEG on FBP self-aggregation and protein corona 
formation. Additionally, the disruption of FBPNP will likely also have the unintended side effect 
of interfering with free FA transport and metabolism. 
The data and discussion presented here solely focus on FA− polymer conjugates, but we 
suggest that the necessary considerations of serum protein interactions and aggregation apply 
generally to the field of drug delivery research. Along with attention to solubility, stability, 
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toxicity, and immunogenicity, researchers designing targeted nanocarrier systems must take into 
account (and possibly even beneficially exploit) these natural protein coronas. 
4.5. Experimental Procedures 
4.5.1. Materials 
All materials were purchased from commercial sources. G5 PAMAM dendrimers were 
purchased from Dendritech, Inc. (Midland, MI) and were purified before conjugation procedure 
as previously reported.51,76−78 Folic acid and sepharose 4B beads were purchased from Sigma-
Aldrich (St. Louis, MO) and used as received. PEG-FA conjugates were purchased from Nanocs, 
Inc. (Pittsburgh, PA) and used as received following characterization of active FA material by 1H 
NMR. HPLC grade water, acetonitrile, and methanol were purchased from Fisher-Scientific 
(Waltham, MA) and used as received. A 500 MHz Varian NMR instrument was used for all 1H 
NMR measurements. FA and FA-containing materials were shielded from light when handling. 
4.5.2. Extraction and purification of FBP 
FBP was purified from whey protein powder using a FA affinity column as previously 
described.52 In brief, sepharose 4B beads (200 mL bed volume) were activated with cyanogen 
bromide and subsequently conjugated to FA. A pH 7.0 2% (w/v) solution of whey protein was 
centrifuged (20,000g) for 20 min at 4 °C. The supernatant was transferred to the affinity column. 
Unbound protein was washed away with 1× phosphate buffer containing 1 M NaCl (pH 7, 1 L). 
The column was then washed with nanopure water (at least 2 L) until no protein was detected in 
the eluent. FBP was released from the column using 0.2 M acetic acid (300 mL). The first 30 mL 
of the acid wash was discarded because this volume was shown to contain very little protein, and 
what was present was not pure. For the remaining 270 mL of FBP-containing acetic acid solution 
the pH was adjusted to 7 by the addition of 5 and 1 M NaOH. The neutralized protein solutions 
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were frozen in liquid N2 and lyophilized to yield a white powder comprising sodium acetate salt 
and FBP. The concentration (w/w) of the FBP in the powder was determined using a NanoDrop 
fluorospectrometer with absorption at 280 nm. The purity of the FBP was assessed by 
fluorescence spectroscopy, AFM, SDS−PAGE, and MALDITOF-MS (sinapic acid matrix). 
Fractions containing FBP with at least 90% purity were combined. Note that bovine FBP was 
used for this study. Bovine FBP and human FBP have >80% homology overall, including 100% 
homology in the binding pocket. The human and bovine forms have been shown to exhibit 
similar aggregation phenomena. For this work, we have employed the substantially more 
accessible bovine FBP. 
4.5.3. Synthesis of G5 PAMAM-FA polymer conjugates 
Biomedical grade G5 PAMAM was purified using reverse phase HPLC to obtain G5 
dendrimer without trailing generations (G1−G4), dimers, and trimers.78,75 G5Ac and G5Ac-COG-
FA1.0 were synthesized according to previously reported methods.
51 
Synthesis of G5Ac-FA4(avg) was based on previous methods.
54,79,80 Small changes were 
made to the procedure and are briefly described here. Amine-terminated G5 PAMAM dissolved 
in methanol was reacted with fluorescein isothiocyanate (FITC) for 24 h. The resulting material 
was purified by dialysis against a 10,000 MWCO membrane. G5(NH2)-FITC was allowed to 
react with FA which was preactivated with EDC and NHS. The reaction was stirred for 3 days. 
The product was purified using dialysis and centrifugation against 10 000 MWCO membranes. 
After lyophilization to dryness, 1H NMR analysis demonstrated the presence of both FITC and 
FA conjugated to the dendrimer. Finally, the remaining terminal amine groups were fully 
acetylated by exposing the dendrimer conjugate to excess acetic anhydride in the presence of 
triethylamine. The product was purified by centrifugation against a 10,000 MWCO membrane. 
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Remaining unconjugated small molecules were removed by dialysis to yield G5Ac-FA4(avg). 
Ultraperformance liquid chromatography and 1H NMR analyses demonstrated the removal of 
small molecules. 1H NMR integration determined an average of 4.2 folic acids and 2.2 FITC per 
G5 dendrimer (Figure B.1). 
4.5.4. Fluorescence experiments 
Fluorescence experiments were performed on a Varian Cary Eclipse fluorescence 
spectrophotometer. The excitation wavelength for tryptophan was 280 nm, and the detected 
emission wavelength was 342 nm. The temperature was controlled to 22 °C. Experiments were 
carried out in a 1× PBS without Ca2+ and Mg2+. Fluorescence measurements were taken after the 
solutions had reached equilibrium. 
4.5.5. AFM sample preparation 
Full experimental details have been previously reported.46 Briefly, FBP and FA−polymer 
conjugate solutions were made using serial dilutions in 1× PBS. In all cases, the FA−polymer 
conjugate solution was added to the FBP solution. The resulting FBPNP solutions were stored at 
4 °C and shielded from light. To image the nanoparticles, FBPNP solution was spin-coated onto 
freshly cleaved mica. The mica surface was rinsed with nanopure water to remove the salt and 
dried under a stream of N2. 
For PEG-FA samples, the percent FA-conjugation of the commercial material was 
assessed by 1H NMR (PEG2kDa-FA ~25%; PEG30kDa  ~15%). The amount of PEG-FA conjugate 
used in each solution was adjusted to account for the fact that not all of the material was active. 
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4.5.6. AFM imaging and analysis 
The AFM imaging procedures and nanoparticle analysis have been previously reported.46 
Briefly, all AFM imaging was carried out in air using a PicoPlus 5500 AFM (Agilent) or a 
Nanoscope III (Digital Instruments). Imaging was performed in tapping mode using Aspire 
CT300R probes (NanoScience, AZ; silicon cantilever, nominal radius 8 nm, force constant 40 
N/m, resonance frequency 300 kHz, length 125 μm). For the G5Ac, G5AcFA4(avg), and G5Ac-COG-
FA1.0 samples, FBPNP were quantified in 1.5 μm × 1.5 μm images, with line scan rates set at 1.5 
Hz and 512 pixels per line (∼2.9 nm/pixel). Random locations on the mica surfaces were 
imaged. 
The AFM images were analyzed and the volume of the FBPNP was determined using the 
automated “Particle & Pore Analysis” feature in SPIP (version 6.2.6, Image Metrology, 
Hørsholm, Denmark). See our previous report for full details on the image processing and 
nanoparticle measurement methods.46 Histograms of the nanoparticle volumes and radii are 
shown in Figure B.2. 
 
Supporting information in Appendix B. 
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5.1. Abstract 
Using a KB xenograft model in severe combined immunodeficient (SCID) mice, we 
investigated whether pre-binding the chemotherapeutic methotrexate (MTX) to folate binding 
protein (FBP) would enable the protein to serve as a targeted therapeutic vector, enhancing 
uptake into tumor cells and improving therapeutic efficacy. Three concentrations of FBP were 
tested (MTX dose was held constant between the groups), in addition to FBP alone. Despite 
displaying substantial toxicity, FBP alone inhibited tumor growth compared to the saline control 
and free MTX. This is the first time this effect of FBP has been reported. We hypothesize the 
excess unbound FBP resulted in folate starvation of the tumors. The groups treated with MTX 
and FBP also showed inhibition of tumor growth, but toxicity increased with FBP concentration. 
It is likely that instead of specifically targeting the cancer cells, FBP facilitated widespread 
uptake of MTX, resulting in systemic toxicity. The substantial reduction observed in tumor 
volume suggest that FBP alone could be employed as a chemotherapeutic. As an endogenous 
serum protein, FBP avoids complications associated with synthetic nanoscale therapeutics, 
primarily immune reactions (e.g., opsonization) and heterogeneity in manufacturing.  
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5.2. Introduction 
Folic acid (FA) targeting has been widely explored as a targeting agent for cancer 
therapy.1–14 High-affinity folate receptors (FRs), with which FA has a nanomolar dissociation 
constant, are overexpressed in a wide range of human cancers, including breast, ovary, 
endometrium, kidney, lung, brain, head, and neck.3,4,15–19 Cancers are postulated to overexpress 
FRs because FA is a critical component in DNA synthesis, and rapidly dividing cancer cells must 
have access to a large amount of FA.20–23 Researchers have sought to leverage this 
overexpression to achieve active, selective targeting to the cancer cells. Despite a number of 
clinical trials in humans,1,2 FA-targeted cancer therapies have yet to be deployed in the clinic. In 
the mid-2000s an FA-targeted cancer therapeutic designed by colleagues was cleared to begin 
clinical trials. However, synthesizing consistent batches of material on the kilogram scale proved 
a challenge, and the trial was never started. At that time, we began investigating why FA-
targeted therapies broadly were not performing as expected or desired and why the 
manufacturing scale-up of these materials was so difficult. 
 Over approximately the last decade, we have published a number of papers investigating 
this phenomenon.13,24–27 In particular, we focused on the interaction between the targeted 
therapies and proteins, both FRs and serum proteins.11,12,28–30 Based on these studies, we 
postulate that the role of serum folate binding protein (the soluble form of cellular membrane-
bound FRs) may play an important role in trafficking and biotransport of the FA-targeted 
materials. 
Folate binding protein (FBP) is derived from membrane-bound FRs through cleavage of 
the glycosylphosphatidylinositol (GPI) anchor and is present at 1-2 nM in human blood serum 
and <1 nM in human tissues.31,32 The 21 residues in the binding pocket of FR- (the isoform of 
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FR from which the majority of FBP is derived) and FBP are 100% homologous. Therefore, any 
targeted therapeutic will have the same strong binding interaction with FBP as it will with 
membrane-bound FRs. This binding event and subsequent FBP aggregation/protein corona 
formation we and others previously reported,12,28–30,33–41 will dictate the biotransport and uptake 
of the therapeutic before it reaches the targeted cells. Therefore, FA-targeted therapies in vivo are 
likely to operate by a different mechanism that those predicted by in vitro experiments in the 
absence of soluble FBP.  
 In the research presented here, we sought to leverage the interaction of therapeutics with 
serum FBP present in vivo. We took advantage of the fact that members of the antifolate (aFA) 
class of drugs bind to FBP due to the structural similarities between FA and aFAs.22,23,41 We and 
others have reported that the most commonly used aFA, methotrexate (MTX), causes FBP 
aggregation similar to the aggregation processes induced by FA.12,41 Protein aggregation is often 
considered to be an indication of disease or physiological disfunction (e.g., β-amyloid formation 
associated with Alzheimer’s disease).42 With FBP, however, self-aggregation is postulated to be 
a natural and healthy process.12,33–41  It has been shown that the FBP aggregates are quite 
stable.39 This is consistent with research demonstrating clusters of FBP and FRs taken up into 
cells in one endocytosis event.43–46 In vitro and in vivo work by Birn et al.,47Kur et al.,48 and 
Piedrahita et al.49 highlight the critical role FBP plays in uptake of FA, in healthy cellular 
processes, and embryonic development. In unpublished research, we also demonstrated that one 
large dose of MTX administered once per week inhibited tumor growth and was significantly 
less toxic than the same cumulative amount being divided into daily doses. We hypothesize this 
is because the initial dose of FBP swamps out endogenous serum FBP, and time between doses 
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is needed for the FBP to regenerate. When another dose is administered too soon, off-target 
uptake and toxicity increase.  
In the context of this previous work, we hypothesized that by pre-binding MTX to FBP 
we could actively target FR-overexpressing cancer cells. In addition to providing a transport 
vehicle to the MTX, pre-binding the drug to FBP avoids the problem of over-saturating 
endogenous serum FBP, potentially leading to toxicity due to off-target uptake of MTX not 
bound to FBP. 
Pre-binding already clinically approved drugs to serum proteins to increase targeting and 
efficacy is not unprecedented. Abraxane® is a 130 nm albumin-bound form of paclitaxel (Taxol 
®) that is used to treat metastatic breast and pancreatic cancer and advanced lung cancer.50,51 The 
biotrafficking of the drug is coupled to albumin trafficking and absorption, likely as a complex of 
one drug and one protein. A number of other albumin-based therapies are also already in the 
clinic or in clinical trials.50,51 One of the major problems associated with using albumin, 
however, is that it is highly promiscuous – it is the most common human serum protein (0.6-0.7 
mM). FBP is present at much lower concentrations than albumin and functions on a much more 
specific metabolic pathway associated with FA trafficking and cellular delivery. We therefore 
hypothesized that we could take advantage of the specific FBP trafficking pathway to deliver 
targeted therapy. The following Communication describes our first efforts testing this hypothesis 
using a KB xenograft model in mice. 
5.3. Results and discussion 
5.3.1. FBP as a therapeutic.  
In this study we investigated whether pre-binding the antifolate cancer therapeutic MTX 
to FBP provided enhanced targeting of tumor cells and reduced toxicity. In an in vivo study using 
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a KB xenograft model in SCID mice, we compared how well three different ratios of MTX to 
FBP controlled tumor growth. Free MTX, free FBP, and saline were used as controls. Table 5.1 
shows a summary of the treatment groups and survival outcomes. In all treatment groups with 
MTX (Groups A-D), the drug was administered at 0.3 mg/kg (approximately 10 µM in blood 
serum), giving a maximum cumulative dose of 5 mg/kg. FBP doses ranged from approximately 
5-80 mg/kg (3-45 µM). Mouse blood volume was estimated at 1.2 mL. 
 
Table 5.1. Summary of treatment groups and survival statistics. The cumulative mass ratio gives the theoretical maximum mass 
ratio of MTX and FBP that would have been administered if the mouse survived the entire 56-day trial (15 injections). 
 
Figure 5.1 shows measured tumor volume as a function of time. The solid lines represent 
tumor growth up to lethality of (LD50), and the dashed lines show the tumor growth for the 
remaining two mice past that point. Figure 5.2 shows the survival rate of the mice. All of the 
mice dosed with free MTX (Group A) survived the entirety of the 56-day trial, while mice given 
any MTX + FBP (Groups B-D) or FBP alone (Group E) experienced substantial toxicity effects. 
As discussed in detail below, this likely due to a combination of adverse responses to both FBP 
itself and increased toxicity from enhanced systemic uptake of MTX. 
Despite concerns relating to the toxicity of the FBP-containing treatment and the survival 
rate of the mice, FBP alone (Group E) suppressed tumor growth. In fact, this group had the 
smallest tumors of all the treatment groups. This indicates that the protein itself can act as a 
Group Treatment 
Molar ratio 
MTX:FBP 
Dose 
(mg/kg) ratio  
MTX : FBP 
Cumulative mass 
(mg/kg) ratio 
MTX:FBP 
Day at LD50 
(<3 mice 
surviving) 
Day by  
which mice 
died/sacrificed 
A MTX only 1 : 0 0.3 : 0 5 : 0  N/A 56 
B MTX : FBP 1 : 0.25 0.3 : 5 5 : 80 31 56 
C MTX : FBP 1 : 1.1 0.3 : 24 5 : 353 35 38 
D MTX : FBP 1 : 3.7 0.3 : 79  5 : 1,186 18 21 
E FBP only 0 : 3.7 0 : 79 0 : 1,186 24 28 
F Saline N/A N/A N/A N/A 56 
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therapeutic. This effect of FBP has never before been reported, and its physiological mechanism 
is unknown. We hypothesize that FBP inhibited tumor growth by acting as a competitor for 
uptake of FA-bound FBP into the cancer cells, thus effectively starving the tumors of folate. In 
these studies, each dose in Group E (as well as Group D) resulted in serum FBP concentrations 
approximately four orders of magnitude higher than natural human FBP concentrations (40 µM 
after injection vs. 1-2 nM). It is unclear whether the folate starvation was a result of the tumors 
taking up the more available apo-FBP or if the tumors rejected apo-FBP (signaled by the 
conformational change in the protein upon ligand binding) but did not have sufficient access to 
FA-bound FBP. The mechanism 
and therapeutic efficacy of this 
potential treatment warrant further 
study.  
Taking both survival and 
tumor inhibition into account, 
Group B fared the best. Based on 
these data, it is unclear whether the 
observed effect was due to the FBP 
only or a synergistic effect between 
FBP and MTX. Based on the slow 
rate of tumor growth as compared 
to free MTX (Group A) and the 
toxicity of the treatment –  Group 
B was lethal (LD50) by 31 days – it 
Figure 5.1. Tumor growth in SCID mice with KB xenografts during treatment 
with MTX+FBP, free MTX, free FBP, or saline (control). Solid lines represent 
the tumor growth up to lethality (LD50) and the dashed lines represent the 
tumor growth for the remaining two mice in the treatment group. The vertical 
lines represent the standard deviation. a) Tumor growth over 56 days; b) 
Zoomed view of tumor growth over the first 28 days of the experiment. 
 123 
appears that FBP is the primary contributor to the observed physiological outcomes. It is also 
possible that the combination of equal parts MTX and FBP (Group C) suppressed tumor growth, 
but none of the mice survived far enough into the study to know whether this trend would hold. 
The drop in tumor volume between Day 31 and Day 35 for the last remaining mouse in Group C 
is anomalous and unexplained. Regardless, these data indicate that FBP administered at lower 
doses than tested in this study could be therapeutically useful in inhibiting tumor growth. FBP 
could be used alone or synergistically with other drugs. 
5.3.2. Toxicity of FBP-containing treatments 
Despite the potential therapeutic properties of FBP or FBP+MTX, the data presented in 
Table 5.1, Figure 5.1, and Figure 5.2 demonstrate that high doses of FBP – even without any 
MTX present – were toxic. In Groups D and E, both of which had 3.7 equivalents of FBP, none 
of the mice survived past day 28, even with the tumor growth inhibition demonstrated in Group 
E. LD50 for Group D was 17 days, and all the animals in Group D died by day 21. It should also 
be noted that several mice in Groups D and E died approximately 30 seconds after injection, 
likely from stroke. If this phenomenon were to occur again in future experiments, the mice 
would be sent to a pathologist for further study. Mice given lower concentrations of FBP 
(Groups B and C) survived longer, but 
none lived to the end of the 56-day trial 
like the mice administered free MTX 
(Group A) and saline (Group F). 
We propose several possible 
explanations for the toxicity results, some 
or all of which could have contributed to 
Figure 5.2. Survival rate of SCID mice bearing KB xenograft tumors 
treated with MTX+FBP, free MTX, free FBP, or saline (control). 
Each treatment group comprised five mice. 
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the observed outcomes. The first is that the FBP itself was acutely toxic when administered at 
concentrations much higher than natural physiological levels. The animals may have experienced 
an adverse reaction to the rapid infusion of high concentrations of exogenous protein. In 
particular, this hypothesis may explain the sudden deaths (within one minute of injection) of 
several mice in Groups D and E. It is unclear why FBP was highly toxic to animals who survived 
immediately following the injection. Based on previous reports an immune response to the 
bovine FBP is not expected.53 
The data from Group D suggest that in Groups B-D, the high toxicity was not due solely 
to the FBP itself, but from the FBP carrying MTX as well. As mentioned above and shown in the 
figures, the animals in Group D died most quickly. In designing this study, our hypothesis was 
that FBP would provide a vehicle for active targeting of the KB tumor cells. Additionally, the 
FBP would facilitate uptake of the MTX into the tumor cells. The results indicate, however, that 
FBP enhanced widespread, systemic uptake of MTX, not just targeted uptake into tumor cells. 
Combined the adverse reaction to FBP itself, the Group D treatment was highly toxic, which 
countered our initial hypotheses. In Groups B and C, the mice likely experienced toxicity effects 
from both FBP alone and enhanced, widespread uptake of MTX facilitated by FBP. 
In general, these data suggest that FBP can therapeutically suppress tumor growth. 
Research testing lower concentrations of FBP that were used in this study will help to assess 
whether the toxicity effects can be minimized to acceptable levels. It is possible that the observed 
tumor growth inhibition was a toxicity-related effect. That is, sick mice do not grow big tumors, 
and the longer-surviving mice in Groups B and C did lose up to 30% of their body weight (mice 
in the other FBP groups did not experience such a weight loss because they did not survive long 
enough). However, this study was carried out at FBP concentrations approximately four orders 
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of magnitude higher than healthy blood serum levels, and the data show that even the lowest 
dose of FBP may have been therapeutic. Future dose-response studies should clarify the effect of 
FBP concentrations, both for the protein alone and in combination therapy. 
5.3.3. Comparison to another folic acid-targeted polymer therapeutic. 
As mentioned in the Introduction, we have unpublished data showing that a single dose 
of MTX is less toxic than the same cumulative dose spread out over multiple injections. Despite 
this, we designed this study to have a direct comparison to previous research carried out by 
colleagues (Kukowska-Latallo et al.) in which they tested poly(amidoamine) (PAMAM) 
dendrimers as a scaffold for a nanoscale therapeutic, injected twice weekly.54 A dendrimer 
conjugate very similar to this one was eventually approved for Phase I clinical trials, and we 
wanted to be able to assess the tumor growth suppression our method achieved in that context. 
Furthermore, the more frequent dosing schedule provided a method of testing the hypothesis that 
MTX toxicity associated with more frequent dosing was caused by consumption of endogenous 
FBP – by pre-binding the MTX to FBP the deleterious effect could potentially be avoided.  
The PAMAM dendrimers were conjugated to FA (targeting agent), MTX (therapeutic), 
and a fluorescent dye (imaging agent). In that study, the dose of MTX on the targeted conjugate 
was equal to the lowest dose of free MTX tested. In the research presented here, Groups A-D 
were administered MTX at the same concentration as the lowest dose tested in the Kukowska-
Latallo et al. study.54 The targeted PAMAM conjugate suppressed tumor growth to 
approximately 45% the volume of the tumors in mice administered saline, free MTX, or the 
carrier control. Additionally, the conjugate was not toxic over the course of the 56-day trial. 
Comparatively, the Group E treatment (FBP only) was lethal by day 24, but the tumors were 
suppressed to approximately 22% of the volume of the tumors in the saline group at the same 
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time point. In Group B, the group administered the lowest concentration of FBP, at lethality the 
tumor volume was 34% of the tumors in the mice treated with saline. At 56 days, the surviving 
mouse had a tumor approximately 24% the volume of the tumors in the saline-treated mice and 
35% the volume of the mice treated with free MTX (Group A).  
FBP offers potential advantages over synthetic (e.g. polymer, micelle, quantum dot) 
scaffolds. FBP is an endogenous serum protein and, therefore, avoids common immune 
reactions. The trafficking and biodistribution of nanomaterials injected into the bloodstream are 
often dictated by opsonization processes (formation of protein coronas) affecting their 
therapeutic efficacy. FBP will likely not induce the formation of further protein coronas, as 
aggregated FBP can be considered a type of protein corona itself.12,28,30 The use of a serum 
protein as the targeted scaffold also avoids complications related to conjugation heterogeneity. 
Synthesizing targeted conjugates with multiple types of ligands (i.e., targeting agents, drugs, and 
dyes) often results in thousands of different species.13,24–27,55,56 When the resulting mixtures are 
tested in vitro and in vivo¸ it is impossible to know materials are inducing the observed 
outcomes. Given these advantages of FBP, we will pursue further research into using FBP itself 
as a therapeutic. 
5.4. Conclusions and ongoing studies 
This Communication presents new data demonstrating the possibility of using FBP 
targeted carrier for aFA therapies. Surprisingly, the results suggested that FBP itself may act as a 
cancer therapeutic. We demonstrated that FBP suppressed tumor growth. We hypothesize that 
the presence of unligated FBP at concentrations higher than serum FA led to folate starvation of 
the tumor cells. In vitro assays examining the effect of excess FBP on FA uptake and directly 
measuring FA levels in tissues will provide insights into this hypothesis. The studies presented 
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here did not include treatment of comparatively low doses of FBP alone (no pre-binding of MTX 
to FBP), but future studies will include an investigation of the therapeutic efficacy of FBP over a 
wide range of concentrations. The treatment group with the lowest dose of FBP (which had MTX 
present) still displayed tumor suppression. We predict that by decreasing the FBP concentration 
more and removing the MTX we can still achieve a therapeutic effect while decreasing the 
toxicity. Finally, future work will include research exploring how FBP-induced folate starvation 
could be synergistic with other therapies, e.g., with 5-fluorouracil.57,58 It will also include 
research on the observed systemic toxicity, by radiolabeling the FBP to examine which tissues 
take it up. Overall, these early results present a promising new endogenous protein therapy that 
negates the need for a toxic small molecule chemotherapeutic and avoids problems associated 
with the manufacturing process, immunogenicity, and biodegradability in synthetic targeted drug 
delivery scaffolds. 
5.5. Materials and methods 
5.5.1. Materials 
All materials were purchased from commercial sources. Folic acid and methotrexate were 
purchased from Sigma-Aldrich (St. Louis, MO) and used as received. Whey powder was 
purchased from Z Natural Foods (West Palm Beach, FL). 
5.5.2. FBP isolation and purification 
FBP was isolated from bovine whey powder according to previously published 
methods.11,30 Multiple isolations were performed to acquire enough protein, and all batches 
were combined and thoroughly mixed prior to characterization. The fully combined batch of 
FBP was used in the animal trials. The concentration (w/w) of the FBP in the powder was 
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determined using a NanoDrop Fluorospectrometer. FBP purity was assessed by fluorescence 
spectroscopy, AFM, SDS−PAGE, and MALDI TOF-MS as previously described.11,30 
Note that bovine FBP was used for this study. Bovine FBP and human FBP have >80% 
homology overall, including 100% homology in the binding pocket.22,52 The human and bovine 
forms have been shown to exhibit similar aggregation phenomena.33–41 For this work, we have 
employed the substantially more accessible bovine FBP. Previous in vivo studies found no 
adverse effects of homologous (e.g., goat FBP used in goats) versed heterologous (e.g., goat FBP 
used in rats) FBP circulation.53 
5.5.3. Preparation of treatment solutions 
For all treatment solutions, 10% extra volume was prepared (0.220 mL total) to account 
for loss in the syringe. 
MTX+FBP solutions: The powder resulting from the FBP isolation was 1.71% (w/w) 
FBP in sodium acetate. The powder was dissolved in water and centrifuged against a 10,000 
MWCO filter to remove the sodium acetate. The final solution contained 8.4 mg/mL FBP. Given 
this constraint, the highest molar ratio of MTX:FBP that could be delivered was 1:3.7. FBP in 
PBS solutions were prepared at concentrations such that, for each treatment group, the correct 
amount of FBP could be delivered in a 0.2 mL injection. The solutions were aliquoted into 
individual vials and 20 L of MTX stock solution added so that the final MTX dose was 0.33 
mg/kg (5 mg/kg total over 15 doses). The three molar ratios of MTX:FBP were 1:0.25, 1:1.1, and 
1:3.7. 
FBP only solution: The highest concentration FBP solution was aliquoted (0.2 mL) as 
described above, but instead of adding MTX, 20 L of PBS was added to bring the final volume 
to 220 L. 
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MTX only solutions: A solution of MTX in PBS at 0.33 mg/kg/dose (0.033 mg/mL) and 
aliquoted. 
5.5.4. Animal model 
Female Fox Chase severe combined immunodeficient (SCID CB17) mice were purchased 
from Charles River (Wilmington, MA). The mice were housed in a specific animal-care facility 
at the University of Michigan Medical Center in accordance with the regulations of the 
University's Committee on the Use and Care of Animals as well as with  
federal guidelines. Animals were fed ad libitum with folic acid deficient mouse chow 
from Test Diets (Richmond, IN) for three weeks before tumor cell injections.  
5.5.5. Xenograft tumor treatment 
Directly after lifting and collecting the cells, the cell suspension (4x106 cells in 0.2 mL 
PBS) was injected s.c. into the right flank of each mouse. The tumors were allowed to grow for 
seven days before starting treatment. Twice a week, the animals were injected via the tail vein 
with MTX + FBP (three ratios), FBP only, MTX only, or saline. Each treatment group comprised 
five mice. Each dose was administered in 0.2 mL of PBS (saline). In all treatment groups with 
MTX, each MTX dose was 0.3 mg/kg, to give a theoretical maximum cumulative dose of 5 
mg/kg if a mouse received all 15 treatments in the 56-day trial. The final cumulative doses were 
not identical due to different survival rates between the groups. Tumors were measured using 
calipers. Tumor volume was estimated using the standard formula of an ellipsoid: V = 4/3(l/2 * 
w/2 * d/2), where l = length, w=width, and d=depth. Using the assumption that =3 and 
width=depth, the equation used to calculate tumor volume simplifies to: V  = (l*w2)/2. The body 
weight of all the mice was monitored throughout the study as an indication of adverse toxicity 
effects. 
 130 
5.6. References 
(1)  Low, P. S.; Henne, W. A.; Doorneweerd, D. D. Discovery and Development of Folic-
Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory 
Diseases. Acc. Chem. Res. 2008, 41 (1), 120–129. 
(2)  Low, P. S.; Kularatne, S. A. Folate-Targeted Therapeutic and Imaging Agents for Cancer. 
Curr. Opin. Chem. Biol. 2009, 13 (3), 256–262. 
(3)  Sega, E.; Low, P. Tumor Detection Using Folate Receptor-Targeted Imaging Agents. 
Cancer Metastasis Rev. 2008, 27 (4), 655–664. 
(4)  Hilgenbrink, A. R.; Low, P. S. Folate Receptor-Mediated Drug Targeting: From 
Therapeutics to Diagnostics. J. Pharm. Sci. 2005, 94 (10), 2135–2146. 
(5)  Leamon, C. P.; Reddy, J. A. Folate-Targeted Chemotherapy. Adv. Drug Deliv. Rev. 2004, 
56 (8), 1127–1141. 
(6)  Assaraf, Y. G.; Leamon, C. P.; Reddy, J. A. The Folate Receptor as a Rational 
Therapeutic Target for Personalized Cancer Treatment. Drug Resistance Updates. 2014. 
(7)  Sudimack, J.; Lee, R. J. Targeted Drug Delivery via the Folate Receptor. Adv. Drug Deliv. 
Rev. 2000, 41 (2), 147–162. 
(8)  Wu, Y.; Guo, R.; Wen, S.; Shen, M.; Zhu, M.; Wang, J.; Shi, X. Folic Acid-Modified 
Laponite Nanodisks for Targeted Anticancer Drug Delivery. J. Mater. Chem. B Mater. 
Biol. Med. 2014, 2 (42), 7410–7418. 
(9)  Hu, Y.; Wang, R.; Wang, S.; Ding, L.; Li, J.; Luo, Y.; Wang, X.; Shen, M.; Shi, X. 
Multifunctional Fe3O4 @ Au Core/shell Nanostars: A Unique Platform for Multimode 
Imaging and Photothermal Therapy of Tumors. Sci. Rep. 2016, 6 (February), 28325. 
(10)  Ward, B. B.; Dunham, T.; Majoros, I. J.; Baker, J. R. Targeted Dendrimer Chemotherapy 
in an Animal Model for Head and Neck Squamous Cell Carcinoma. J. Oral Maxillofac. 
Surg. 2011, 69 (9), 2452–2459. 
(11)  Chen, J.; van Dongen, M. A.; Merzel, R. L.; Dougherty, C. A.; Orr, B. G.; Kanduluru, A. 
K.; Low, P. S.; Marsh, E. N. G.; Banaszak Holl, M. M. Substrate-Triggered Exosite 
Binding: Synergistic Dendrimer/Folic Acid Action for Achieving Specific, Tight-Binding 
to Folate Binding Protein. Biomacromolecules 2016, 17 (3), 922–927. 
(12)  Merzel, R. L.; Boutom, S. M.; Chen, J.; Frey, C.; Shedden, K.; Marsh, E. N. G.; Banaszak 
Holl, M. M. Folate Binding Protein: Therapeutic Natural Nanotechnology for Folic Acid, 
Methotrexate, and Leucovorin. Nanoscale 2017, 9 (7), 2603–2615. 
(13)  van Dongen, M. A.; Silpe, J. E.; Dougherty, C. A.; Kanduluru, A. K.; Choi, S. K.; Orr, B. 
G.; Low, P. S.; Banaszak Holl, M. M. Avidity Mechanism of Dendrimer–Folic Acid 
Conjugates. Mol. Pharm. 2014, 11 (5), 1696–1706. 
 131 
(14)  Mullen, D. G.; McNerny, D. Q.; Desai, A.; Cheng, X.; DiMaggio, S. C.; Kotlyar, A.; 
Zhong, Y.; Qin, S.; Kelly, C. V; Thomas, T. P.; et al. Design, Synthesis, and Biological 
Functionality of a Dendrimer-Based Modular Drug Delivery Platform. Bioconjug. Chem. 
2011, 22 (4), 679–689. 
(15)  Weitman, S. D.; Weinberg, A. G.; Coney, L. R.; Zurawski, V. R.; Jennings, D. S.; Kamen, 
B. A. Cellular Localization of the Folate Receptor: Potential Role in Drug Toxicity and 
Folate Homeostasis. Cancer Res. 1992, 52 (23), 6708–6711. 
(16)  Campbell, I. G.; Jones, T. A.; Foulkes, W. D.; Trowsdale, J. Folate-Binding Protein Is a 
Marker for Ovarian Cancer Folate-Binding Protein Is a Marker for Ovarian Cancer. 
CANCER Res. 1991, 51 (33), 5329–5338. 
(17)  Weitman, S. D.; Lark, R. H.; Coney, L. R.; Fort, D. W.; Frasca, V.; Zurawski, V. R.; 
Kamen, B. A. Distribution of the Folate Receptor GP38 in Normal and Malignant Cell 
Lines and Tissues. Cancer Res. 1992, 52 (12), 3396–3401. 
(18)  Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential Regulation of Folate Receptor 
Isoforms in Normal and Malignant Tissues in Vivo and in Established Cell Lines. 
Physiologic and Clinical Implications. Cancer 1994, 73 (9), 2432–2443. 
(19)  Bandara, N. A.; Hansen, M. J.; Low, P. S. Effect of Receptor Occupancy on Folate 
Receptor Internalization. Mol. Pharm. 2014, 11 (3), 1007–1013. 
(20)  Bailey, L. B.; Gregory, J. F. Folate Metabolism and Requirements. J. Nutr. 1999, 129 (4), 
779–782. 
(21)  Kompis, I. M.; Islam, K.; Then, R. L. DNA and RNA Synthesis: Antifolates. Chemical 
Reviews. American Chemical Society 2005, pp 593–620. 
(22)  Chen, C.; Ke, J.; Zhou, X. E.; Yi, W.; Brunzelle, J. S.; Li, J.; Yong, E.-L.; Xu, H. E.; 
Melcher, K. Structural Basis for Molecular Recognition of Folic Acid by Folate 
Receptors. Nature 2013, 500 (7463), 486–489. 
(23)  Wibowo, A. S.; Singh, M.; Reeder, K. M.; Carter, J. J.; Kovach, A. R.; Meng, W.; 
Ratnam, M.; Zhang, F.; Dann, C. E. Structures of Human Folate Receptors Reveal 
Biological Trafficking States and Diversity in Folate and Antifolate Recognition. Proc. 
Natl. Acad. Sci. 2013, 110 (38), 15180–15188. 
(24)  van Dongen, M. A.; Rattan, R.; Silpe, J.; Dougherty, C.; Michmerhuizen, N. L.; Van 
Winkle, M.; Huang, B.; Choi, S. K.; Sinniah, K.; Orr, B. G.; et al. Poly(amidoamine) 
Dendrimer–Methotrexate Conjugates: The Mechanism of Interaction with Folate Binding 
Protein. Mol. Pharm. 2014, 11 (11), 4049–4058. 
(25)  van Dongen, M. A.; Dougherty, C. A.; Banaszak Holl, M. M. Multivalent Polymers for 
Drug Delivery and Imaging: The Challenges of Conjugation. Biomacromolecules 2014, 15 
(9), 3215–3234. 
 132 
(26)  Mullen, D. G.; Banaszak Holl, M. M. Heterogeneous Ligand–Nanoparticle Distributions: 
A Major Obstacle to Scientific Understanding and Commercial Translation. Acc. Chem. 
Res. 2011, 44 (11), 1135–1145. 
(27)  Mullen, D. G.; Fang, M.; Desai, A.; Baker, J. R.; Orr, B. G.; Banaszak Holl, M. M. A 
Quantitative Assessment of Nanoparticle−Ligand Distributions: Implications for Targeted 
Drug and Imaging Delivery in Dendrimer Conjugates. ACS Nano 2010, 4 (2), 657–670. 
(28)  Merzel, R. L.; Chen, J.-J.; Marsh, E. N. G.; Holl, M. M. B. Folate Binding protein—
Outlook for Drug Delivery Applications. Chinese Chem. Lett. 2015, 26 (4), 426–430. 
(29)  Chen, J.; Klem, S.; Jones, A. K.; Orr, B.; Banaszak Holl, M. M. Folate-Binding Protein 
Self-Aggregation Drives Agglomeration of Folic Acid Targeted Iron Oxide Nanoparticles. 
Bioconjug. Chem. 2017, 28 (1), 81–87. 
(30)  Merzel, R. L.; Frey, C.; Chen, J.; Garn, R.; van Dongen, M.; Dougherty, C. A.; Kandaluru, 
A. K.; Low, P. S.; Marsh, E. N. G.; Banaszak Holl, M. M. Conjugation Dependent 
Interaction of Folic Acid with Folate Binding Protein. Bioconjug. Chem. 2017, 28 (9), 
2350–2360. 
(31)  Hoier-Madsen, M.; Holm, J.; Hansen, S. I.; Høier-madsen, M.; Holm, J.; Hansen, S. I. α 
Isoforms of Soluble and Membrane-Linked Folate-Binding Protein in Human Blood. 
Biosience Reports 2008, 28 (3), 153–160. 
(32)  Kamen, B. A. Folate Receptors and Therapeutic Applications. In Targeted Drug 
Strategies for Cancer and Inflammation; Jackman, A. L., Leamon, C. P., Eds.; Springer, 
2011. 
(33)  Pedersen, T.; Svendsen, I.; Hansen, S.; Holm, J.; Lyngbye, J. Aggregation of a Folate-
Binding Protein from Cow’s Milk. Carlsberg Res. Commun. 1980, 45 (2), 161–166. 
(34)  Hansen, S. I.; Holm, J.; Lyngbye, J.; Pedersen, T. G.; Svendsen, I. Dependence of 
Aggregation and Ligand Affinity on the Concentration of the Folate-Binding Protein from 
Cow’s Milk. Arch. Biochem. Biophys. 1983, 226 (2), 636–642. 
(35)  Holm, J.; Schou, C.; Babol, L. N.; Lawaetz, A. J.; Bruun, S. W.; Hansen, M. Z.; Hansen, 
S. I. The Interrelationship between Ligand Binding and Self-Association of the Folate 
Binding Protein. The Role of Detergent?tryptophan Interaction. Biochim. Biophys. Acta - 
Gen. Subj. 2011, 1810 (12), 1330–1339. 
(36)  Holm, J.; Lawaetz, A. J.; Hansen, S. I. Ligand Binding Induces a Sharp Decrease in 
Hydrophobicity of Folate Binding Protein Assessed by 1-Anilinonaphthalene-8-
Sulphonate Which Suppresses Self-Association of the Hydrophobic Apo-Protein. 
Biochem. Biophys. Res. Commun. 2012, 425 (1), 19–24. 
(37)  Christensen, U.; Holm, J.; Hansen, S. I. Stopped-Flow Kinetic Studies of the Interaction of 
Bovine Folate Binding Protein (FBP) and Folate. Biosci. Rep. 2006, 26 (4), 291–299. 
 133 
(38)  Kaarsholm, N. C.; Kolstrup, A.-M.; Danielsen, S. E.; Holm, J.; Hansen, S. I. Ligand-
Induced Conformation Change in Folate-Binding Protein. Biochem. J. 1993, 292 (3), 921–
925. 
(39)  Holm, J.; Babol, L. N.; Markova, N.; Lawaetz, A. J.; Hansen, S. I. The Interrelationship 
between Ligand Binding and Thermal Unfolding of the Folate Binding Protein. The Role 
of Self-Association and pH. Biochim. Biophys. Acta - Proteins Proteomics 2014, 1844 (3), 
512–519. 
(40)  Bruun, S. W.; Holm, J.; Hansen, S. I.; Jacobsen, S. Application of Near-Infrared and 
Fourier Transform Infrared Spectroscopy in the Characterization of Ligand-Induced 
Conformation Changes in Folate Binding Protein Purified from Bovine Milk: Influence of 
Buffer Type and pH. Appl. Spectrosc. 2006, 60 (7), 737–746. 
(41)  Bruun, S. W.; Holm, J.; Hansen, S. I.; Andersen, C. M.; Norgaard, L.; Nørgaard, L. A 
Chemometric Analysis of Ligand-Induced Changes in Intrinsic Fluorescence of Folate 
Binding Protein Indicates a Link between Altered Conformational Structure and Physico-
Chemical Characteristics. Appl. Spectrosc. 2009, 63 (12), 1315–1322. 
(42)  Chiti, F.; Dobson, C. M. Amyloid Formation by Globular Proteins under Native 
Conditions. Nat. Chem. Biol. 2009, 5 (1), 15–22. 
(43)  Rothberg, K. G.; Ying, Y. S.; Kamen, B. A.; Anderson, R. G. Cholesterol Controls the 
Clustering of the Glycophospholipid-Anchored Membrane Receptor for 5-
Methyltetrahydrofolate. J. Cell Biol. 1990, 111 (6). 
(44)  Rothberg, K. G.; Ying, Y. S.; Kolhouse, J. F.; Kamen, B. A.; Anderson, R. G. The 
Glycophospholipid-Linked Folate Receptor Internalizes Folate without Entering the 
Clathrin-Coated Pit Endocytic Pathway. J. Cell Biol. 1990, 110 (3). 
(45)  Smart, E. J.; Mineo, C.; Anderson, R. G. W. Clustered Folate Receptors Deliver 5-
Methyltetrahydrofolate to Cytoplasm of MA104 Cells. J. Cell Biol. 1996, 134 (5), 1169–
1177. 
(46)  Moradi, E.; Vllasaliu, D.; Garnett, M.; Falcone, F.; Stolnik, S. Ligand Density and 
Clustering Effects on Endocytosis of Folate Modified Nanoparticles. RSC Adv. 2012, 2 
(7), 3025. 
(47)  Birn, H.; Zhai, X. Y.; Holm, J.; Hansen, S. I.; Jacobsen, C.; Christensen, E. I.; Moestrup, 
S. K. Megalin Binds and Mediates Cellular Internalization of Folate Binding Protein. 
FEBS J. 2005, 272 (17), 4423–4430. 
(48)  Kur, E.; Mecklenburg, N.; Cabrera, R. M.; Willnow, T. E.; Hammes, A. LRP2 Mediates 
Folate Uptake in the Developing Neural Tube. J. Cell Sci. 2014, 127 (10), 2261–2268. 
(49)  Piedrahita, J. A.; Oetama, B.; Bennett, G. D.; Van Waes, J.; Kamen, B. A.; Richardson, J.; 
Lacey, S. W.; Anderson, R. G. W.; Finnell, R. H. Mice Lacking the Folic Acid-Binding 
Protein Folbp1 Are Defective in Early Embryonic Development. Nat. Genet. 1999, 23 (2), 
 134 
228–232. 
(50)  Kratz, F.; Elsadek, B. Clinical Impact of Serum Proteins on Drug Delivery. J. Control. 
Release 2012, 161 (2), 429–445. 
(51)  Elsadek, B.; Kratz, F. Impact of Albumin on Drug Delivery — New Applications on the 
Horizon. J. Control. Release 2012, 157 (1), 4–28. 
(52)  Sadasivan, E.; Rothenberg, S. P. The Complete Amino-Acid Sequence of a Human Folate 
Binding Protein from KB Cells Determined from the cDNA. J. Biol. Chem. 1989, 264 
(10), 5806–5811. 
(53)  Rubinolf, M.; Abramson, R.; Schreiber, C.; Waxman, S. Effect of a Folate-Binding 
Protein on the Plasma Transport and Tissue Distribution of Folic Acid. Acta Haematol. 
1981, 65 (3), 145–152. 
(54)  Kukowska-Latallo, J. F.; Candido, K. A.; Cao, Z.; Nigavekar, S. S.; Majoros, I. J.; 
Thomas, T. P.; Balogh, L. P.; Khan, M. K.; Baker, J. R. Nanoparticle Targeting of 
Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial 
Cancer. Cancer Res. 2005, 65 (12). 
(55)  Dougherty, C. A.; Furgal, J. C.; van Dongen, M. A.; Goodson, T.; Banaszak Holl, M. M.; 
Manono, J.; DiMaggio, S. Isolation and Characterization of Precise Dye/Dendrimer 
Ratios. Chem. – A Eur. J. 2014, 20 (16), 4638–4645. 
(56)  Dougherty, C. A.; Vaidyanathan, S.; Orr, B. G.; Banaszak Holl, M. M. 
Fluorophore:Dendrimer Ratio Impacts Cellular Uptake and Intracellular Fluorescence 
Lifetime. Bioconjug. Chem. 2015, 26 (2), 304–315. 
(57)  Backus, H. H. J.; Pinedo, H. M.; Wouters, D.; Padrón, J. M.; Molders, N.; Van Der Wilt, 
C. L.; Van Groeningen, C. J.; Jansen, G.; Peters, G. J. Folate Depletion Increases 
Sensitivity of Solid Tumor Cell Lines to 5-Fluorouracil and Antifolates. Int. J. Cancer 
2000, 87 (6), 771–778. 
(58)  Tucker, J. M.; Davis, C.; Kitchens, M. E.; Bunni, M. A.; Priest, D. G.; Spencer, H. T.; 
Berger, F. G. Response to 5-Fluorouracil Chemotherapy Is Modified by Dietary Folic 
Acid Deficiency in ApcMin/+mice. Cancer Lett. 2002, 187 (1–2), 153–162.
 135 
CHAPTER 6. Conclusions 
6.1. Summary and future outlook 
The body of research presented in this dissertation focused on characterizing and 
understanding the self-aggregation of serum FBP into nanoparticles. We sought to develop 
greater scientific understanding of the connection between the structure of nanoparticulate FBP 
and its biological function and activity. Inspired by therapeutics using serum proteins as 
carriers,1–5 our goal was to investigate the possibility of using FBP itself as a delivery vector.  
Before now, other researchers have extensively investigated the self-aggregation of FBP 
as a function of both concentration and ligand binding.6–14 In particular, they were interested in 
the role FA plays in these processes. FA is necessary for DNA synthesis and can only be 
obtained through diet.15–18 FA binds strongly to both FRs and soluble FBP, and researchers 
postulated FBP assists in the biotransport and cellular uptake, helps prevent degradation, and 
protects against bacterial utilization of FA.19–22 The aggregated, nanoparticulate form of FBP 
may play a role in these processes. The size of the FBP aggregates (i.e., the degree of 
aggregation) likely acts as signaling mechanism to cells regarding what FBPNP is carrying. This 
hypothesis agrees well with microscopy images showing clustered FBP at sites of FA 
endocytosis, as well as data presented here on changes to FBPNP size as a function of ligand 
identity.23,24 Recently, researchers have demonstrated in vitro and in vivo the critical role FBP 
plays in cellular uptake of FA and embryonic development.25,26  
These earlier studies on concentration- and ligand-dependent aggregation of FBP were 
limited by the detection limits of the analytical techniques used: FBP concentrations were at least 
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an order of magnitude higher (and usually more) than physiological concentrations. In our work, 
we sought to build upon this previous research and extend the study of FBP aggregation and 
activity to biologically relevant conditions. 
 
Chapter 227 is a mini-review on serum proteins as delivery vectors, as well as the specific 
advantages and challenges associated with FBP. It provides broader context for our research on 
FBP aggregation and outlines a general approach for our subsequent work. Data up to that point 
from our group and others indicated that FBP aggregation is natural, healthy, and occurs in vivo. 
In addition, some of our more recent research focused on the binding interactions of FA-
PAMAM conjugates with FBP and their relationship to the FBP aggregation process.28,29 We 
postulated it was possible to control the degree of aggregation and therefore influence the 
biological activity of the FBPNP through the conjugate. FBP has a key advantage over other 
serum proteins (primarily albumin) used as vectors: it has a particular role in folate metabolism 
and follows a specific trafficking pathway. This would allow it to function as a targeted vector. 
As a comparison, albumin, which is used in several clinically approved therapies, is present at 
much higher concentrations and much more promiscuous in terms of its binding of molecules, 
trafficking pathways, and biological activity.1–5 As a critical component in the folate metabolic 
pathway, FBP is mechanistically linked to the antifolate class of drugs. We hypothesized that by 
pre-binding these drugs to FBP prior to injection, we could increase specificity and decrease 
toxicity. This key hypothesis informed the rest of the research presented here.  
 
Chapter 330 focused on the binding interaction between FBP and FA, MTX, and LEUC. 
We examined FBP aggregation as a function of FBP concentration, ligand identity, and ligand 
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concentration on a particle-by-particle basis using AFM. Analysis of the FBPNP distributions, as 
opposed to reliance on averaged values obtained from bulk measurements, yielded valuable 
insights about the role of FBP in transporting small molecules. FBPNP with healthy levels of FA 
had a different distribution than FBPNP with therapeutic levels of MTX. These data suggest that 
the in vivo mechanism for MTX trafficking follows a different pathway than the pathway for FA. 
This is consistent with previous in vitro data showing that MTX is taken up into cells through 
different membrane receptor than FA. However, it is unclear the extent to which the role of 
soluble FBP was considered in these studies, and explicit inclusion of it in in vitro experiments 
could yield different results. Further investigation on the mechanism of action of MTX, and other 
antifolate drugs, would be a valuable line of research to pursue, particularly with the ultimate 
goal of developing methods to increase efficacy and decrease toxicity of these drugs. Analysis of 
distributions of FA-FBPNP and LEUC-FBPNP at therapeutically relevant concentrations of the 
ligands also produced surprising results. FBP exposed to high concentrations of FA resulted in 
FBPNP nearly identical to the distributions of unligated FBP and MTX-FBP at high MTX 
concentrations. Comparatively, FBPNP with of healthy levels of FA or therapeutically relevant 
levels LEUC and had distributions that were not statistically different. This suggests that 
therapeutic levels of FA are transported like MTX. As a result, high doses of FA cannot bypass 
the MTX trafficking pathway and mitigate toxicity effects. This is consistent with data indicating 
that healthy levels of FA and therapeutic MTX enter cells via different uptake pathways. The 
FBPNP formed with therapeutic levels of LEUC are indistinguishable from healthy FA-FBPNP, 
allowing LEUC to follow the FA trafficking pathways. These results provided the first 
mechanistic explanation for the puzzling phenomenon that LEUC must be used for FA rescue 
because FA itself has no therapeutic benefit at the required concentrations.  
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Chapter 431 built upon our work analyzing the small molecule-FBP interactions, as well 
as previous efforts in making and characterizing PAMAM dendrimers with precise numbers of 
ligands.28,29,32–36 Using four different FA-polymer conjugates (two FA-PAMAM dendrimers and 
two FA-PEG conjugates), we examined the FBP aggregation process as a function of polymer 
identity and conjugation method. For these studies, we employed both AFM and fluorescence 
spectroscopy.37 The complementary data obtained from both techniques provided important 
information on conformational changes in FBP upon ligand binding and FBP aggregation. 
Notably, the data illustrated the risks in relying only on bulk techniques (fluorescence 
spectroscopy in solution in this case) to reach conclusions on the structure of biological 
materials.  
Fluorescence spectroscopy experiments showed that FA, either free or conjugated, 
induced conformational changes throughout the FBP population, even with an excess of FBP. 
Conformational changes in ligated FBP started a cascade through which unligated FBP also 
underwent a conformational rearrangement. The only way for this to have occurred was through 
aggregation, a result confirmed by AFM, as described below. By fluorescence spectroscopy, 
G5Ac-FA4(avg) appeared to have a similar interaction with FBP as FA with FBP. They induced the 
same degree of fluorescence quenching, indicating comparable levels of FBP conformational 
change. In the absence of other information, it could be interpreted that G5Ac-FA4(avg) could form 
the basis of a successful targeting vector. However, AFM studies showed that FA and G5Ac-FA4-
(avg) induced dramatically different aggregation processes in FBP. The FA-FBPNP distribution 
was shifted towards smaller particles than the distributions of unligated FBPNP, while G5Ac-
FA4(avg)-FBPNP distributions contained significantly larger particles than unligated FBPNP. 
G5Ac-COG-FA1.0 produced strong fluorescence quenching and very large FBP aggregates, even 
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at sub-stoichiometric concentrations. At stoichiometric concentrations of G5Ac-COG-FA1.0 and 
FBP, AFM images showed excess polymer on the surface, indicating that each G5Ac-COG-FA1.0 
was aggregating more than one FBP. PEG-FA of all chain lengths and at all concentrations 
disrupted FBPNP and prevented the formation of new nanoparticles. 
As argued above, the structure of FBPNP is critical for trafficking of FA, and our data 
show that the FA conjugates produced FBPNP that are significantly different than the FBPNP 
formed with free FA. As a result, the conjugates and FA would likely follow different biological 
pathways, diminishing the therapeutic targeting effects of the conjugations. Furthermore, PEG is 
the most common polymer in biomedical applications, and its inclusion in targeted therapeutics 
should be carefully considered. Disruption of natural FBP aggregation may not only result in off-
target uptake of drugs but also artificially induce folate deficiency. These studies illustrate some 
of the challenges of clinical translation of targeted conjugates and highlight the importance of 
considering specific serum protein interactions in the rational design of delivery vectors. 
 
As described in Chapter 5,38 we applied our knowledge of distributions and our insights 
on the role of FBP in the folate metabolic pathway to testing our key hypothesis. Using KB 
xenograft tumor model in mice, we investigated whether pre-binding MTX to FBP would 
increase therapeutic efficacy and reduce toxicity. As a control, we included a group treated with 
only FBP, and we obtained the remarkable and entirely unexpected result that FBP alone 
dramatically reduced tumor growth. We hypothesize that the presence of unligated FBP at 
concentrations higher than serum FA led to folate starvation of the tumor cells. This means, there 
was no need for treatment to include a toxic chemotherapeutic such as MTX. The groups treated 
with MTX and FBP also showed inhibition of tumor growth, but toxicity increased with FBP 
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concentration. It is likely that instead of specifically targeting the cancer cells, FBP facilitated 
widespread uptake of MTX, resulting in systemic toxicity. These data indicate that by solely 
manipulating the serum concentration of FBP, by administering endogenous protein, it may be 
possible to treat a wide range of tumor types. This would be a completely novel approach to 
treating to treating a variety of cancers. The next step in this research is to follow up on these 
results by testing the therapeutic efficacy of lower concentrations of FBP.  
These results are particularly interesting when viewed in the context of the success of 
Abraxane, an albumin-bound form of paclitaxel.1–5 Abraxane is considered is one of the most 
impactful achievements in drug delivery over the last decade. Many more albumin-based 
approaches are currently under development or in clinical trials. Researchers recently reported a 
cancer vaccine using albumin as a carrier showing great promise in in vivo trials.39 FBP-based 
approaches, discussed at length in this dissertation, present an interesting contrast to albumin-
based approaches since FBP is present at far lower serum concentrations and is much more 
selective regarding cell uptake.  
As demonstrated through this body of research, heterogeneity and serum protein 
interactions are two significant obstacles to clinical translation. Researchers may turn more 
towards protein-based therapies to mitigate these challenges. In addition, protein-based therapies 
help to avoid problems of immunogenicity, deleterious serum protein interactions, and 
biodegradability associated with synthetic targeted therapies. 
 
Characterizing and understanding the role of nanoparticle distributions was a central 
theme of the research presented in this dissertation. This work not only built upon colleagues’ 
earlier efforts on targeted drug delivery projects but also drew from methods and expertise 
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developed on tissue analysis projects. The examples discussed in the Introduction (Chapter 1, to 
be submitted) illustrate how this body of work leveraged 20+ years of the research team’s 
institutional knowledge and expertise. The FA-conjugates themselves are the product of years of 
research and several doctoral degrees focused on identifying, characterizing, and controlling 
heterogeneous mixtures.28,29,32–36,40,41 Our studies on FBPNP distributions depended on image 
analysis and statistical methods developed for research on heterogeneity in collagen structure.42–
49 The translation and application of all these techniques in combination was critical for yielding 
valuable insights on the role of FBP in biotrafficking pathways. The scientific understanding we 
developed allowed us to expand our efforts to examining the role of FBP in an in vivo tumor 
model, with remarkable preliminary results.  
In addition to showcasing these specific scientific achievements, this dissertation aims to 
make a broader argument on heterogeneity and distributions in biological materials. The 
magnitude and role of heterogeneity in biological materials is often underappreciated. The ways 
in which analytical techniques or methods of data interpretation mask heterogeneity is not often 
considered. As a result, in vivo results do not match predictions from in vitro models, clinical 
research on mechanisms of disease or therapy is slowed, and clinical translation is hindered. In 
the new research presented in this dissertation, as well as the cases discussed in the 
Introductions, we show how explicit consideration of distributions was necessary for reaching 
key biological conclusions. We make the case here for widespread investment in molecular level 
analyses of biological materials and the development of methods to facilitate this research. 
Understanding molecular level distributions is critical for interpreting the interplay between 
structural variation and function. 
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 Supplementary Information for Chapter 3: Folate binding 
protein: Therapeutic Natural Nanotechnology for Folic Acid, Methotrexate, 
and Leucovorin
Figure A.1. a) Histograms; b) Q-Q plots; c) and CDF plots for the FBPNP formed from 0.2 nM FBP. The K-S test comparing 
FBPNP at 0.2 nM and 2 nM protein rejected the null hypothesis, indicating the two nanoparticle populations are statistically 
different. 
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Figure A.2. Representative detailed frames of AFM images showing FBP nanoparticles. Idealized spherical radii and the number 
of FBP comprising each selected nanoparticle are provided. 
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Figure A.3. Histograms, Q-Q plots, and CDF plots of the full data set of FBPNP formed from 2 nM FA + 2 nM FBP 
demonstrating the biomodal distribution of FBPNP volumes. 
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Figure A.4. Titration of FBP into FA (30 nM). Trytophan fluorescence was excited at 280 nm and emission detected at 
340 nm. The flatter slope of the ligated FBP fluorescence is suggests asymmetrical aggregation of apo- and holo-FBP. 
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Figure A.5. AFM images of FBPNP formed from a range of MTX:FBP ratios. For all samples, the 
FBP concentration was held constant at 2 nM in 1x PBS. AFM images were captured by spin 
coating the solutions onto freshly-cleaved mica. 
Figure A.6. AFM images of FBPNP formed from a range of LEUC:FBP ratios. For all samples, the 
FBP concentration was held constant at 2 nM in 1x PBS. AFM images were captured by spin 
coating the solutions onto freshly-cleaved mica. 
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Figure A.7. TANGO output for bovine apo-FBP (P02702). The N-terminus 8-18 LLLLALVAAAW sequence has 
~99% aggregation tendency at 10 μM (the lowest concentration with which the code is compatible). 
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Figure A.8. TANGO output for human apo-hFRα(P02702)+FA. The N-terminus 9-19 LLLLVWVAVV sequence has 
~99% aggregation tendency at 10 μM (the lowest concentration with which the code is compatible). 
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Figure A.9. SDS-PAGE and MALDI of FBP. The protein were collected by fractions and the ~29kDa 
fractions were pooled together. The FBP exhibited a molecular weight distribution around ~29kDa because 
of glycosylation at residue 68N and 160N. 
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Figure A.10. AFM images of 10 nM FA + 2 nM FBP at pH 6.5; b) AFM images of 10 nM FA + 2 nM FBP at pH 4.45. Images in 
both (a) and (b) show substantially less nanoparticle formation as compared to FA+FBP solution at pH 7.4; c) Tryptophan 
fluorescence of FBP over a range of pH values ([FBP]  = 58 nM); d) Tryptophan fluorescence of FBP (58 nM) in the presence of 
FA (50 nM). Excitation: 280 nM; Emission: 340 nM 
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Figure B.1. 1H NMR spectrum (D2O) of G5Ac-FA4(avg)-FITC2 (G5Ac-FA4(avg)). The singlet at 1.97 ppm corresponds to 
the terminal acetyl groups on the dendrimer. The broad singlet at 8.7 corresponds to 1 FA proton, indicating an average 
of ~4 FA per dendrimer. The broad signal with a max at 6.7 ppm includes 2 FA protons and 5 FITC, leading to an 
average of ~2 FITC per dendrimer. 
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Figure A.2. a) Histograms showing the volume (left) and extrapolated radii (right) distributions of FBP nanoparticles generated 
with G5Ac; b) Histograms showing the volume (left) and extrapolated radii (right) distributions of FBP nanoparticles generated 
with G5Ac-FA4(avg). 
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Figure A.3. AFM images (3.5x3.5 µm) of mixtures of FBP + PEG-FA of varying polymer 
molecular weights at different concentrations. In all cases, PEG-FA was added to FBP (2 nM in 
1x PBS). AFM images were captured by spin coating the solutions onto freshly-cleaved mica. 
The lack of nanoparticles indicates that PEG-FA disrupted already existing apo-FBPNP. Higher 
concentrations of PEG-FA were attempted, but multilayers of polymer were observed. This 
phenomenon is already evident in the PEG(30kDa)-FA samples. 
